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ABSTRACT 
 
Investigations into Hyperlipidemia and its Possible Associations with Pancreatitis  
in Dogs. (May 2011) 
Panagiotis Xenoulis, D.V.M., Aristotle University  
Chair of Advisory Committee: Dr. Jörg M. Steiner 
 
The relationship between hyperlipidemia and pancreatitis remains obscure in 
dogs. The aim of the present study was to investigate any possible association between 
hyperlipidemia and pancreatitis in dogs. 
In the first part of the study, Miniature Schnauzers with hypertriglyceridemia 
were found to have significantly higher serum cPLI concentrations than Miniature 
Schnauzers with normal serum triglyceride concentrations (P=0.0001). Also, Miniature 
Schnauzers with severe hypertriglyceridemia (>862 mg/dL) had 4.5 times higher odds 
(P=0.0343) for having a serum cPLI concentration consistent with pancreatitis.  
In the second part of the study, 17 Miniature Schnauzers prospectively enrolled 
with a history of pancreatitis were significantly more likely to have hypertriglyceridemia 
(71%) after resolution of pancreatitis than 34 age-matched Miniature Schnauzers without 
a history of pancreatitis (33%; odds ratio=5.02; P=0.0163).  
For the third part of the study, assessment of the feasibility and usefulness of a 
novel density gradient ultracentrifugation method using NaBiEDTA for lipoprotein 
profiling in dogs was attempted. Density gradient ultracentrifugation using NaBiEDTA 
 iv 
was found to be useful for the study of lipoprotein profiles in dogs. Significant 
differences were detected in the lipoprotein profiles (mainly involving TRL and specific 
LDL fractions) among healthy Miniature Schnauzers, dogs of various other breeds, and 
hypertriglyceridemic Miniature Schnauzers.  
In the fourth part of the study, the effect of a commercially available low-fat diet 
on serum lipid and pancreas-specific lipase (Spec cPL
®
) concentrations and lipoprotein 
profiles in Miniature Schnauzers with primary hypertriglyceridemia was evaluated. The 
study diet was found to be effective in significantly reducing serum triglyceride and 
cholesterol concentrations and changing the lipoprotein profiles of the dogs studied 
within 2 months. However, there was no significant effect of the study diet on serum 
Spec cPL concentrations.  
In the last part of the study, serum triglyceride and cholesterol concentrations and 
lipoprotein profiles were compared between dogs with naturally occurring pancreatitis 
and healthy dogs. The majority of dogs with naturally occurring pancreatitis had normal 
serum triglyceride and cholesterol concentrations. Important differences were identified 
in lipoprotein profiles between dogs with pancreatitis (higher LDL2, LDL3, and LDL4 
fractions and lower TRL, HDL2a, and HDL3c fractions) and healthy control dogs. 
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CHAPTER I 
INTRODUCTION AND 
LITERATURE REVIEW 
 
Lipoprotein metabolism and hyperlipidemia in dogs 
History of the investigation of canine lipoproteins and lipoprotein metabolism  
The first studies investigating canine lipoproteins were published in the 1940s 
and 1950s.
1-5
 Without exception, these studies used dogs as an experimental animal 
model to study human disease. Most of these studies used a combination of methods to 
separate and classify the lipoprotein profiles of the dogs, including different forms of 
ultracentrifugation (e.g., sequential ultracentrifugation, analytical ultracentrifugation), 
flotation rates, precipitation with sulfated polysaccharides (e.g., dextran sulfate), and 
electrophoresis (e.g., paper electrophoresis). These methods are rarely used today, at 
least in the fashion that they were used in those initial studies, and their accuracy is now 
considered to be rather limited. Also, the majority of methods used in these initial 
studies were optimized to analyze lipoproteins in human serum, which, in contrast to 
dogs, predominantly contains low-density lipoproteins (LDL). Thus, complete separation 
of canine LDL and high-density lipoproteins (HDL) was not always achieved.
1-5
  
Furthermore, information about food withholding was not always available, and 
 
____________ 
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the results of these initial studies are hard to interpret today mainly because of the 
different terminology and classification schemes used. Nevertheless, some basic 
information can be derived from those initial studies. For example, these studies showed  
that the majority of lipoproteins found in dogs (~75%) have a very low flotation rate (-
3S) and thus would be classified as HDL molecules today (most likely HDL2 and 
HDL3).
1-5
 Lipoproteins with higher flotation rates (-6S and -27S) were found to represent 
between 1% and 10% of the total lipoproteins of canine serum, and likely included LDL, 
VLDL, and chylomicron molecules.
1-5
 
 Subsequent studies in the 1970s by Solyom and colleagues
6,7
 and Mahley and 
colleagues
8-10
 provided additional information on lipoproteins in fasted healthy dogs, and 
showed that canine plasma lipoproteins consisted primarily of HDL2, with much lower 
concentrations of HDL1 and LDL. Chylomicrons and VLDLs were found only in dogs 
that were fasted for less than 12 hours. These researchers also determined the protein and 
lipid distribution of canine lipoproteins. They reported that 85% of total plasma 
cholesterol was carried by HDL2, and 50% of plasma triglyceride was carried by VLDL. 
The above mentioned studies were also the first ones to describe in more detail some of 
the apoproteins found in each lipoprotein fraction. In their studies, both Solyom and 
colleagues and Mahley and colleagues used ultracentrifugation combined with 
electrophoresis for lipoprotein fractionation and characterization. In addition, 
immunohistochemical studies were performed to describe the apoproteins found in each 
lipoprotein fraction.    
 3 
 A series of subsequent publications from the late 1970s until recently, have 
investigated canine lipoprotein profiles in association with or in response to obesity,
11,12
 
diet change,
13,14
 primary disorders of lipid metabolism,
15-17
 experimentally induced 
pancreatitis,
18-20
 and other (mainly endocrine) diseases.
21
 These studies have used similar 
methodologies to previous studies (i.e., ultracentrifugation combined with 
electrophoresis), and provide information for both healthy dogs (which were used as 
controls) and dogs with several spontaneous or experimentally induced diseases. The 
information on lipoproteins in healthy dogs is similar to that reported by Solyom and 
colleagues and Mahley and colleagues in the 1970s. However, information on specific 
lipoprotein profile patterns associated with certain diseases or conditions has been new 
for these studies. For example, Whitney and colleagues
17
 reported that idiopathic 
hypertriglyceridemia in Miniature Schnauzers is mainly characterized by increases in 
serum VLDL concentrations, with or without an increase in chylomicrons. Jeusette and 
colleagues
12
 reported that obesity results in increased serum cholesterol and triglyceride 
concentrations in all lipoprotein fractions, and that appropriate dietary modification 
resulted in improvement of these concentrations. The studies investigating the effect of 
experimental pancreatitis on plasma lipids and lipoprotein concentrations,
18-20
 are hard to 
compare because different methods of induction of pancreatitis were used, and the 
resulting pancreatic inflammation differed in severity between studies. However, some 
common trends can be identified. Experimental induction of pancreatitis did not 
generally lead to clinically significant changes in serum triglyceride or cholesterol 
concentrations. With regard to lipoproteins, a trend towards an increase in serum LDL 
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and HDL1 concentrations and a decrease in serum HDL2 concentration was evident in 
most studies.
18-20
 
 Finally, several relatively recent studies have been published that report the 
qualitative and quantitative apoprotein, enzyme, and/or fatty acid composition of 
lipoproteins in healthy and diseased dogs.
22-27
 In addition to the standard 
ultracentrifugation and electrophoresis methods for lipoprotein fractionation, these 
studies used other methods, including gas chromatography, size-exclusion 
chromatography-mass spectrometry, and enzyme activity assays, depending on the goal 
of each study. Important information regarding the composition of canine lipoproteins 
was reported in these studies. For example, one study reported the identification of 
apoprotein A-II in canine HDL molecules, which until then was believed to be absent in 
this species.
26
 In another study, it was confirmed that dogs have undetectable activities 
of cholesteryl-ester transfer protein (CETP), an enzyme responsible for transferring 
cholesterol among different types of lipoproteins that plays a key role in the so called 
reverse cholesterol transport.
24
 The results of this study explain at least in part the 
uniqueness of dogs with regard to cholesterol metabolism.     
 The standard methodological approach for lipoprotein fractionation and 
characterization in the vast majority of the reported studies has been ultracentrifugation 
and electrophoresis. Several variations of these techniques have been reported; however, 
the general principles remain the same. Ultracentrifugation has proven to be extremely 
useful in the evaluation of lipoproteins. The underlying principle is that lipoproteins are 
naturally arrayed in a variety of classes and subclasses that differ in their density. One of 
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the most commonly used ultracentrifugation techniques, especially in older studies, is 
sequential ultracentrifugation. The principle of this technique is the stepwise adjustment 
of non-protein solvent density by the addition of a dense solute (e.g., KBr). The 
sequential addition of dense solutes allows for the sequential (from the less dense to the 
most dense) separation of chylomicrons, VLDL, LDL, and HDL as separate classes. 
Clear separation of triglyceride-rich lipoproteins (i.e., chylomicrons, VLDLs) and 
lipoprotein subclasses is not always possible to achieve with this method. Density-
gradient ultracentrifugation is another method commonly used for lipoprotein 
fractionation studies. For this approach, solutions providing a stepwise decrement of 
density are layered in the tube, thus providing vertical stability. During 
ultracentrifugation, lipoproteins are distributed in the solution based on their densities. 
This technique is less time consuming than sequential ultracentrifugation, and with 
appropriate modifications allows for separation of subclasses of certain lipoproteins 
(LDL and HDL). The other standard methodology used for lipoprotein characterization 
(typically in combination with ultracentrifugation) is electrophoresis. Electrophoresis 
can be applied to whole serum or specific ultracentrifugation fractions. A variety of 
bands can be seen on the gel after electrophoresis (e.g., β, pre-β, α-lipoproteins). A 
complete lipoprotein analysis should include both ultracentrifugation and 
electrophoresis, and this combination has been used for the majority of studies on canine 
lipoproteins.  
 The above mentioned studies provide sufficient information on the major 
lipoprotein classes found in dogs. Healthy fasted dogs primarily have HDL molecules 
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and, in smaller concentrations, LDL and VLDL molecules. However, the existence and 
distribution of subclasses of these lipoproteins is less certain. Studies in humans using 
ultracentrifugation with novel density gradient solutions with or without affinity 
separation methods have revealed the existence of several subfractions of each of the 
major lipoproteins, with important health implications.
28-30
 The existence and 
significance of such lipoprotein subfractions has yet to be determined in dogs. 
 
Definitions 
The term hyperlipidemia refers to an increased concentration of lipids 
(triglycerides, cholesterol, or both) in the blood.
31-33
 More specifically, an increased 
blood concentration of triglycerides is referred to as hypertriglyceridemia, while an 
increased blood concentration of cholesterol is referred to as hypercholesterolemia. The 
term hyperlipoproteinemia refers to increased blood concentrations of lipoproteins, but it 
is often used interchangeably with the term hyperlipidemia.
34
 However, the term 
hyperlipoproteinemia should ideally be limited to cases where measurements of 
lipoprotein concentrations have been conducted.
31,34
 
The term lipemia is used to describe a turbid or lactescent appearance of serum 
or plasma.
31-33
 Lipemia is a result of hypertriglyceridemia, but not 
hypercholesterolemia.
31,33-35
 Mild hypertriglyceridemia does not cause lipemia. Usually, 
lipemia is apparent when serum triglyceride concentrations exceed 200 to 300 mg/dL.
34
 
As serum triglyceride concentrations increase, serum becomes turbid (cloudy) and then 
lactescent (milky).
31,33-35
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Hypertriglyceridemia is a relatively common clinicopathologic finding in dogs. 
In a study of 1,022 blood samples from both healthy and diseased dogs of various 
breeds, 5.4% had an increased serum triglyceride concentration, but the study did not 
include grossly lipemic samples.
36
 Postprandial hypertriglyceridemia is normal, and 
typically resolves within 7-12 hours after a meal, depending on the fat content of the 
meal.
14,37
 Persistent fasting hypertriglyceridemia is abnormal and can be either primary 
(most commonly idiopathic) or secondary to other diseases or drug administration.
37
 
 
Overview of canine lipoproteins and lipoprotein metabolism 
Canine lipoproteins can be divided into 4 major classes based on their hydrated 
density after ultracentrifugation: chylomicrons, very low density lipoproteins (VLDL), 
LDL, and HDL.
23,32,38
 In humans, a class of intermediate density lipoproteins (IDL) and 
lipoprotein (a) have also been identified. These 2 classes of lipoproteins have not been 
described in dogs.
39,40
 In addition, the existence of several other lipoprotein subclasses 
has been recently proposed for humans (LDL-1 through LDL-5, HDL-2a, HDL-2b, and 
HDL-3a through HDL-3b), but these subclasses have not been described in dogs to date.  
Canine chylomicrons consist of triglycerides, phospholipids, free and esterified 
cholesterol, and apo B48.
34,37,39-41
 Human chylomicrons also contain apo A-I and apo A-
IV, but this has not been reported in dogs.
34,37,39-41
 Human and canine VLDL molecules 
are formed by endogenously synthesized triglycerides, cholesterol, phospholipids, and 
apo B100, while canine VLDL molecules also contain B48.
39-41
 LDL molecules in humans 
contain mainly cholesteryl esters and B100, but in dogs they also contain B48.
37
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HDL molecules can be further subdivided into HDL1, HDL2, and HDL3.
8,31,32,37-40,42
 
HDLs play an important role as donors and acceptors of apolipoproteins C (I, II, III), apo 
E, and various lipids from other lipoproteins in the circulation.
32,37,39,40,43
 In humans, they 
also contain apo A-I, apo A-II, and apo A-IV. In dogs, HDL molecules have been 
reported to contain apo A-I,
8
 while other apo A proteins were reported to be absent.
44
 
However, recent evidence suggests that canine HDLs also contain apo A-II and apo A-
IV.
26
 HDLs play a fundamental role in the metabolic pathway known as the reverse 
cholesterol transport pathway (see below).
32,37,39,45
 Dogs appear to have predominantly 
HDLs (mainly HDL2, but also HDL3 and HDL1), and the majority of cholesterol (~85%) 
is found in HDL, while LDL is found in very low concentrations.
8,26,37
  
Lipid metabolism can be divided into 2 basic pathways: the exogenous pathway, 
which is associated with the metabolism of exogenous (dietary) lipids, and the 
endogenous pathway, which is associated with the metabolism of endogenously 
produced lipids.
37,39,40
 
 
Exogenous pathway 
The first step of dietary lipid metabolism is digestion.
41,46
 Dietary lipids that 
reach the duodenum undergo emulsification and are then hydrolyzed by gastric and 
pancreatic lipases.
41,46,47
 Hydrolysis products are transferred to the microvilli of the 
intestinal epithelial cell brush border in the form of micelles, where they diffuse through 
the epithelial cell membranes into the enteric mucosal cells.
41,46
 In the intestinal mucosal 
cell, free fatty acids and monoglycerides reassemble to form new triglycerides, which 
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then combine with phospholipids, free and esterified cholesterol, and the Apo B48 
protein to form chylomicrons.
34,37,39-41
 
Chylomicrons are the lipoprotein class responsible for transfer of dietary lipids. 
After formation in the enterocytes, chylomicrons, which mainly contain triglycerides, are 
secreted into the lacteals and enter first the lymphatic and later the blood circulation 
where they acquire apolipoproteins C and apo E from circulating HDL molecules.
34,37,39-
41
 Apolipoprotein C-II, which is exposed on the chylomicron surface, activates the 
lipoprotein lipase attached to the capillary beds in adipose and skeletal muscle tissues, 
which then hydrolyzes triglycerides into free fatty acids and glycerol.
34,37,39-41
 Free fatty 
acids enter the muscle cells (where they are used for energy production) and/or 
adipocytes (where they are re-esterified into triglycerides for storage). The cholesteryl-
rich remaining particles (chylomicron remnants), return their apo C-II molecule to HDL 
and are recognized by specific hepatic apo E receptors that rapidly remove them from 
the circulation by endocytosis.
34,37,39-41
 The cholesterol found in chylomicron remnants 
can be used for lipoprotein (VLDL) and/or bile acid formation or can be stored as 
cholesteryl esters.
34,41
 
 
Endogenous pathway 
While chylomicrons are responsible for transport of dietary lipids, VLDL, LDL, 
and HDL are mainly involved in the metabolism of endogenously produced lipids.
41
 
Endogenously synthesized triglycerides and cholesterol (and cholesteryl esters) combine 
with phospholipids, apo B100, and apo B48 to form VLDL.
37,39-41
 After VLDL molecules 
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reach the vasculature, they acquire apolipoproteins C and apo E from HDL.
34,37,39,40
 
VLDL apo C-II activates lipoprotein lipase located in the capillary beds, which in turn 
leads to hydrolysis of triglycerides and the production of free fatty acids and glycerol. 
The VLDL molecules remaining after hydrolysis of VLDL triglycerides (VLDL 
remnants), are either removed from the circulation in the liver or undergo further 
transformation by lipoprotein lipase and/or hepatic lipase to form LDL.
31,34,37,39-41
 
LDL, which contains mainly cholesteryl esters, circulates in the blood and binds to 
specific receptors that are widely distributed throughout tissues in order to deliver 
cholesterol, which can be used for the synthesis of steroid hormones and cell membranes 
and for hepatic metabolism.
39-41
 
HDL molecules, which are synthesized primarily in the liver, play an important 
role as donors and acceptors of apolipoproteins C, apo E, and various lipids from other 
lipoproteins in the circulation.
32,37,39,40
 They play a fundamental role in the reverse 
cholesterol transport pathway, through which cholesterol is transferred from peripheral 
tissues to the small circulating discoid HDL molecules, thus converting them to nascent 
HDL3 molecules. 
32,37,39,45
 Cholesterol is then esterified by the action of lecithin-
cholesterol acyltranferase (LCAT), and cholesteryl esters move to the core of the HDL3 
molecule, thus allowing more free cholesterol to get absorbed onto their surface. 
Continued absorption of free cholesterol and subsequent esterification by LCAT leads to 
the formation of the larger, cholesteryl ester-rich HDL2.
37,39,40,45
 In humans, an additional 
enzyme (cholesteryl ester transfer protein; CETP) is involved in this process but the 
presence of this enzyme has not been documented in dogs.
24,31,32,37,39,42,48
 The role of this 
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enzyme is to transfer triglycerides from LDL, VLDL, and chylomicrons to HDL2 in 
exchange for cholesteryl esters. This results in the production of cholesteryl ester-rich 
LDL and triglyceride-rich HDL2 molecules.
31,32,37,39,40
 Due to the absence of this enzyme 
in dogs, HDL2 molecules continuously acquire cholesteryl esters, resulting in the 
formation of HDL1 molecules, which are unique to dogs. Cholesteryl esters are 
transferred from various tissues to the liver for disposal or reuse through HDL1, rather 
than through LDL or VLDL molecules, which transfer cholesterol to peripheral 
tissues.
31,32,37
 Thus, it is this function of HDL1 that accounts for the lower incidence of 
atherosclerotic disorders in dogs compared to humans.
31
 
 
Hyperlipidemia in dogs 
Postprandial hyperlipidemia is physiologic and typically resolves within 7-12 
hours after a meal, depending on the fat content of the meal.
14,31,37,49
 Therefore, any 
determination of serum lipid concentrations should always follow a fast of at least 12 
hours. Persistent fasting hyperlipidemia is abnormal and can be either primary or 
secondary to other diseases or drug administration.  
 
Secondary causes of hyperlipidemia 
Secondary hyperlipidemia is the most common pathologic form of 
hyperlipidemia in dogs.
50
 Several diseases have been reported to cause hyperlipidemia.  
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Endocrine disease 
Most commonly, canine hyperlipidemia is the result of an endocrine disorder, 
such as hypothyroidism, diabetes mellitus, or hyperadrenocorticism.
21,31,37,49,51,52
 
Increases of both serum triglyceride and cholesterol concentrations have been reported in 
dogs with hypothyroidism.
21,53-56
 In 1 study, hypertriglyceridemia and 
hypercholesterolemia were found in 88% and 78% of dogs with hypothyroidism, 
respectively.
53
 Usually, lipid abnormalities resolve after treatment of hypothyroidism.
21
 
In dogs with diabetes mellitus, hyperlipidemia is most commonly associated with 
hypertriglyceridemia, but hypercholesterolemia can also occur.
21,31,49,51,54,57
 
Hypertriglyceridemia usually resolves after successful management of diabetes mellitus, 
but hypercholesterolemia might persist despite therapy.
49,58
 Finally, both naturally 
occurring hyperadrenocorticism and iatrogenic Cushing’s disease have been associated 
with hyperlipidemia (hypertriglyceridemia and/or hypercholesterolemia) in 
dogs.
31,37,49,51,54,59,60
 Hypertriglyceridemia might be present more frequently than 
hypercholesterolemia and increases of both types of lipids are usually mild or 
moderate.
31,37,51
 
 
Pancreatitis 
The presence of hyperlipidemia (hypertriglyceridemia and/or 
hypercholesterolemia) has long been associated with naturally occurring pancreatitis in 
dogs.
21,31,37,49,52,61-66
 However, it remains uncertain whether hyperlipidemia develops as a 
result of pancreatitis or can be the cause of pancreatitis in some cases.
49,66
 In models of 
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experimentally induced pancreatitis in dogs, hyperlipidemia does not develop after 
induction of pancreatitis.
18-20
 However, the role of naturally occurring pancreatitis in the 
development of secondary hyperlipidemia is unknown. Thus, based on the current 
literature, it is possible either that hyperlipidemia is a preexisting abnormality in some 
dogs with naturally occurring pancreatitis, which might or might not contribute to the 
development of the disease, or that naturally occurring pancreatitis differs in its ability to 
produce hyperlipidemia from the experimental models of pancreatitis applied in the 
above mentioned studies. 
 
Obesity 
Increased serum triglyceride and/or cholesterol concentrations have been 
observed in obese dogs.
11,12,67
 The most profound changes were associated with severe 
chronic obesity.
12
 Weight loss in obese dogs leads to significant decreases of both serum 
triglyceride and cholesterol concentrations.
12,68
 
 
Protein losing nephropathy (PLN) 
Proteinuria associated with PLN, regardless of the cause, is often associated with 
hyperlipidemia in dogs. The typical lipid abnormality in dogs with PLN is 
hypercholesterolemia, which is usually mild or moderate.
69-73
 
Hypercholesterolemia is usually part of a more complex syndrome, the nephrotic 
syndrome, which in addition to hypercholesterolemia, is characterized by 
hypoalbuminemia, proteinuria, and ascites.
31,37
 Hypercholesterolemia has been reported 
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with varying frequencies in dogs with acquired glomerular disease and proteinuria, as 
well as in several hereditary forms of PLN (e.g., in Chinese Shar-Peis and Golden 
Retrievers).
69-73
 
 
Cholestasis 
Cholestasis has been reported to lead to mild or moderate hypercholesterolemia 
and mild hypertriglyceridemia in dogs.
49,74,75
 Changes in lipoproteins, most importantly 
excessive esterification of lipoprotein cholesterol, have also been reported in dogs with 
experimentally induced cholestasis.
76,77
 
 
Other causes 
Several other causes of hyperlipidemia have been reported or suspected in dogs. 
These include high fat diets, lymphoma, infection with Leishmania infantum, congestive 
heart failure due to dilated cardiomyopathy, and administration of certain drugs (e.g., 
glucocorticoids, estrogen, phenobarbital, and potassium bromide).
14,78-81
 Finally, in a 
recent study, significantly increased serum triglyceride concentrations were reported in 
association with other lipid abnormalities in dogs with parvoviral enteritis.
82
 
 
Primary causes of hyperlipidemia in dogs 
Primary lipid abnormalities are usually, but not always, associated with specific 
breeds. Depending on the breed, the prevalence of primary lipid abnormalities can vary 
widely.  
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Primary hyperlipidemia in Miniature Schnauzers 
Primary hyperlipidemia in Miniature Schnauzers was the first breed-related 
primary lipid disorder described in dogs.
15,17,34,37,49,83
 This condition was first reported 
more than 30 years ago in Miniature Schnauzers in the United States.
15,17,49,83
 It is 
characterized by an abnormal accumulation of VLDL or a combination of VLDL and 
chylomicrons. Although hypercholesterolemia may also be present, this finding is not 
consistent.
17,49,83
 A recent study has shown that primary hypertriglyceridemia is common 
in healthy Miniature Schnauzers in the United States, being present in 32.8% of 192 
healthy Miniature Schnauzers investigated.
84
 However, hypertriglyceridemia was much 
more prevalent among older dogs; more than 75% of healthy Miniature Schnauzers ≥ 9 
years of age had hypertriglyceridemia. In addition, the severity of hypertriglyceridemia 
increased with age and the vast majority (> 80%) of Miniature Schnauzers with 
moderate to severe hypertriglyceridemia were ≥6 years of age.84 There was no difference 
between male and female Miniature Schnauzers with regard to the prevalence of 
hypertriglyceridemia. These findings would suggest that hypertriglyceridemia of 
Miniature Schnauzers is the most common primary lipid disorder in dogs. It has been 
recommended that all Miniature Schnauzers in the United States should be evaluated for 
hypertriglyceridemia while they are healthy, because this information may be useful for 
the avoidance of misinterpretation of increased serum triglyceride concentrations when 
the dogs are presented for a clinical illness.
84
 In addition, knowing the serum triglyceride 
status of the dog, the veterinarian might consider offering to switch the affected dog to a 
low-fat diet to avoid possible complications of hypertriglyceridemia. Due to the fact that 
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hypercholesterolemia was found only in association with hypertriglyceridemia, the 
presence of hypercholesterolemia alone in Miniature Schnauzers might require 
additional diagnostic investigation. 
The cause of primary hypertriglyceridemia in Miniature Schnauzers is unknown. 
The fact that hypertriglyceridemia is highly prevalent within a single breed suggests a 
genetic cause.
15,17,83
 Because lipoprotein lipase is the major enzyme involved in 
triglyceride clearance, deficiency of this enzyme has been considered as a possible cause 
of hypertriglyceridemia in this breed.
15,17,83
 The crucial role of lipoprotein lipase in 
lipoprotein metabolism has been demonstrated in experimental animals (knockout mice), 
cats, dogs, and humans with lipoprotein lipase deficiency, which leads to severe 
hypertriglyceridemia.
85,86
 However, a pilot study in Miniature Schnauzers with 
hypertriglyceridemia and pancreatitis failed to identify any mutations of the lipoprotein 
lipase gene, suggesting that inherited lipoprotein lipase dysfunction might not be the 
cause of hypertriglyceridemia in this breed.
87
 In that particular study, however, dogs had 
both hypertriglyceridemia and pancreatitis, and the hypertriglyceridemia might have 
been a result of pancreatitis rather than the underlying condition.  
Another plausible explanation for hypertriglyceridemia in Miniature Schnauzers 
is apo-CII deficiency. Deficiency of this enzyme was first described in 1978 by 
Breckenridge et al. in a human patient with severe hypertriglyceridemia.
88
 Since then 
several reports of apo C-II deficient patients have been published and the abnormal apo 
C-II protein has been sequenced.
89-96
 To date, at least 16 mutations of the apo C-II gene 
have been reported in humans.
97-111
  In a recent preliminary study, the gene encoding 
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apolipoprotein C-II, which is an activator of lipoprotein lipase, was evaluated for the 
presence of possible mutations in Miniature Schnauzers with primary 
hypertriglyceridemia. However, no variants of the apo-CII gene were found to be 
associated with hypertriglyceridemia.
112
 Further studies are warranted to identify the 
genetic basis of primary hypertriglyceridemia in Miniature Schnauzers. 
Until recently, primary hypertriglyceridemia was considered to be a relatively 
benign condition in Miniature Schnauzers. However, recent studies indicate that 
hypertriglyceridemia in Miniature Schnauzers might be associated with pancreatitis, 
hepatobiliary disease, ocular disease, seizures, or possibly other conditions (for further 
discussion on this topic please see “Clinical signs and complications of hyperlipidemia” 
on page 18).  
 
Primary hyperlipidemia in other dog breeds 
Primary hypercholesterolemia without hypertriglyceridemia has been 
documented in 15 Briards from the United Kingdom (UK).
35
 A similar condition has 
also been described in a family of rough-coated Collies also from the UK.
16
 A slightly 
different condition of primary hypercholesterolemia with or without concurrent 
hypertriglyceridemia has been reported in Shetland Sheepdogs.
113
 The cause of these 
lipid abnormalities that mainly involve cholesterol metabolism has not yet been 
determined, but hereditary factors were suspected.
16,35,113
 In addition, primary 
hypercholesterolemia has been reported anecdotally in Doberman Pinschers and 
Rottweilers.
114
 
 18 
Primary hyperlipidemia with hypercholesterolemia and hypertriglyceridemia has 
been reported in 2 related Beagles.
115
 Finally, primary hypertriglyceridemia has been 
reported in 2 related Brittany Spaniels and 1 mixed-breed 28-day old puppy.
116,117
  
 
Clinical signs and complications of hyperlipidemia  
In general, dogs with secondary hyperlipidemia display clinical signs associated 
with the primary disorder. In contrast, dogs with primary lipid disorders are often 
asymptomatic for long periods or throughout their lives, depending on many factors, 
including the type and severity of hyperlipidemia. However, some dogs with 
hyperlipidemia develop secondary diseases as a result of hyperlipidemia that may 
account for the development of specific clinical signs.  
 
Pancreatitis 
 For a detail discussion on this topic please see “Relationship between 
hyperlipidemia and pancreatitis” on page 47. 
 
Hepatobiliary disease 
Clinical studies and anecdotal observations suggest that 2 hepatic disorders might 
be associated with hypertriglyceridemia in dogs: vacuolar hepatopathy and gallbladder 
mucocele.
118,119
 Hyperlipidemia-associated vacuolar hepatopathy has been anecdotally 
associated with hyperlipidemia in Miniature Schnauzers. Also, a gallbladder mucocele 
has been commonly reported in dog breeds that are predisposed to idiopathic 
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hyperlipidemia (e.g., Miniature Schnauzers and Shetland Sheepdogs), and 
hyperlipidemia has been implicated as a cause of gallbladder disease in humans.
120-122
 In 
a recent study, an association between gallbladder mucocele formation and 
dyslipidemias (hypertriglyceridemia and hypercholesterolemia) was described in 
Shetland Sheepdogs.
121
 In this study, many of the dogs with a gallbladder mucocele had 
no clinical signs or biochemical abnormalities, except for an increased serum ALP 
activity in some cases.
121
 Although asymptomatic in many dogs, both vacuolar 
hepatopathy and gallbladder mucocele can be associated with significant morbidity and 
even mortality. 
In a recent study, idiopathic hypertriglyceridemia (especially ≥ 400 mg/dL) was 
found to be associated with increased serum hepatic enzyme activities in healthy 
Miniature Schnauzers.
123
 In that study, 60% and 45% of the Miniature Schnauzers with 
serum triglyceride concentrations ≥ 400 mg/dL had increased serum ALP and ALT 
activities, respectively. In contrast, 0% and 9% of the Miniature Schnauzers with normal 
serum triglyceride concentrations had increased ALP and ALT activities, respectively. 
Whether or not such cases require additional diagnostic investigation of the cause of the 
liver disease remains to be determined. Given the fact that in this particular study most 
dogs had increases in more than 1 serum liver enzyme activity that were considered 
significant (i.e., > 2 times the upper limit of the reference range), additional diagnostic 
work-up and/or retesting would appear to be appropriate. 
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Atherosclerosis 
Although dogs appear to be resistant to atherosclerosis due to their lipoprotein 
composition and metabolism, they have been reported to develop atherosclerosis in both 
experimental and clinical studies.
9,10,124-126
 Spontaneous atherosclerosis has been 
reported in dogs mainly in association with secondary hypercholesterolemia due to 
endocrinopathies.
124,126
 In 1 study, 60% of 30 dogs with atherosclerosis had 
hypothyroidism and 20% had diabetes mellitus.
126
  
 
Ocular disease  
Several ocular manifestations of hyperlipidemia, such as lipemia retinalis, 
lipemic aqueous, and lipid keratopathy have been reported in dogs.
127
 Recently, solid 
intraocular xanthogranuloma formation was reported as a unique disorder of 
hyperlipidemic Miniature Schnauzers.
128
  
 
Other possible complications of hyperlipidemia 
Seizures and other neurologic signs have been reported to occur potentially as a 
result of severe hyperlipidemia in dogs.
15,34,129,130
 However, the relationship between 
these disorders remains obscure in dogs. Also, some authors report that hyperlipidemia 
can cause clinical signs of abdominal pain, lethargy, vomiting, and/or diarrhea without 
evidence of pancreatitis or other diseases.
33,83
 This is highly speculative, however, 
because published reports are lacking and, given the difficulty in diagnosing pancreatitis 
especially in past decades, pancreatitis could have easily been missed in these patients.  
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Treatment of hyperlipidemia 
The initial step in the treatment of hyperlipidemia is the determination of whether 
the patient has a primary or a secondary lipid disorder.
31,33,52
 Thus, specific diagnostic 
investigations should be performed in order to diagnose or rule-out diseases that can 
cause secondary hyperlipidemia. Treatment of secondary hyperlipidemia relies on the 
successful treatment of the underlying disorder after which hyperlipidemia usually 
resolves.
31,33,49,52
 Resolution of secondary hyperlipidemia after treatment of the cause 
should always be confirmed by laboratory testing (usually 4-6 weeks after correction of 
the primary disease). If hyperlipidemia has not resolved, a wrong diagnosis, ineffective 
treatment, or concurrent primary or secondary hyperlipidemia due to other causes should 
be considered. 
After secondary causes of hyperlipidemia have been ruled out, a presumptive 
diagnosis of a primary lipid disorder can be made.
49
 It has been anecdotally 
recommended that hypertriglyceridemia that exceeds 500 mg/dL should be treated in 
order to avoid possible complications.
33,49
 It also has been recommended that the 
treatment goal should be to keep fasting serum triglyceride concentrations below 500 
mg/dL.
33
 Primary hypercholesterolemia is usually associated with less severe 
complications compared to hypertriglyceridemia. Treatment of hypercholesterolemia 
should aim to lower serum cholesterol concentrations below 500 mg/dL. 
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Dietary management 
 Typically, the first step in the management of primary hyperlipidemia is dietary 
modification.
31,33,49,52
 Dogs with primary hyperlipidemia should be offered a low-fat diet 
throughout their lives.
33
 Diets that contain less than 25 g of fat per 1,000 Kcal are 
recommended.
31,33,131
 Many commercially available diets are suitable for dogs with 
primary hyperlipidemia. Also, many home-made low-fat diets (e.g., boiled lean turkey 
breast and rice) are suitable for these dogs, but care should be taken to make sure that 
these diets are balanced. Treats and table scraps should be avoided unless they are low in 
fat.
131
 Serum lipid concentrations should be re-evaluated after feeding a low-fat diet for 
about 3-4 weeks.
33
 If the serum triglyceride concentration has decreased to < 500 mg/dL, 
dietary therapy should be continued and the new diet should be offered for the rest of the 
animal’s life, and serum triglyceride concentrations should be re-evaluated intermittently 
every 6 months.
33
 In dogs that do not sufficiently respond to low-fat diets, an ultra low-
fat diet (< 20 g of fat per 1,000 Kcal) can be offered, or medical treatment can be 
initiated.
131
 
 
Medical management 
 Some dogs with primary hyperlipidemia will not sufficiently respond to feeding a 
low or ultra low-fat diet alone, especially when hypertriglyceridemia is due to 
endogenously formed triglycerides.
32-34,83
 In these cases, medical treatment is required in 
addition to the low-fat diet in an effort to effectively reduce serum lipid 
concentrations.
32,83
 It needs to be pointed out that no studies have evaluated the efficacy 
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of lipid-lowering drugs in dogs, and therefore, evidence-based recommendations cannot 
be made.  
 Polyunsaturated fatty acids of the n-3 series (omega-3 fatty acids) are abundant 
in marine fish.
132
 Omega-3 fatty acid supplementation, usually in the form of fish-oil, 
has been shown to lower serum lipoprotein concentrations in humans with primary 
hypertriglyceridemia, normal humans, and experimental animals.
133,134
 In a recent study 
in healthy dogs, fish-oil supplementation led to a significant reduction of serum 
triglyceride concentrations, suggesting that this supplement may be helpful in the 
treatment of primary canine hypertriglyceridemia.
135
 No major side effects were 
observed.
135
 However, studies evaluating the efficacy of fish-oil supplementation in dogs 
with hyperlipidemia are lacking and clinical experience is limited. Because side effects 
are rarely reported and because omega-3 fatty acids maybe effective in lowering 
lipidemia, some authors recommend that fish-oil should be administered in dogs with 
primary hypertriglyceridemia that do not respond to a low-fat diet alone.
31,34,132,135
 
Menhaden fish-oil capsules have been successfully used at doses ranging from 220-330 
mg/kg of body weight once a day.
34,135
 Periodic retesting of serum triglyceride 
concentrations is recommended during treatment.   
 Gemfibrozil belongs to the group of fibric acid derivatives and has been reported 
to reduce serum triglyceride concentrations in both healthy humans and patients with 
hypertriglyceridemia.
136,137
 In dogs, its use is anecdotal and it is usually administered at a 
fixed dose of 200 mg/day.
34
 Because side effects are believed to be minimal and only 
occur rarely, gemfibrozil is commonly recommended in combination with dietary 
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therapy when the latter fails to lower serum triglyceride concentrations below 500 
mg/dL.
34,49
  
 Niacin is a vitamin that has been used successfully for the treatment of 
hyperlipidemia in humans for many years.
138
 In dogs, niacin treatment has been reported 
in very few patients with primary hypertriglyceridemia. Niacin reduced serum 
triglyceride concentrations for several months without causing any side effects.
31,34,49
 
However, large clinical trials regarding the efficacy and safety of niacin in dogs with 
primary hypertriglyceridemia are lacking. As is the case in humans, niacin 
administration in dogs is potentially associated with side effects such as erythema and 
pruritus.
34,138
 Niacin is usually administered at a dose of 25-100 mg/day.
34
 
 
Pancreatitis in dogs 
History of the study of pancreatitis in dogs 
The first known studies that involved the canine pancreas were reported several 
centuries ago. In 1682, J. C. Brunner published his book Experimenta Nova Circa 
Pancrease, in which he described his interesting experiments on dogs, in an effort to 
determine the role the pancreas in digestion.
139
 Since then, several other studies, 
including the famous work published by J.P. Pawlow in 1897 entitled The Work of the 
Digestive Glands, have investigated mainly the function of the canine pancreas, but 
always as model for understanding human pancreatic physiology.
139
 Although 
pathologic conditions of the human pancreas (most likely representing inflammatory 
diseases of the pancreas) had been noticed and described in antiquity, centuries before 
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the understanding of the function of the pancreas, pancreatitis in humans was described 
in more detail as a disease entity in the late 19
th
 century.
139
 Following that, several 
studies of experimentally induced pancreatitis in dogs were reported, which initially had 
the sole goal to study human disease in canine models.
140-143
 However, later, 
experimental studies were also designed to study canine disease.
144-149
 Although these 
experimental studies provided some initial information about pancreatitis in dogs, it was 
later recognized that experimentally-induced pancreatitis does not mirror the 
spontaneous disease. This lack of clinical applicability of findings from experimental 
studies as well as the invasiveness of experimentally-induced pancreatitis dramatically 
limited the number of such studies.   
Before the 1930s, canine pancreatitis was either not mentioned as a disease entity 
in veterinary textbooks at all or it only was mentioned in veterinary pathology textbooks 
as an extremely rare condition that was only diagnosed during necropsy.
150
 The first 
reports of spontaneous canine pancreatitis in English were published in the 1930s and 
1940s, and up until the 1950s each described isolated or a very small number of 
cases.
151-153
 The first published case series that investigated canine pancreatitis in more 
detail appeared in the 1960s.
61
 These studies provided the first comprehensive 
information on clinical presentation and histopathology of canine pancreatitis. Due to the 
lack of sensitive and specific tests for the diagnosis of canine pancreatitis in a clinical 
setting at that time, the diagnosis was based almost solely on necropsy and 
histopathologic findings and therefore these studies included mainly patients with severe 
pancreatitis that either died or were euthanized as a result of pancreatitis. Several studies 
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followed from the 1970s until today that investigated the etiology, clinical presentation, 
diagnosis, prediction of severity, and histopathology of spontaneous canine pancreatitis. 
In contrast, there has almost been a complete lack of studies evaluating treatment 
modalities in canine pancreatitis.   
 
Definitions 
Strictly speaking, pancreatitis refers to an inflammation (i.e., infiltration with 
inflammatory cells) of the exocrine pancreas. However, the term pancreatitis is 
commonly expanded also to include diseases of the exocrine pancreas characterized 
mainly by necrosis that may have a minimal inflammatory component (often referred to 
as acute pancreatic necrosis or necrotizing pancreatitis).
154
 It is widely believed that 
pancreatic necrosis is associated with a severe and often fatal course of disease, while 
pancreatitis without necrosis (e.g., edematous interstitial pancreatitis) is usually mild. 
However, no convincing evidence currently exists to support this assumption in clinical 
cases of canine pancreatitis.  
Pancreatitis is generally divided into acute (which typically includes acute 
pancreatic necrosis) and chronic forms, based on the absence or presence of permanent 
histopathologic lesions, such as pancreatic fibrosis and/or atrophy. The term recurrent 
acute pancreatitis is sometimes used to describe recurrent episodes of pancreatitis that 
are not associated with permanent histopathologic changes. A plethora of other clinical 
(e.g., mild or severe, fatal or non-fatal) and histopathological (e.g., edematous, 
interstitial, necrotizing, neutrophilic, lymphocytic) terms have been used to further 
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classify pancreatitis in dogs. However, no universally standardized terminology for 
pancreatitis has been agreed upon for veterinary species, and different authors classify 
pancreatitis differently. It is not clear at this time whether the different forms of 
pancreatitis (e.g., acute edematous pancreatitis, acute pancreatic necrosis, chronic 
pancreatitis) represent different phenotypes of the same disease or distinct disease 
entities, whether they share the same etiologic and pathogenetic mechanisms, or which 
factors determine the development of each form. 
 
Pathogenesis and pathophysiology 
Most of our understanding regarding the pathogenesis of pancreatitis is based on 
animal models and some clinical studies in humans. There is mounting evidence that 
genetic and possibly environmental factors may sensitize the pancreas to injury induced 
by one or more etiologic factors.
155,156
 Regardless of the actual etiology, there appears to 
be a common pathogenetic mechanism in most cases of acute pancreatitis. Evidence 
supports that the initiating events that lead to pancreatitis take place in the acinar cell. 
Two well-documented early intracellular events that have been shown to precede the 
development of acute pancreatitis are retention and intracellular activation of 
zymogens.
155,156
 Zymogens are inactive precursors of pancreatic enzymes that are stored 
in zymogen granules and are normally secreted into the pancreatic duct through the 
apical membrane of the acinar cell. The factors that lead to retention of zymogen 
granules and to premature intracellular activation of the zymogens are not fully 
elucidated. One of the most popular theories is the co-localization theory.
155,156
 Based on 
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this theory, zymogen granules that are accumulating in acinar cells co-localize with 
lysosomes. Lysosomal enzymes, such as cathepsin B, are then thought to activate 
trypsinogen into trypsin, which subsequently activates other zymogens. Evidence from 
other studies indicate that the cytosolic concentration of free ionized calcium also plays 
an important role in the intracellular activation of zymogens.
157-159
 In addition to the 
decreased secretion and intracellular activation of pancreatic enzymes, there is evidence 
of disruption of the paracellular barrier in the pancreatic duct that allows its contents to 
leak into the paracellular space, and also redirect the secretion of zymogen granules from 
the apical pole to the basolateral region of the acinar cell and into the interstitial space.
156
 
Once intracellular activation of pancreatic enzymes has taken place, autodigestion of the 
acinar cell follows and activated enzymes escape, initially into the pancreatic tissue 
(leading to local effects) and subsequently into the peritoneal cavity and the systemic 
circulation (potentially contributing to systemic effects). Local effects vary and can 
range from mild interstitial edema to severe acinar cell necrosis, hemorrhage, and 
peripancreatic fat necrosis. The extent and severity of local effects determine to a large 
degree the systemic response. Acinar cell injury leads to recruitment and activation of 
inflammatory cells (most importantly neutrophils and macrophages), which release 
proinflammatory cytokines and other inflammatory mediators (such as interleukin [IL]-
1, IL-2, IL-6, IL-18, tumor necrosis factor-α, substance P, platelet-activating factor 
[PAF]) that play a crucial role in modulating systemic complications of the disease.
155,160
 
Such systemic complications can include cardiovascular shock, acute renal failure, 
neurologic abnormalities, disseminated intravascular coagulation (DIC), systemic 
 29 
inflammatory response syndrome (SIRS), acute respiratory failure, and/or multiple organ 
failure, and can be seen in cases of severe acute pancreatitis.
155,160
 
 
Etiologic and risk factors 
In contrast to humans, in whom an etiology of pancreatitis can be identified in 
the vast majority of cases, the etiology of pancreatitis in dogs usually remains unknown 
(idiopathic pancreatitis).
161,162
 It is expected, however, that recognition of new causes of 
canine pancreatitis will allow etiologic classification in a bigger proportion of cases in 
the future. Several factors have been reported as risk factors for pancreatitis in dogs, but 
the majority of these factors have been implicated by association, and therefore, very 
few definitive causes of pancreatitis have actually been reported.
161
 The main causes of 
human pancreatitis (i.e., biliary obstruction and alcoholism) do not represent common 
problems in small animals.
155,162
 Other well defined causes of human pancreatitis (e.g., 
autoimmune pancreatitis) have not been proven in dogs as of yet.  
 
Breed 
Several dog breeds have been reported to be at increased risk for pancreatitis, 
although findings among studies are not always in agreement with each other. A breed 
predisposition most likely reflects either a genetic cause of pancreatitis or a 
predisposition to other diseases or conditions that are risk factors for pancreatitis (e.g., 
hypertriglyceridemia in Miniature Schnauzers). Differences with regard to breed 
predisposition probably exist among different geographic regions, as blood-lines might 
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be quite different, especially in older breeds that were introduced to a geographic region 
several decades ago. Miniature Schnauzers, Yorkshire Terries, and Terriers in general 
have all been consistently shown to have a higher odds of pancreatitis.
63-65,163
 Boxers, 
Cavalier King Charles Spaniels, Cocker Spaniels, and Collies have been shown to be 
overrepresented in a cohort of dogs with chronic pancreatitis in the United Kingdom.
164
 
 
Hypertriglyceridemia 
Hypertriglyceridemia has long been suspected to be a risk factor for pancreatitis 
in dogs, but convincing evidence is lacking.
64,65,165
 A definitive etiological association 
between hypertriglyceridemia and pancreatitis has been difficult to prove, mainly due to 
the fact that hypertriglyceridemia may be the result of pancreatitis rather than the cause. 
(For the association between hypertriglyceridemia and pancreatitis please see 
corresponding section on page 47). 
 
Hereditary pancreatitis 
In a recent study, a combination of 3 variants of the serine protease inhibitor 
Kazal type 1 (SPINK1) gene was identified in Miniature Schnauzers, and an association 
of these variants with pancreatitis was demonstrated.
166
 Mutations of the SPINK1 gene, 
although different from those described in Miniature Schnauzers, have also been 
described and associated with pancreatitis in humans.
167
 The product of the SPINK1 
gene, pancreatic secretory trypsin inhibitor (PSTI), is found in acinar cells and acts as 
one of the defensive mechanisms against prematurely activated trypsin. It is possible that 
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the mutant protein lacks this function, thereby leaving the acinar cell more susceptible to 
injury, although this has not been convincingly shown in either humans or dogs. Thus, 
the exact role of variants of the SPINK1 gene in the development of pancreatitis in 
Miniature Schnauzers remains to be determined. It has been hypothesized that mutations 
of this gene may not actually cause pancreatitis, but may sensitize the pancreas to injury 
through other factors. Based on the fact that some breeds have been found to be 
overrepresented in some reports, genetic causes of pancreatitis have also been suspected 
in other breeds (e.g., Yorkshire Terriers).
64
 
 
Diet 
The role of diet, and more specifically the fat content of the diet, in the 
development of canine pancreatitis remains largely unclear. Based on anecdotal clinical 
observations, foods high in fat increase the risk of pancreatitis. Older experimental 
studies have suggested that diets with a very high fat content may induce pancreatitis 
and may increase the severity of experimentally induced pancreatitis in dogs.
144,165
 The 
mechanism by which high-fat diets increase the risk for pancreatitis is not known, but it 
is possible that high-fat diets may predispose dogs to pancreatitis through 
hypertriglyceridemia as a result of a fatty meal. In a recent retrospective case-control 
study of dogs, several factors such as getting into the trash, consuming table scraps, and 
ingestion of “unusual” food were found to be associated with increased odds of 
pancreatitis.
163
 However, no specific foods were identified that could be associated with 
an increased risk of pancreatitis.  
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Drugs 
As in humans, drug-induced pancreatitis has been reported mainly in the form of 
case reports or case series, but a cause-and-effect relationship has not been established 
for most cases.
168
 Nevertheless, a history of drug administration in conjunction with 
compatible findings should raise a concern for pancreatitis due to a pharmacological 
substance. Based on the remarkably large number of drugs prescribed in both human and 
veterinary medicine, and the fact that drug-induced pancreatitis appears to be quite rare, 
most drugs implicated are thought to cause pancreatitis in an idiosyncratic fashion. 
Theoretically, any drug can potentially cause pancreatitis. However, pancreatitis seems 
to be more commonly associated with the use of certain drugs. Drugs believed to be 
most commonly associated with pancreatitis in dogs include potassium bromide, 
phenobarbital, L-asparaginase, azathioprine, and meglumine antimonate.
169-171
  
 
Endocrine disease 
In 1 study, hyperadrenocorticism, hypothyroidism, and diabetes mellitus were 
reported to be more commonly present in dogs with pancreatitis than in dogs with no 
evidence of pancreatitis.
65
 In another study, 13% of 221 dogs with diabetes mellitus were 
reported to have pancreatitis.
172
 However, evidence is currently far from convincing that 
these endocrine diseases represent risk factors for canine pancreatitis. It has been 
hypothesized that hypertriglyceridemia associated with these endocrine diseases might 
be a more significant risk factor for pancreatitis in dogs than the conditions themselves. 
Also, diabetes mellitus may be an effect of pancreatitis rather than a cause.  
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Obesity 
A relationship between obesity and pancreatitis has been suggested for dogs. 
Studies have shown that dogs diagnosed with pancreatitis are more frequently obese than 
dogs that do not have pancreatitis.
64,65,163
 However, a pathogenetic link between obesity 
and pancreatitis has not been convincingly shown to date.   
 
Other factors 
Age is often listed as a risk factor for pancreatitis because most dogs with 
pancreatitis are middle aged or older. No clear sex predisposition has been identified to 
date. Hypotension (e.g., during anesthesia or after severe blood loss), hypercalcemia 
(both iatrogenic and as a result of diseases such as neoplasia and hyperparathyroidism), 
abdominal trauma, extensive surgical manipulation of the pancreas, certain infections 
(e.g., an infection with certain Babesia spp. strains) and obstruction  of the pancreatic 
duct (e.g., due neoplasia) are also suspected risk factors for pancreatitis in dogs, but 
scientific evidence is weak or lacking at this point.
161,173
 Chronic gastrointestinal disease 
might also be a risk factor for pancreatitis in dogs.
174
 Primary or metastatic neoplasia of 
the pancreatic parenchyma is often associated with secondary inflammation of the 
exocrine pancreas. Previous surgery and epilepsy have also been reported as potential 
risk factors for canine pancreatitis.
65,163
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Signalment 
Dogs of any age, breed, or sex can develop pancreatitis. In several reports, most 
affected dogs are middle-aged to older.
63,65
 Miniature Schnauzers and Yorkshire Terriers 
appear to be at increased risk for pancreatitis, while a predisposition for other breeds is 
less clear.
64,65,161,163
 In 1 study some other breeds (e.g., Boxers, Cavalier King Charles 
Spaniels, Cocker Spaniels, and Collies) have been suggested to be predisposed to 
chronic pancreatitis, but this has not been confirmed by other studies.
164
 No clear sex 
predisposition has been identified.  
 
Clinical signs and physical examination findings  
It has been recognized that dogs with pancreatitis can be subclinical or present 
with a wide variety of clinical signs, ranging from mild partial anorexia with no apparent 
gastrointestinal signs to severe systemic signs with cardiovascular shock and DIC. There 
is no single clinical sign or combination of clinical signs that is pathognomonic for 
pancreatitis in dogs. Clinical signs have been well described in dogs with severe acute 
pancreatitis and may include anorexia (91%), vomiting (with or without blood; 90%), 
weakness (79%), polyuria and polydipsia (50%), and diarrhea (with or without blood; 
33%).
64
  Many of the clinical signs reported in dogs with pancreatitis are likely to be the 
result of complicating or concurrent diseases rather than pancreatitis per se (e.g., 
polyuria and polydipsia are more likely to be the result of concurrent diabetes mellitus). 
The most common physical examination findings in dogs with severe acute pancreatitis 
include dehydration (97%), abdominal pain (58%), fever (32%), and icterus (26%).
64
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The combination of vomiting and abdominal pain, although suggestive of pancreatitis, is 
also seen with other diseases (e.g., gastrointestinal foreign bodies, peritonitis). Other 
possible findings include shock, hypothermia, a cardiac murmur, tachycardia, bleeding 
diathesis, ascites, a palpable abdominal mass, and/or harsh lung sounds.
64
 Patients with 
less severe or chronic pancreatitis typically manifest less profound clinical signs, such as 
anorexia and depression, or might even be subclinical. 
 
Clinical pathology
64,175
 
Results of complete blood count (CBC), serum biochemistry profile, and 
urinalysis are nonspecific, and thus of limited usefulness for the diagnosis of pancreatitis 
in dogs. However, these tests should always be performed in dogs with suspected 
pancreatitis because they are useful for ruling out other differential diagnoses and also 
provide important information about the systemic condition of the animal. 
Often, especially in mild cases, the CBC, serum biochemistry profile, and 
urinalysis are normal. Possible hematologic findings in dogs with pancreatitis include 
anemia or hemoconcentration, leukocytosis or leucopenia, and thrombocytopenia. 
Evidence of coagulopathy, such as prolonged activated clotting time (ACT), 
prothrombin time (PT), and/or partial thromboplastin (PTT) time, are seen in some 
cases, and may or may not be associated with spontaneous bleeding. In other cases, there 
might be clinical evidence suggestive of DIC, such as thrombocytopenia, prolongation of 
clotting times (i.e., ACT, PT, PTT), and a positive d-dimer test. Different combinations 
of increases in liver enzyme activities and hyperbilirubinemia are common and might 
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erroneously direct the clinician to suspect primary liver disease. Increases in serum 
creatinine and blood urea nitrogen (BUN) concentrations are variable and most often 
associated with dehydration due to vomiting, diarrhea, and/or decreased water intake. In 
severe cases, azotemia might be the result of secondary renal failure. Other possible 
findings include hypoalbuminemia, hypertriglyceridemia, hypercholesterolemia, and 
hyperglycemia or hypoglycemia. Electrolyte abnormalities are commonly present and 
variable, with hypokalemia, hypochloremia, and/or hyponatremia being most common.  
 
Clinical enzymology 
Serum pancreatic lipase immunoreactivity (PLI) concentration 
The only cell type known to synthesize pancreatic lipase is the pancreatic acinar 
cell. An immunoassay for specific measurement of canine pancreatic lipase has been 
developed and analytically validated.
176
 In contrast to the traditional activity assays for 
lipase, which indiscriminately measure the activity of lipases of a variety of different 
cellular origins, this immunoassay specifically quantifies pancreatic lipase based on its 
unique antigenic structure using specific antibodies. The original in-house immunoassay 
for canine pancreatic lipase (cPLI) has been replaced by a widely available commercial 
immunoassay (Spec cPL
®
), which performs similarly to the original cPLI ELISA.
177,178
 
Clinical studies suggest that serum cPLI (or Spec cPL) has high specificity for 
canine pancreatitis. In one study of 31 dogs with a normal pancreas on histopathology 
the specificity of Spec cPL was very high (96.8%).
179
 In a recent multicenter study in 
which dogs with clinical evidence of pancreatitis were studied, the specificity of this 
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assay was reported at 78%.
180
 Experimentally induced chronic renal failure and 
prednisone administration were not found to have a clinically significant effect on serum 
cPLI concentration.
181,182
  The specificity of cPLI needs further investigation in dogs 
with various gastrointestinal diseases but no pancreatitis. It also remains to be 
determined whether serum cPLI concentration can be increased in patients with 
histopathologically mild pancreatitis that might be of minor clinical importance and does 
not contribute to the development of clinical signs. Overall, compared to other serum 
tests currently available, serum cPLI is considered to have the highest specificity for 
pancreatitis.
179-185
  
Studies also show that serum cPLI concentration is sensitive for the diagnosis of 
pancreatitis in dogs.
177,180,186,187
 The reported sensitivity of cPLI for the diagnosis of 
canine pancreatitis ranges between 64% and 93%, possibly depending on the severity of 
the disease in the patients studied. Overall, the sensitivity of serum cPLI is higher than 
any other serum test currently available.
177,180,186,187
 However, false negative results are 
likely to occur especially in mild cases.  
Overall, serum cPLI concentration appears to be a sensitive and specific marker 
of canine pancreatitis, and is currently considered to be the serum test of choice for the 
diagnosis of pancreatitis in this species. 
Based on clinical observations and the results of studies available to date,
177
 
serum cPLI concentration does not appear to correlate with the severity of pancreatitis. 
Therefore, an individual measurement of serum cPLI concentration cannot be used to 
predict the severity of pancreatitis. No controlled studies have looked at the significance 
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of changes over time in serum Spec cPL concentrations in individual patients with 
pancreatitis. 
A point-of-care test for the estimation of pancreatic lipase in serum (SNAP 
cPL
®
) has become available. Published studies evaluating the performance of this test 
are currently lacking but it is claimed to show the same clinical performance as the 
serum Spec cPL assay. The recommended use of this test is for the rule-out of 
pancreatitis in dogs presenting for acute clinical signs that are consistent with 
pancreatitis. Due to the high sensitivity of Spec cPL, a negative result makes a diagnosis 
of pancreatitis unlikely. However, false negative results might occur in some cases. A 
positive test result should be followed by laboratory measurement of serum Spec cPL 
concentration.  
 
Serum amylase and lipase activities 
Serum amylase and lipase activities have been considered as markers for 
pancreatitis in dogs for several decades, but several studies have shown that they are not 
good markers for spontaneous canine pancreatitis due to their low sensitivity and 
specificity.
183,188
 In one study, about 50% of dogs with increased activity of either serum 
amylase or lipase activity had no histopathologic evidence of pancreatitis.
183
 This means 
that a large proportion of dogs that have diseases other than pancreatitis (e.g., certain 
renal, hepatic, intestinal, and neoplastic diseases) might have increased serum lipase 
and/or amylase activities.
183
 This is due to the fact that there are many lipases and 
amylases of different cellular origins that cannot be specifically analyzed by use of 
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enzymatic assays. Even significant increases of amylase and lipase activities can result 
from non-pancreatic disorders, and should always be followed by the use of more 
specific and sensitive tests.
165,183,184,189
 In addition, the sensitivity of serum amylase and 
lipase activities for spontaneous canine pancreatitis varies but is generally low (14%-
73% for serum lipase activity and 18%-69% for serum amylase activity).
64,177,187
 
Therefore, pancreatitis cannot be definitively diagnosed or ruled out based on serum 
amylase and/or lipase activities.
64,183
 
 
Serum trypsin-like immunoreactivity (TLI) concentration 
The canine TLI assay is a species-specific immunoassay that measures 
trypsinogen, trypsin, and also potentially trypsin molecules that are bound to trypsin 
inhibitors in serum. Trypsinogen is the inactive precursor of trypsin and is synthesized 
exclusively in pancreatic acinar cells. The sensitivity of serum cTLI for the diagnosis of 
canine spontaneous pancreatitis is low (36%-47%), probably due to its short half-
life.
177,184,187
 In addition, although there is strong evidence that trypsinogen is exclusively 
of pancreatic origin,
190
 it is believed that it is cleared by glomerular filtration in dogs, 
and serum cTLI concentration can be increased in dogs with renal failure.
184,185
  
 
Other diagnostic tests 
 Several other tests have been developed and evaluated for the diagnosis of canine 
pancreatitis. However, none of these tests can currently be recommended for clinical use, 
either because their clinical usefulness has not been sufficiently determined or because 
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they have been shown to have a low specificity and/or sensitivity. In addition, most of 
these tests have limited availability or are only available for experimental use.  
Trypsinogen activation peptide (TAP) is a small peptide that is released when 
trypsinogen is activated to trypsin.
184
 Under physiologic conditions, trypsinogen is 
activated mainly in the intestinal lumen, and thus serum TAP concentrations are low or 
undetectable.
184
 During pancreatitis, trypsinogen is prematurely activated in the pancreas 
and TAP is released into the circulation.
184,191
 Plasma and urinary TAP concentrations 
have been evaluated in healthy dogs, dogs with spontaneous pancreatitis, and dogs with 
other systemic diseases in a single study.
184
 In this study, plasma TAP concentrations 
showed a fairly good specificity (87.9%) but a low sensitivity (53.3%) for the detection 
of pancreatitis. Urine TAP concentrations did not show any advantage over serum TAP 
concentrations in diagnosing pancreatitis. Both tests showed increases in dogs with 
severe pancreatitis, but were normal or even decreased in cases of mild pancreatitis. 
However, this study suggested that, as in humans, serum and urine TAP concentrations 
might be more useful as a prognostic indicator in dogs with pancreatitis.
184
 
Measurement of lipase activity in peritoneal fluid and comparison with serum 
lipase activity has been evaluated as a tool for the diagnosis of acute pancreatitis in 
dogs.
192
 However, further well-designed studies are needed before such a tool can be 
recommended for clinical use in canine patients. Other tests that have been evaluated for 
the diagnosis of canine pancreatitis include serum concentrations of trypsin-α1-
proteinase inhibitor complexes or α2-macroglobulin, but neither of these tests proved to 
be particularly sensitive or specific for the diagnosis of canine pancreatitis.
193-196
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Diagnostic imaging 
Abdominal radiography  
Conclusive diagnosis or exclusion of pancreatitis is not possible based on 
abdominal radiography alone.
64
 In the majority of cases of canine pancreatitis, 
abdominal radiographs are normal or only show non-specific changes.
64
 Despite that, 
abdominal radiography remains a logical initial approach for patients suspected of 
having pancreatitis, because it is useful for the rule-out of other differential diagnoses.  
Non-specific radiographic findings that may be found in dogs with pancreatitis 
include an increased soft tissue opacity and decreased serosal detail in the cranial right 
abdomen, displacement of the stomach and/or duodenum from their normal positions, 
dilation of bowel loops adjacent to the pancreas, and the presence of a cranial abdominal 
mass.
64
  
 
Abdominal ultrasound 
Abdominal ultrasound is considered the imaging modality of choice for the 
diagnosis of pancreatitis in dogs. However, abdominal ultrasonography is also associated 
with disadvantages, and its clinical utility in the diagnosis of pancreatitis is highly 
dependent on the experience of the ultrasonographer and the quality of the equipment 
used. It has been reported to have a relatively high sensitivity of about 68% for severe 
acute pancreatitis in dogs.
64
 In a recent study where ultrasonography was performed in 
26 animals (both dogs and cats) with suspected gastrointestinal disease, 6 (23.1%) of the 
animals had ultrasonographic evidence consistent with pancreatitis, while histopathology 
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revealed either a normal pancreas or pancreatic hyperplasia.
197
 In the same study, there 
was only 22% agreement between the ultrasonographic and the histopathologic 
diagnoses.
197
 Although not free of limitations, this study highlights that ultrasonographic 
findings in animals with suspected pancreatitis should be interpreted with caution. It is 
also important to note that a normal ultrasonographic appearance of the pancreas does 
not rule-out pancreatitis.
64,198
 If stringent criteria are applied, the specificity of 
abdominal ultrasonography for pancreatitis is considered to be relatively high, although 
other diseases of the pancreas (e.g., neoplasia, hyperplastic nodules, pancreatic edema 
due to portal hypertension or hypoalbuminemia) may display similar ultrasonographic 
findings and sometimes cannot be definitively differentiated from pancreatitis.
199,200
 
The most important ultrasonographic findings suggestive of pancreatitis in dogs 
include hypoechoic areas within the pancreas, increased echogenicity of the surrounding 
mesentery (due to necrosis of the peripancreatic fat), fluid around the pancreas, and 
enlargement and/or irregularity of the pancreas.
64,198,201
 Differentiation between 
necrotizing and edematous pancreatitis might be possible based on ultrasonographic 
examination, although this has not been confirmed in clinical studies. On occasion, 
hyperechoic areas of the pancreas possibly indicating the presence of pancreatic fibrosis 
may be present. Less specific findings may include a dilation of the pancreatic or biliary 
duct, and abdominal effusion. Abdominal ultrasonography is also very useful for the 
diagnosis of local complications of pancreatitis such as pancreatic abscesses, pancreatic 
pseudocysts, and biliary obstructions.
201
 In addition, ultrasound-guided fine-needle 
aspiration is a useful tool for the management of non-infectious fluid accumulations of 
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the pancreas (e.g. pancreatic pseudocyst), and for obtaining pancreatic specimens for 
cytological evaluation.
202
  
 
Other imaging modalities 
Several other imaging modalities are routinely used to diagnose or evaluate 
pancreatitis in human patients. Contrast enhanced computed tomography (CECT) is an 
extremely valuable tool for the evaluation of human patients with suspected pancreatitis 
and might also prove to be useful in dogs, but it has not been evaluated in an adequate 
number of canine pancreatitis cases.
203
 Other imaging modalities (e.g., endoscopic 
retrograde cholangiopancreatography (ERCP), endoscopic ultrasonography), have been 
studied in healthy dogs and dogs with gastrointestinal diseases with varying results.
204,205
 
However, due to the lack of standardized criteria for the diagnosis of pancreatitis, the 
complexity of these modalities, their limited availability, and the cost of the equipment 
they cannot be currently recommended for the diagnosis of canine pancreatitis.  
 
Pathology 
Certain macroscopic lesions identified during surgery, laparoscopy, or necropsy 
are highly suggestive of pancreatitis and are preferred sites for biopsy collection.
177
  
Macroscopic pancreatic lesions suggestive of pancreatitis may include peripancreatic fat 
necrosis, pancreatic hemorrhage and congestion, and a dull granular capsular surface.
177
 
However, gross pathologic lesions may not always be apparent in dogs with pancreatitis, 
and in some cases, they might be difficult to differentiate from nodular hyperplasia.
206
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At present, a definitive diagnosis of pancreatitis can only be made by 
histopathologic examination of the pancreas. Histopathology is also the only way to 
differentiate acute and chronic pancreatitis and, in some cases, pancreatitis from 
pancreatic neoplasia. Although not clearly defined in veterinary species, the presence of 
permanent histopathologic changes (such as fibrosis and acinar atrophy) is considered 
suggestive of chronic pancreatitis.
165,206
 Acute pancreatitis is characterized by the 
absence of permanent histopathologic lesions. The predominant inflammatory cellular 
infiltrate (neutrophils or lymphocytes) is often used to describe pancreatitis as 
suppurative or lymphocytic, respectively, and a significant degree of necrosis is usually 
used to characterize the pancreatitis as necrotizing.  
Several limitations are associated with pancreatic histopathology as a definitive 
diagnostic tool for pancreatitis. First, determining the clinical significance of 
histopathologic findings may be challenging. At the same time, exclusion of pancreatitis 
based on histopathology is difficult because inflammatory lesions of the pancreas are 
often highly localized and can easily be missed.
206
 Therefore, multiple sections of the 
pancreas must be evaluated in order to increase the likelihood of finding microscopic 
lesions, although this is not always feasible in clinical cases.
206
 Finally, although 
pancreatic biopsy per se is considered safe, it requires invasive procedures that are 
expensive and potentially detrimental in patients that are hemodynamically unstable.
197
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Cytology 
Fine-needle aspiration (FNA) of the pancreas and cytological examination has 
been recently introduced as a diagnostic tool for pancreatitis in small animals. It should 
be performed either under ultrasonographic guidance or during laparotomy.
207
 To date 
there are no studies that have evaluated the sensitivity and specificity of this diagnostic 
modality for the diagnosis of canine pancreatitis, but the finding of acinar cells and 
inflammatory cells in the aspirate is considered specific for pancreatitis. Pancreatic 
acinar cells constitute the majority of the cells found in FNA smears from a normal 
pancreas.
207
 In patients with acute pancreatitis the cytological picture is mainly 
characterized by hypercellularity and the presence of intact and degenerated neutrophils 
and degenerated pancreatic acinar cells. It should be noted that, as for histopathology, 
localized lesions might be missed. Therefore, negative results are not sufficient to rule-
out pancreatitis. Fine-needle aspiration cytology might also be useful in differentiating 
other conditions of the pancreas (e.g., neoplasia) from pancreatitis. 
 
Treatment 
 The etiology of pancreatitis remains unknown in the majority of cases, and 
therefore, treatment of pancreatitis remains almost exclusively supportive. It is expected 
that future recognition of specific causes of canine pancreatitis will lead to the 
development of more specific treatments for different forms of pancreatitis that are now 
classified as idiopathic. Until then, the presence of possible risk factors or etiologic 
 46 
factors should always be investigated in dogs with pancreatitis. If any of these factors are 
present, they should be managed as possible.  
Other than that, the treatment of pancreatitis in dogs remains almost exclusively 
supportive and symptomatic. Fluid therapy, in some cases including plasma transfusion, 
is considered important in both humans and dogs with severe disease and hypovolemia 
and/or dehydration.
165,196,208-215
 Pain management is also considered crucial in cases of 
both acute and chronic pancreatitis, when pain is present.
216-218
 The use of antiemetic 
medications is recommended in cases of pancreatitis where vomiting is present.
219-221
 
Routine antibiotic therapy is highly controversial and it is usually not recommended in 
dogs unless an infection is present.
155,208,222-225
 Finally, surgical intervention of 
pancreatitis is rarely recommended in dogs unless certain complications occur (such as 
pancreatic abscess, pancreatic pseudocyst, or extrahepatic biliary tract obstruction).
226-237
 
A plethora of other therapeutic agents have been recommended by some authors in both 
veterinary and human medicine.
238-240
  but there is currently no convincing evidence that 
any of these agents is beneficial for the treatment of spontaneous pancreatitis in dogs.  
The role of nutrition in the management of pancreatitis needs some attention. The 
nutritional approach of humans with pancreatitis (especially acute pancreatitis) has been 
the focus of extensive basic and clinical research for several decades. 
241-243
 
Unfortunately, studies in dogs suffering specifically from either acute or  pancreatitis are 
sparse and therefore the nutritional approach in these cases is based on clinical 
experience.
244-251
 Questions regarding the nutritional approach of dogs with pancreatitis 
have to do with the timing of feeding during an episode of acute pancreatitis, the route of 
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nutrient delivery (which also mainly is related to dogs with acute pancreatitis), and the 
type of diet administered, which might be important in dogs with both acute and chronic 
pancreatitis. Although the diet of choice for the management of dogs with pancreatitis 
has not been systematically studied to date, based on anecdotal experience, a balanced 
ultra-low-fat diet is currently the preferred choice for dogs. This is mainly based on 
studies that suggest that high-fat diets (typically table scraps) might be related to the 
development of pancreatitis in some dogs.
252
 This is further supported by studies that 
implicate hypertriglyceridemia in the development of pancreatitis in humans and 
experimental models.
252
 However, no studies have evaluated whether the fat content of 
commercially available canine diets is important in treating or preventing acute and 
chronic pancreatitis. While several supportive measures are important in the 
management of acute pancreatitis, nutritional management might be the only measure 
for the long-term management of dogs with chronic pancreatitis. 
 
The association between hyperlipidemia and pancreatitis 
An association between hyperlipidemia and pancreatitis was first noted in 
humans by Speck in 1865.
253
 Several clinical and experimental studies in humans and 
animals, respectively, have been conducted since then, and today, severe 
hypertriglyceridemia is a well recognized risk factor for pancreatitis in humans.
254-257
 
Hypertriglyceridemia is believed to be the 3rd most common cause of pancreatitis in 
humans, after alcohol- and gallstone-induced pancreatitis, accounting for up to 10% of 
cases.
258
 However, within specific groups, the prevalence of hypertriglyceridemia-
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associated pancreatitis is much higher; for example, hypertriglyceridemia has been listed 
as a cause in 56% of patients with gestational pancreatitis and up to 41% of patients with 
primary hypertriglyceridemia.
258
 Hypertriglyceridemia-associated pancreatitis can occur 
as a result of primary hypertriglyceridemia in humans (mainly types I, IV, and V, based 
on the classification by Fredrickson), but also as a result of hypertriglyceridemia 
secondary to other diseases (most commonly poorly controlled diabetes mellitus, 
alcoholism, or obesity), special physiologic states (e.g., pregnancy), or drug 
administration (e.g., estrogens, tamoxifen).
258
 
An increased risk for pancreatitis due to hypertriglyceridemia has been 
conventionally thought to exist when serum triglyceride concentrations exceed 1,000 
mg/dL.
254
 In contrast, hypercholesterolemia does not constitute a risk factor for 
pancreatitis in humans.
254
 The mechanism by which hypertriglyceridemia induces 
pancreatitis is not clear, but it has been suggested that serum triglycerides are hydrolyzed 
by the action of pancreatic lipase, leading to excessive production of free fatty acids, 
which are toxic to the pancreatic acinar cell.
259,260
 Another possible hypothesis is that 
hyperviscosity develops as a result of increased chylomicrons and/or VLDLs in the 
capillaries, which in turn leads to ischemia of pancreatic tissue.
258
 Finally, genetic 
factors, such as mutations of the cystic fibrosis transmembrane conductance regulator 
gene or the SPINK1 gene may play a role by sensitizing the pancreas to the effects of 
hypertriglyceridemia.
258
   
A similar relationship between hypertriglyceridemia and pancreatitis has been 
suggested for dogs, and an association between the 2 conditions has been shown in 
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several studies.
15,33,34,37,49,52,66,83,165
 However, this association remains obscure in dogs as 
the etiology of hypertriglyceridemia cannot always be determined in these studies. The 
presence of hypertriglyceridemia in dogs with pancreatitis might be due to a pre-existing 
disorder of lipid metabolism, which may or may not be related to the etiology of 
pancreatitis, but might also be the result of pancreatitis, or it might just be an incidental 
finding in some cases.
252
  
Although it is widely believed that hypertriglyceridemia can develop as a result 
of pancreatitis, this has not been convincingly shown in dogs with naturally occurring 
pancreatitis. Furthermore, with the exception of the results of 1 older study,
261
 
hypertriglyceridemia does not seem to be a consequence of experimental pancreatitis in 
dogs.
18-20
 In order for hypertriglyceridemia to be considered as a possible etiologic factor 
for pancreatitis it should precede the development of pancreatitis.  
Miniature Schnauzers have been reported to develop pancreatitis more 
commonly than dogs of other breeds, and this high prevalence of pancreatitis in 
Miniature Schnauzers has been attributed to the fact that dogs of this breed commonly 
develop hypertriglyceridemia.
33,49,66,165
 Available clinical and experimental data to 
support the above hypotheses are limited, however. In experimental studies, pancreatitis 
has been shown to develop in dogs after feeding a high-fat, low-protein diet, and is more 
severe when induced in dogs being fed a high-fat diet.
144,146
 Also, in vitro studies on an 
isolated canine pancreas showed that high triglyceride concentrations can induce 
pancreatitis possibly through the release of free fatty acids.
260
 Clinical studies have 
shown an association between hyperlipidemia and pancreatitis in dogs, although it is not 
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clear whether hyperlipidemia was the cause or a result of pancreatitis, or just an 
incidental finding in some cases.
15,19,21,63-66
 Secondary hyperlipidemia seen in dogs with 
some endocrinopathies (e.g., hyperadrenocorticism) or obesity may be responsible for 
the increased risk for pancreatitis associated with these diseases.
11,65,65,172
 Based on these 
studies, there is strong evidence for an association between hypertriglyceridemia and 
pancreatitis in dogs, but the exact nature of this relationship has not been established.  
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CHAPTER II 
ASSOCIATION BETWEEN SERUM TRIGLYCERIDE AND CANINE 
PANCREATIC LIPASE IMMUNOREACTIVITY CONCENTRATIONS IN 
MINIATURE SCHNAUZERS* 
 
Introduction 
Primary (idiopathic) hypertriglyceridemia is a common condition in Miniature 
Schnauzers in the United States.
84
 In a recent study, hypertriglyceridemia was present in 
32.8% of 192 Miniature Schnauzers investigated. Also, hypertriglyceridemia was shown 
to be age-related, with a much higher prevalence in older Miniature Schnauzers.
84
 
Hypertriglyceridemia in Miniature Schnauzers has previously been shown to be 
associated with an abnormal accumulation of VLDL (very low density lipoproteins) or a 
combination of VLDL and chylomicrons, with or without hypercholesterolemia.
17,83
 The 
fact that hypertriglyceridemia is especially prevalent within a certain breed suggests a 
hereditary mechanism, but the metabolic and genetic bases of this disorder have not been 
identified.
49,83
 
Investigations into the disease conditions potentially associated with 
hypertriglyceridemia have only recently been reported in dogs. For example, as is the 
case in humans, hypertriglyceridemia has been recently reported to be associated with
___________ 
*Xenoulis PG, et al. Association between serum triglyceride and canine pancreatic lipase 
immunoreactivity concentrations in miniature schnauzers. J Am Anim Hosp Assoc 
2010;46(4):229-34. 
Reprinted with permission from the Journal of the American Animal Hospital Association. 
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hepatobiliary disease in both Miniature Schnauzers and dogs of other breeds.
121,123
 In 
humans, severe hypertriglyceridemia is also a known risk factor for pancreatitis.
254,255,262
 
Miniature Schnauzers are generally considered to have a high incidence of 
pancreatitis.
63,163,165,216
 In a recent study, bivariable screening showed that Miniature 
Schnauzers were 4.1 times (95% CI, 1.9 to 9.2; P < 0.001) more likely to have 
pancreatitis than dogs of other breeds.
163
 The basis for this predisposition is unknown, 
but hypertriglyceridemia has long been considered as a possible cause of pancreatitis in 
the Miniature Schnauzer.
17,83,165
 However, studies investigating any association between 
these 2 disorders in dogs are lacking, and this consideration is mainly based on clinical 
impressions. In vitro studies support the concept that hypertriglyceridemia can initiate 
pancreatic inflammation, and there is evidence that high fat diets or even a single fatty 
meal can induce pancreatitis in dogs.
144,165,260
 In contrast to hypertriglyceridemia, 
hypercholesterolemia does not appear to be a risk factor for pancreatitis in humans or 
dogs.
33,254,255
 Recognition of an association between hypertriglyceridemia and 
pancreatitis in Miniature Schnauzers is clinically important because management of 
hypertriglyceridemia with low-fat diets and/or lipid-lowering drugs may prevent or 
resolve pancreatitis in these dogs.  
Until recently, a clinical diagnosis of pancreatitis was problematic in dogs 
because no specific and sensitive tests were available. However, the recent development 
and analytical validation of an ELISA specific for canine pancreatic lipase, canine 
pancreatic lipase immunoreactivity (cPLI), has facilitated the diagnosis of pancreatitis in 
dogs as it has been reported to be sensitive (reported sensitivity ranging from 64% for 
 53 
mild pancreatitis to 82% for severe pancreatitis) and specific for the diagnosis of canine 
pancreatitis.
a,b,c,d,176,177,182,263,264
 
The aim of this study was to investigate possible associations between serum 
triglyceride and cPLI concentrations in a large group of Miniature Schnauzers. 
 
Materials and methods 
Serum samples from 195 Miniature Schnauzers were collected and triglyceride 
and cPLI concentrations measured. Serum samples were collected on a sequential basis; 
no bias was given to lipemic samples. Based on the submission form, food needed to be 
withheld from dogs for at least 12 hours before blood collection. Serum triglyceride 
concentrations were measured by an enzymatic in vitro assay (reference range 26 to 108 
mg/dL).
e
 Serum cPLI concentration was measured using an in-house ELISA as 
described elsewhere.
176
 The reported reference range for cPLI is 2.2 to 102.1 μg/L, and 
serum cPLI concentrations ≥200 μg/L are considered consistent with canine 
pancreatitis.
176
 Serum cPLI concentrations that fall between 102.1 µg/L and 200 µg/L 
are considered equivocal, and retesting is suggested. It should be noted that cPLI is 
currently measured as Spec cPL
TM
, which shows the same clinical performance as the 
original cPLI assay, but has a different reference range (0 to 200 μg/L) from the assay 
used in the present study.   
Dogs were divided into 2 groups according to their serum triglyceride 
concentration. Group 1 consisted of dogs with serum triglyceride concentrations within 
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the reference range, while Group 2 consisted of dogs with serum triglyceride 
concentrations above the upper limit of the reference range (>108 mg/dL).  
 
Statistical analysis  
The data were analyzed for normal distribution using the Kolmogorov-Smirnov 
test. All data failed normality testing and non-parametric methods were used for further 
analysis. The data were analyzed for correlation between serum cPLI and triglyceride 
concentrations using the Spearman rank correlation coefficient. The median serum cPLI 
concentration was compared between groups with the Mann-Whitney U test. Receiver 
operator characteristic (ROC) analysis was performed and the likelihood ratio, which 
indicates an estimate of how much a positive or negative result affects the likelihood that 
a patient would have the disease, was calculated.
265
 Proportions of dogs with increased 
serum cPLI concentrations were compared between groups using Fisher’s exact tests. 
Odds ratios and their 95% CI were also calculated. Dogs with serum cPLI concentrations 
in the equivocal range (e.g., neither within the reference range nor consistent with 
pancreatitis; n=33), were excluded from this analysis as this could potentially affect the 
validity of the results. All statistical analyses were performed using a statistical software 
package
f
 and a p value of < 0.05 was considered significant. 
 
Results 
There was a significant but weak positive correlation between serum cPLI and 
triglyceride concentrations in all dogs (Spearman r=0.3215; P<0.0001; Figure 1).  
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Figure 1. Correlation between serum triglyceride and cPLI concentrations in 195 
Miniature Schnauzers. There was a significant positive correlation between the 2 
parameters (Spearman r=0.3215; P<0.0001). 
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ROC analysis and calculation of likelihood ratios at different triglyceride 
concentrations for serum cPLI concentrations consistent with pancreatitis revealed that 
the likelihood ratio remained close to 1.0 for serum triglyceride concentrations below 
approximately 800 mg/dL and increased sharply at serum triglyceride concentrations of 
more than 800 mg/dL (Figure 2). The lowest serum triglyceride concentration that 
produced a statistically significant increased risk for a cPLI ≥200 μg/L (a serum cPLI 
concentration that is considered consistent with pancreatitis) was 862 mg/dL. This 
concentration was used for further statistical analysis. The likelihood ratio at this 
concentration for a cPLI ≥200 μg/L was 3.3. 
Eighty of the 195 dogs (41%) had serum triglyceride concentrations below the 
upper limit of the reference range and these dogs were designated as Group 1. One 
hundred and fifteen of the 195 dogs (59%) had serum triglyceride concentrations above 
the upper limit of the reference range and were designated as Group 2.  
Dogs in Group 2 had a significantly higher median serum cPLI concentration 
(99.5 μg/L) than dogs in Group 1 (39.3 μg/L; P=0.0001; Figure 3). In addition, dogs in 
Group 2 with serum triglyceride concentrations ≥862 mg/dL (as determined by ROC 
analysis) had significantly higher median serum cPLI concentrations (223.4 μg/L) than 
dogs in Group 1 (P=0.0077; Figure 4).  
After excluding the dogs with serum cPLI concentrations in the equivocal range 
(n=33), there were 75 dogs with normal serum triglyceride concentrations and 87 dogs 
with hypertriglyceridemia. 
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Figure 2. Likelihood ratios for different serum triglyceride concentrations for serum 
cPLI concentrations consistent with pancreatitis (≥200 μg/L). The likelihood ratio 
remained between 1.0 and 2.0 for serum triglyceride concentrations below 
approximately 800 mg/dL, and increased sharply for serum triglyceride concentrations 
of more than 800 mg/dL. The lowest serum triglyceride concentration that produced a 
statistically significant likelihood for a cPLI ≥ 200 μg/L was 862 mg/dL. 
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Figure 3. Serum cPLI concentrations in Miniature Schnauzers with normal serum 
triglyceride concentrations (TG≤108 mg/dL) and in Miniature Schnauzers with serum 
triglyceride concentrations above the upper limit of the reference range (TG>108 
mg/dL). The lines represent the median of each group. There was a statistically 
significant difference in the median serum cPLI concentrations between the 2 groups 
(P=0.0001). 
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Figure 4. Serum cPLI concentrations in Miniature Schnauzers with normal 
serum triglyceride concentrations (TG≤108 mg/dL) and in Miniature Schnauzers with a 
severely increased serum triglyceride concentration (TG>862 mg/dL). The lines 
represent the median of each group. There was a statistically significant difference in the 
median cPLI concentration between the 2 groups (P=0.0077). 
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There was no significant difference in the proportion of dogs with serum cPLI 
concentrations consistent with pancreatitis between dogs with hypertriglyceridemia (29 
of 87 dogs; 33.3%) and dogs with normal triglyceride concentrations (21 of 75 dogs; 
28%; P=0.4986). However, of the 87 dogs with hypertriglyceridemia, 11 had serum 
triglyceride concentrations ≥862 mg/dL, and there was a statistically significant 
difference in the proportion of dogs with serum cPLI concentrations consistent with 
pancreatitis between the dogs with serum triglyceride concentrations ≥862 mg/dL (7 of 
11 dogs; 63.6%) and dogs with serum triglyceride concentrations in the reference range 
(21 of 75 dogs; 28%; P=0.0343; odds ratio, 4.5; 95% CI, 1.2 to 17.0).  
 
Discussion  
Results of the present study suggest an association between serum triglyceride 
and cPLI concentrations in Miniature Schnauzers. Miniature Schnauzers with 
hypertriglyceridemia were found to have significantly higher serum cPLI concentrations 
than Miniature Schnauzers with normal serum triglyceride concentrations. In addition, 
Miniature Schnauzers with serum triglyceride concentrations ≥862 mg/dl were 4.5 times 
(95% CI, 1.2 to 17.0) more likely to have serum cPLI concentrations considered 
consistent with pancreatitis (>200 μg/L) than Miniature Schnauzers with normal serum 
triglyceride concentrations. Although previous studies have shown a frequent co-
existence of hypertriglyceridemia and pancreatitis in dogs, the present study is the first 
to implicate the degree of hypertriglyceridemia as a cause of increased serum cPLI 
concentrations consistent with pancreatitis in Miniature Schnauzers.
19,63,65
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A serum triglyceride concentration of 862 mg/dL was selected based on ROC 
analysis, and this concentration was associated with a greater than 3-fold likelihood for 
having a serum cPLI concentration that is considered consistent with pancreatitis 
compared to the likelihood for dogs with triglyceride concentrations ≤ 862 mg/dL. The 
likelihood ratio for having a serum cPLI concentration that is consistent with pancreatitis 
was often higher (up to 8.5) when higher serum triglyceride concentrations were selected 
(Figure 2). Increases of serum triglyceride concentrations ≥ 862 mg/dL are generally 
considered to be rather severe. Results of the present study suggest that the severity of 
hypertriglyceridemia is an important factor affecting the risk for increased cPLI 
concentration consistent with pancreatitis in Miniature Schnauzers, and that only 
severely increased serum triglyceride concentrations are associated with an increased 
risk for an increased cPLI concentration consistent with pancreatitis in this breed. Mildly 
or moderately elevated serum triglyceride concentrations (e.g., < 800 mg/dL) did not 
appear to represent a risk factor for a serum cPLI concentration suggestive of 
pancreatitis in this study. These findings are in agreement with studies in humans, in 
which only severe hypertriglyceridemia is recognized as a cause of pancreatitis.
254,255
 In 
humans, it has been reported that a serum triglyceride concentration above 1,000 mg/dL 
is an identifiable risk factor for pancreatitis.
255
  
In human patients, it has been described that hypertriglyceridemia can either be 
the cause or the result of pancreatitis, and the same has also been suggested for 
dogs.
19,165,255
 When hypertriglyceridemia is the result of pancreatitis in humans it is 
usually mild to moderate, while hypertriglyceridemia that causes pancreatitis is usually 
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severe (typically ≥1,000 mg/dl).255 In the present study, many dogs had serum 
triglyceride concentrations above the upper limit of the reference range and it is possible 
that some of these dogs might have had hypertriglyceridemia secondary to pancreatitis 
rather than the opposite. However, this speculation is not supported by the current 
literature. In 1 study where acute pancreatitis was experimentally induced in dogs, 
hypertriglyceridemia did not develop up to 96 hours after induction of pancreatitis.
19
 
Similar results were reported in another study where pancreatitis was experimentally 
induced in dogs by ligation of the major and minor pancreatic ducts.
18
 In this study, 
pancreatitis did not result in hypertriglyceridemia or hypercholesterolemia up to 14 days 
after induction of pancreatitis.
18
 In a more recent study, mild increases in serum 
triglyceride concentrations were noted in dogs after induction of pancreatitis.
20
 Although 
serum triglyceride concentrations significantly increased, they remained within the 
reference range even after induction of pancreatitis.
20
 However, this was not clearly 
discussed in this report.
20
 Based on these studies, it can be concluded that 
hypertriglyceridemia is not a feature of experimentally induced pancreatitis in dogs. 
However, it remains unknown whether this is also the case for spontaneous canine 
pancreatitis. It should be mentioned that in another study of 56 dogs of different breeds 
(not including Miniature Schnauzers) with serum cPLI concentrations diagnostic for 
pancreatitis, only 14 (25%) had hypertriglyceridemia and of these only 1 (1.8%) had 
serum triglyceride concentration ≥862 mg/dL.g Collectively, the above data indicate that 
severe hypertriglyceridemia with triglyceride concentrations above 862 mg/dL, which in 
this study showed a significant association with serum cPLI concentrations consistent 
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with pancreatitis, appears to be unlikely to be the result of pancreatitis. Furthermore, in 
our clinical experience with Miniature Schnauzers, the vast majority of Miniature 
Schnauzers with pancreatitis and severe hypertriglyceridemia have preexisting 
hypertriglyceridemia, and most of these patients also have persistent 
hypertriglyceridemia even after recovery from pancreatitis, unless a low-fat diet is being 
offered.  
Because of the high incidence of idiopathic hypertriglyceridemia in Miniature 
Schnauzers,
84
 many of the dogs with elevated serum triglyceride concentrations enrolled 
in this study are likely to have this condition. However, secondary causes of 
hypertriglyceridemia, mostly endocrinopathies such as diabetes mellitus, 
hyperadrenocorticism, and hypothyroidism cannot be excluded as potential causes of the 
hypertriglyceridemia in these dogs.
49
 There is no evidence to support that the source 
(rather than the severity) of hypertriglyceridemia can affect the risk for pancreatitis, and 
severe hypertriglyceridemia of any cause (primary or secondary) should be considered a 
risk factor for high cPLI concentrations consistent with pancreatitis in Miniature 
Schnauzers.
65
 This is also the case in human patients, where severe hypertriglyceridemia 
secondary to other diseases (e.g., uncontrolled or untreated diabetes mellitus, diabetic 
ketoacidosis) has also been associated with pancreatitis.
257,266
 
One limitation of the present study is the fact that the medical histories of the 
dogs enrolled were not available. Because of this, the true disease status of these patients 
(e.g., whether they had clinical signs of pancreatitis) was unknown. However, the 
majority of samples submitted the authors’ laboratory come from animals with 
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gastrointestinal signs or suspected gastrointestinal disease. In addition, any concurrent 
conditions or medications administered cannot be excluded as factors contributing to the 
serum cPLI concentrations observed. It is important to note, however, that there are 
currently no known factors other than pancreatitis that have been shown to increase 
serum cPLI concentrations above 200 µg/L (the current cut-off value for 
pancreatitis).
c,d,182 
Therefore, the finding of this study that there is an association 
between serum triglyceride and cPLI concentrations cannot be arbitrarily translated into 
an association between serum triglycerides and clinical pancreatitis, though such an 
association remains possible. To definitely make such a conclusion further studies are 
needed to prospectively evaluate the risk for increased cPLI concentrations and 
pancreatitis in Miniature Schnauzers with hypertriglyceridemia. In addition, further 
studies are warranted to investigate the association between hypertriglyceridemia and 
pancreatitis in dogs of other breeds. 
In conclusion, this is the first clinical study supporting an association between 
hypertriglyceridemia, especially when severe (≥862 mg/dL), and increased serum cPLI 
concentrations consistent with pancreatitis in Miniature Schnauzers. Miniature 
Schnauzers with severe hypertriglyceridemia (≥862 mg/dl) were 4.5 times more likely to 
have a serum cPLI concentration consistent with pancreatitis than Miniature Schnauzers 
with a normal serum triglyceride concentration.  
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CHAPTER III 
SERUM TRIGLYCERIDE CONCENTRATIONS IN MINIATURE 
SCHNAUZERS WITH AND WITHOUT A HISTORY OF PROBABLE 
PANCREATITIS* 
 
Introduction  
The cause of pancreatitis usually remains unknown in dogs.
65,162
 Several risk 
factors for pancreatitis have been indentified or suspected in dogs including trauma, 
certain drugs, endocrine diseases, obesity, and dietary indiscretion, but a definitive 
cause-and-effect relationship has not been established for most of them.
63,65,163
 
Hypertriglyceridemia has long been considered a possible cause of or risk factor for 
pancreatitis in dogs.
19,63,65,165,252
 Furthermore, it is widely believed that a suspected high 
prevalence of pancreatitis in Miniature Schnauzers
63,163
 might be associated with the 
documented high prevalence of hypertriglyceridemia in this breed.
15,17,19,84,165,252
  
The association between hypertriglyceridemia and pancreatitis remains obscure 
in dogs. Hypertriglyceridemia is commonly reported in dogs with pancreatitis, but the 
etiology of hypertriglyceridemia is not always possible to determine in these 
cases.
19,21,63-65
  
 
 
_____________ 
*Xenoulis PG, et al. Serum triglyceride concentrations in Miniature Schnauzers with and without 
a history of probable pancreatitis. J Vet Intern Med 2011;25(1):20-25.  
Reprinted with permission from the Journal of Veterinary Internal Medicine. 
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The presence of hypertriglyceridemia in dogs with pancreatitis might be due to a 
pre-existing disorder in lipid metabolism, which may or may not be related to the 
etiology of pancreatitis, or it might be the result of pancreatitis.
252
 Although it is widely 
believed that hypertriglyceridemia can develop as a result of pancreatitis, this has not 
been convincingly shown in dogs with naturally occurring pancreatitis. Furthermore, 
with the exception of the results of an older study,
261
 hypertriglyceridemia does not seem 
to be a consequence of experimental pancreatitis in dogs.
18-20
 In order for 
hypertriglyceridemia to be considered as a possible etiologic factor for pancreatitis it 
should precede the development of pancreatitis. Hypertriglyceridemia that precedes the 
development of pancreatitis might be primary such as hypertriglyceridemia of certain 
breeds such as Miniature Schnauzers or secondary to other diseases including diabetes 
mellitus, hyperadrenocorticism, hypothyroidism or drug administration (such as 
glucocorticoids).
252
 A possible role of hypertriglyceridemia as a cause of pancreatitis in 
Miniature Schnauzers or other dog breeds has been suspected based on knowledge 
extrapolated from human medicine, where severe hypertriglyceridemia is a well 
recognized cause of pancreatitis,
255,257,258,267
 in vitro or in experimental studies,
144,260
 and 
anecdotal clinical impressions.
165
  
The possibility of hypertriglyceridemia potentially developing as a result of 
pancreatitis complicates the determination of the role of hypertriglyceridemia as an 
etiologic factor of pancreatitis in both humans and dogs.
252,255
 One approach that is often 
used in human studies in order to overcome this obstacle is the measurement of serum 
triglyceride concentrations after pancreatitis has resolved.
256,267-270
 This is based on the 
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logical assumption that a defect in lipid metabolism causing hypertriglyceridemia must 
be a pre-existing condition in order for a patient to develop pancreatitis as a result of 
hypertriglyceridemia. If this is the case, hypertriglyceridemia should also persist after 
resolution of pancreatitis.
256,267-270
 In contrast, hypertriglyceridemia secondary to 
pancreatitis should resolve when pancreatitis is no longer present. Therefore, the 
presence of hypertriglyceridemia soon after resolution of pancreatitis provides 
retrospective evidence of a pre-existing condition, which if severe enough, could be 
considered as an etiologic factor for pancreatitis.
256,267-270
 
Studies investigating disorders of lipid metabolism in patients with a history of 
naturally occurring pancreatitis have been reported in humans but not in veterinary 
species. The aim of this study was to compare serum triglyceride concentrations between 
Miniature Schnauzers with a recent history of pancreatitis and those without such a 
recent history of pancreatitis.  
 
Materials and methods 
Study design 
 This study is a prospective case-control study. 
 
Dogs with pancreatitis (Group 1) 
Over a 2-year period (November 2006 – November 2008), a total of 35 Miniature 
Schnauzers with a diagnosis of pancreatitis were initially considered for prospective 
enrollment into this study. The diagnosis of pancreatitis was based on the presence of at 
 69 
least 2 clinical signs compatible with pancreatitis ( vomiting, anorexia, depression, 
abdominal pain, diarrhea) and a serum Spec cPL
®
 concentration ≥400 μg/L (the 
currently recommended cut-off value for pancreatitis).
a,b,178
 The dogs were enrolled on a 
sequential basis based solely on whether the owner had agreed to submit a follow-up 
sample after clinical resolution of pancreatitis. The 35 dogs considered for enrollment 
into the study were from various regions of the United States of America.  
After clinical recovery from pancreatitis, the owners of these dogs were asked to 
have a follow-up blood sample collected. The person communicating with the owners 
concerning the request for a follow-up sample was blinded to the serum triglyceride 
concentration of the dog during the initial evaluation. Thus, no preference was given to 
dogs with hypertriglyceridemia. The dogs were eventually included in the study if at the 
time the follow-up sample was collected they had: a) complete absence of any clinical 
signs, b) a serum Spec cPL concentration within the reference interval (<200 μg/L),178 c) 
a serum free T4 or total T4 concentration within the reference interval, and d) no history 
of diseases or use of drugs known to affect lipid metabolism (other than pancreatitis). 
Dogs fulfilling these enrollment criteria were designated as Group 1 (dogs with 
clinically resolved pancreatitis and a serum Spec cPL concentration within the reference 
interval). Only the follow-up blood sample, which was obtained after clinical and 
biochemical resolution of pancreatitis, was used for statistical comparison with the 
control group. The initial sample (during pancreatitis) was excluded from the analysis 
because it would not have been possible to determine whether possible 
hypertriglyceridemia in this initial sample was primary or had developed secondary to 
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pancreatitis. For the same reason, serum Spec cPL concentration was measured in the 
follow-up sample of each dog, and dogs with serum Spec cPL concentrations outside the 
reference interval (i.e., >200 μg/L) were excluded from further analysis. Serum 
triglyceride and cholesterol concentrations were evaluated in both the initial (during 
pancreatitis) and the follow-up sample for all dogs in Group 1.   
 
Control dogs (Group 2) 
Each dog enrolled into Group 1 was age-matched with 2 clinically healthy 
Miniature Schnauzers with no history of pancreatitis (Group 2). The selection of dogs 
into this group was based solely on their age (which had to match the age of each one of 
the dogs in Group 1). The person selecting the dogs was blinded to the serum 
triglyceride concentration of the dog. Inclusion criteria for dogs in Group 2 were 
identical to those for dogs of Group 1, with the exception of the history of pancreatitis. 
Therefore, dogs in Group 2 were included in the study if they had: a) absence of any 
clinical signs at the time of blood collection, b) a serum Spec cPL concentration within 
the reference interval, c) a serum free T4 or total T4 concentration within then reference 
interval, and d) no history of diseases or current drug use known to affect lipid 
metabolism. Serum triglyceride and cholesterol concentrations were measured in all 
dogs of Group 2.   
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Blood collection and handling 
Owners that decided to participate in the study were sent styrofoam boxes 
containing ice packs and the material necessary for blood collection, and were asked to 
schedule an appointment with their veterinarian. Veterinarians were instructed to collect 
10 ml of blood into a red-top tube (with no additive), wait for clot formation, centrifuge 
the sample, separate the serum from the clot, transfer the serum to another red-top tube, 
and send the samples to the Gastrointestinal Laboratory packed on ice by overnight 
courier. Owners had been instructed not to feed their dogs for at least 12 hours before the 
scheduled blood collection. Upon receipt, serum samples were immediately aliquoted 
and stored at -80
o
C until further use.  
 
Questionnaires and consent forms 
Owners were asked to complete a questionnaire for each dog. Questions covered 
date of birth, sex, body weight, current diet(s), current medications, and current and past 
health history of the dogs. Questionnaires from all dogs were reviewed to determine 
whether the dogs fit the inclusion criteria for each group. All owners had to sign an 
informed owner consent form. The study protocol was reviewed and approved by the 
Clinical Research Review Committee at Texas A&M University. 
 
Assays 
Serum triglyceride (reference range: 26 to 108 mg/dL) and cholesterol (reference 
range: 124 to 335 mg/dL) concentrations were measured by enzymatic assays.
c 
Serum 
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Spec cPL concentrations were measured using an analytically validated immunoassay as 
described elsewhere.
178,271
 Serum free T4 concentration was measured using a 
commercial equilibrium dialysis radioimmunoassay.
d 
Serum total T4 concentrations 
were measured using a solid-phase chemiluminescent competitive assay.
e 
 
Statistical analyses 
A commercial statistical software package was used for all statistical analyses.
d
 
Data were analyzed for normal distribution using the Shapiro-Wilk test. Normally 
distributed data were analyzed using t-tests or paired t-tests where appropriate. Non- 
normally distributed data were analyzed using Wilcoxon tests or Wilcoxon rank sum 
tests. Proportions were compared between groups using the Fisher’s exact test. 
Significance was set at P<0.05 for all analyses. 
 
Results 
Dogs in Groups 1 and 2 
All dogs were prospectively enrolled into this study. Of the 35 dogs initially 
considered for enrollment in Group 1, 17 met the inclusion criteria for this group. Five 
dogs were excluded because they had clinical sings of anorexia, diarrhea, and/or 
abdominal pain at the time of the second blood collection, 4 dogs were excluded because 
they had been diagnosed with diabetes mellitus (2) or hypothyroidism (2), and 7 dogs 
were excluded because of a Spec cPL concentration in the follow-up sample above 200 
μg/L (3 of these dogs also had clinical signs associated with pancreatitis). Follow-up 
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samples from the 17 Miniature Schnauzers that were included in Group 1 were collected 
within a median interval of 12 weeks (range: 2 to 41 weeks) after the first sample 
collected at the time of diagnosis of pancreatitis. Group 1 consisted of 9 female (8 
spayed) and 8 male (6 castrated) dogs. 
Group 2 consisted of 34 Miniature Schnauzers that had fulfilled the inclusion 
criteria outlined above and had been age-matched with the dogs in Group 1. Group 2 
consisted of 22 female (8 spayed) and 12 male (3 castrated) dogs. 
 
Comparisons between Groups 1 and 2 
All comparisons between Groups 1 and 2 were made using the information and 
test results that corresponded to the follow-up sample (which was collected after clinical 
and biochemical resolution of pancreatitis) for Group 1. The weight was known for 
16/17 dogs in Group 1 and 30/34 dogs in Group 2; there was no significant difference of 
the mean body weight between Group 1 (7.8 kg) and Group 2 (7.6; P=0.6702). As 
outlined in the study’s inclusion criteria, all dogs had a serum free T4 (15 dogs in Group 
1 and 32 dogs in Group 2) or total T4 (2 dogs in each Group) within the respective 
reference interval. Of the dogs in Group 1, 8/16 (50.0%) were mainly on a home-made 
(n=1) or commercial (n=7) diets labeled as low-fat, including prescription (n=5) and 
non-prescription (n=2) diets. Of the 34 dogs in Group 2, 1 was mainly on a home-made 
low-fat diet, none were on prescription low-fat diets at the time of blood collection, 
while 4 dogs (11.8%) were on commercial diets labeled as low-fat. Dogs in Group 1 
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were significantly more likely to be on a low-fat diet than dogs in Group 2 (odds 
ratio=5.8, 95% CI, 1.5 to 22.7, P=0.0143). 
Of the 17 Miniature Schnauzers in Group 1, 12 (71%) had serum triglyceride 
concentrations above the reference interval in the follow-up sample, while only 11 
(33%) of the 34 Miniature Schnauzers in Group 2 had serum triglyceride concentrations 
above the upper limit of the reference interval. Miniature Schnauzers in Group 1 were 
significantly more likely to have hypertriglyceridemia than Miniature Schnauzers in 
Group 2 (odds ratio=5.02; 95% CI, 1.4 to 17.8; P=0.0163). To take into account the 
severity of hypertriglyceridemia, the proportion of dogs with moderate to severe 
hypertriglyceridemia (>500 mg/dL)
252,257
 was compared between groups. Ten out of 17 
(59%) dogs in Group 1 and 3/34 (9%) in Group 2 had serum triglyceride concentrations 
>500 mg/dL (odds ratio=14.8; 95% CI, 3.2 to 68.1; P=0.0003). Serum triglyceride 
concentrations were significantly higher in dogs of Group 1 (median: 605.0 mg/dL; 
range: 41.0 to 2,134.0 mg/dL) than in dogs of Group 2 (median: 73.0 mg/dL; range: 23.0 
to 3,975.0; P=0.002; Figure 5).  
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Serum cholesterol concentrations were significantly higher in dogs of Group 1 
(median: 287.6 mg/dL) than in those of Group 2 (median: 204.0 mg/dL; P=0.0001; 
Figure 6). Five dogs in Group 1 (29.4%) and 1 dog in Group 2 (2.9%; P=0.0136) had 
serum cholesterol concentrations above the upper limit of the reference interval, and 
hypercholesterolemia was associated with hypertriglyceridemia in all cases.  
 
Comparisons within Group 1 
Within Group 1, serum triglyceride concentrations were not significantly 
different during (median: 215.5 mg/dL) and after resolution of pancreatitis (median: 
580.0 mg/dL; P=0.552). However, great variation of values within the same dog existed 
between the two time-points for many of the dogs (Figure 7). Interestingly, serum 
triglyceride concentrations were normal or below the lower limit of the reference 
interval in 3 of the dogs during pancreatitis (20, 51, and 85 md/dL) and increased (429, 
2,134, and 1,851 mg/dL, respectively) after resolution of pancreatitis (Figure 7). These 
dogs were each on the same diet (n=2) or on diets with a similar fat content (n=1) both 
time-points. 
In the same group, mean serum cholesterol concentrations were not significantly 
different during (251.7 mg/dL) and after resolution of pancreatitis (272.7 mg/dL; 
P=0.3523).  
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Figure 5. Comparison of serum triglyceride concentrations between Miniature 
Schnauzers with a history of pancreatitis (Group 1) and Miniature Schnauzers with no 
history of pancreatitis (Groups 2). Serum triglyceride concentrations were significantly 
higher in dogs of Group 1 (median: 605.0 mg/dL) than those in dogs of Group 2 
(median: 73.5.0 mg/dL; P=0.0108). The dashed line represents the upper limit of the 
reference interval. Note: the Y-axis in split. 
 77 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Comparison of serum cholesterol concentrations between Miniature 
Schnauzers with a history of pancreatitis (Group 1) and Miniature Schnauzers with no 
history of pancreatitis (Groups 2). Serum cholesterol concentrations were significantly 
higher in dogs of Group 1 (median: 287.6 mg/dL) than of those in Group 2 (median: 
214.0 mg/dL; P=0.002). Only 5 dogs in Group 1 and 2 dogs in Group 2 had serum 
cholesterol concentrations above the upper limit of the reference interval. The dashed 
line represents the upper limit of the reference interval. 
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Figure 7.  Comparison of serum triglyceride concentrations during pancreatitis and after 
resolution of pancreatitis. This graph shows the distribution and comparison of serum 
triglyceride concentrations in dogs of Group 1 at the time of diagnosis of pancreatitis 
and also after clinical and biochemical resolution of pancreatitis. Serum triglyceride 
concentrations were not significantly different at the time of diagnosis of pancreatitis 
(median: 215.5 mg/dL) than after resolution of pancreatitis (median: 580 mg/dL; 
P=0.552). For many of the dogs great variation of serum triglyceride concentrations 
existed between the 2 time-points. The dashed line represents the upper limit of the 
reference interval. 
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Discussion 
In the present study, Miniature Schnauzers with a history of pancreatitis were 5 
times more likely to have hypertriglyceridemia and almost 15 times more likely to have 
moderate to severe hypertriglyceridemia (defined as >500 mg/dL) than age-matched 
Miniature Schnauzers with no history of pancreatitis. The majority of Miniature 
Schnauzers with a history of pancreatitis (58.8%) had moderate to severe 
hypertriglyceridemia as compared to only 8.8% in the control group. The presence of 
hypertriglyceridemia after resolution of pancreatitis is considered to provide 
retrospective evidence of a pre-existing disorder in lipid metabolism.
256,267,268,270
 
Knowing whether severe hypertriglyceridemia is a risk factor or even a cause of 
pancreatitis is of major importance in dogs, because control of hypertriglyceridemia 
might prevent the development or recurrence of pancreatitis. This has been confirmed in 
human patients with severe hypertriglyceridemia and pancreatitis, in whom control of 
hypertriglyceridemia limits the risk of recurrence of pancreatitis.
267,272
 People with 
uncontrolled severe hypertriglyceridemia commonly have recurrent pancreatitis.
257,272
  
It remains to be determined whether pre-existing hypertriglyceridemia in this 
group of Miniature Schnauzers predisposed them to develop pancreatitis. A clear causal 
association between hypertriglyceridemia and pancreatitis in Miniature Schnauzers is 
very challenging to illustrate in clinical studies. Ideally, samples before, during, and after 
resolution of pancreatitis should be collected in order to clearly determine the 
association between hypertriglyceridemia and pancreatitis. Although this is possible to 
do in experimental models of pancreatitis, it is impossible in cases of naturally occurring 
 80 
pancreatitis as it cannot be predicted which dogs will develop pancreatitis. Therefore, 
evidence of pre-existing hypertriglyceridemia in this study was based on the presence of 
hypertriglyceridemia after recovery from pancreatitis. Most follow-up samples were 
collected soon after pancreatitis was diagnosed (within 1-4 months) and thus it is very 
likely that hypertriglyceridemia was present before the development of pancreatitis. This 
has been shown in a large number of human studies using different methods, in which 
disorders of lipid metabolism that persist after recovery from pancreatitis were 
considered to be pre-existing.
256,267,268,270
 Due to the fact that follow-up samples in 
Group 1 were collected after resolution of pancreatitis (based on both clinical and 
biochemical evidence), it is unlikely that hypertriglyceridemia in these samples was the 
result of pancreatitis. There is a theoretical possibility that pancreatitis could have 
permanently changed lipid metabolism in those dogs but, to the authors’ knowledge, this 
has not been reported or even hypothesized in dogs or any other species.     
It needs to be pointed out that, in this study, Miniature Schnauzers with a history 
of pancreatitis were significantly more likely to be on diets labeled as low-fat than dogs 
of the same breed without such a history. This is very important because the reported 
serum triglyceride concentrations after recovery from pancreatitis likely underestimate 
the true prevalence and severity of serum triglyceride concentrations before the 
development of pancreatitis. Despite that, Miniature Schnauzers with a history of 
pancreatitis were significantly more likely to have hypertriglyceridemia than age-
matched Miniature Schnauzers with no history of pancreatitis. It is very important to 
note, however, that the diets were considered to be low-fat only based on their label and 
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not their actual fat content. Although this is a rather inaccurate way to determine the fat 
content of a diet, such an approach was chosen because several dogs were on home-
made diets, while other dogs were on more than one diets at the same time, and it would 
be impossible to determine that fat content of the diet for each dog. 
Many dogs in the control group had hypertriglyceridemia and yet no known 
history of pancreatitis. This is also commonly reported in humans, and the reason for this 
is unknown.
255,258
 There are several possible explanations for this observation. First, as 
mentioned above, a causal association between hypertriglyceridemia and pancreatitis in 
dogs remains to be determined. If a causal association exists, it is possible that there are 
differences in lipoprotein composition or metabolism between individuals, which may or 
may not predispose to pancreatitis. In addition, individual cases of mild pancreatitis 
might have escaped diagnosis, or some of these patients will develop pancreatitis in the 
future. It should also be pointed out that in the case of the present study, most 
hypertriglyceridemic dogs (91%) in the control group had mild (<500 mg/dL) 
hypertriglyceridemia, which might be less likely to be associated with pancreatitis. 
Several studies in humans have evaluated various methods to predict which 
hypertriglyceridemic individuals will develop pancreatitis but results of these studies are 
inconclusive.
256,268,270
 Such studies have not been reported, but based on the results 
reported here, are clearly warranted in dogs, in order to provide a better understanding of 
the possible lipid disorders associated with pancreatitis. 
 Great variation in serum triglyceride concentrations existed within some 
individual dogs in Group 1 between the 2 time-points (during and after resolution of 
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pancreatitis). Although these results must be interpreted with caution because dietary 
information was not available for all dogs during pancreatitis and because the diet was 
different between the two time-points for some of the dogs, an interesting observation 
can be made. Serum triglyceride concentrations were normal or below the lower limit of 
the reference interval in 3 of the dogs during pancreatitis (20, 51, and 85 md/dL) and 
increased or even dramatically increased (429, 2,134, and 1,851 mg/dL, respectively) 
after resolution of pancreatitis (Figure 7). These dogs were each on the same diet (n=2) 
or on diets with a similar fat content (n=1) during both time-points. Although the reason 
for this finding is unknown, it might be that extensive anorexia (all 3 dogs were reported 
to be anorexic) and/or fasting during pancreatitis led to normalization of serum 
triglyceride concentrations in these dogs during this time-period. Similar findings have 
been reported in humans with pancreatitis, where even profound increases in serum 
triglyceride concentrations (>1,750 mg/dL) returned to normal within 72 hours of initial 
presentation.
267,269,270
 On the other hand, one dog that was on the same diet at both time-
points had severely increased serum triglyceride concentrations during pancreatitis 
(1,363 mg/dL) and normal serum triglyceride concentrations after resolution of 
pancreatitis (52 mg/dL). Regardless of the possible explanation, these findings suggest 
that serum triglyceride concentrations during the course of pancreatitis may not 
accurately reflect the true triglyceride concentrations.
255,258,267
 Therefore, it might be 
recommended that serum triglyceride concentrations be measured after resolution of 
pancreatitis to make sure that the measurements accurately reflect the condition of each 
dog.  
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Although serum cholesterol concentrations were significantly higher in Miniature 
Schnauzers with a history of pancreatitis compared to controls, the medians of both 
groups were within the reference interval. In addition, only 5 dogs in Group 1 had 
hypercholesterolemia, which was always mild and seen only in association with 
hypertriglyceridemia. This is in agreement with the results of a previous study in healthy 
Miniature Schnauzers.
84
 To the authors’ knowledge, there is no evidence to suggest that 
hypercholesterolemia might play a role in the development of pancreatitis in dogs or any 
other species, and this is supported by the findings of the present study.  
Due to the fact that the dogs in this study had normal serum free or total T4 
concentrations, no clinical signs, and no history of a disease or drug administration 
known to affect lipid metabolism, it is logical to assume that hypertriglyceridemia in 
these dogs was likely idiopathic.
84,252
 Although an association between endocrinopathies 
commonly accompanied by secondary hypertriglyceridemia and pancreatitis has been 
previously reported, the retrospective design of these studies does not allow 
determination of whether this was due to hypertriglyceridemia or not.
64,65
 Further studies 
are needed to determine what proportion of dogs with pancreatitis has persisting 
hypertriglyceridemia secondary to other diseases.  
 One limitation of the present study is that even with a normal Spec cPL 
concentration and the absence of clinical signs of pancreatitis, mild residual 
inflammation of the pancreas cannot be definitively excluded. The only way to exclude 
this possibility would be through histopathologic examination of multiple pancreatic 
biopsies, a very invasive procedure that cannot be ethically justified in patients that have 
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recovered from pancreatitis. In addition, even if some mild residual inflammation of the 
pancreas was present in some dogs, it is not known whether this can affect lipid 
metabolism. Theoretically, longer intervals between pancreatitis and the follow-up 
sample could have been used, but then it would have been be more likely that, with 
increasing age, hypertriglyceridemia would develop, because previously reported data 
suggest that hypertriglyceridemia in the Miniature Schnauzer should be regarded as an 
age-related condition.
84
  
 In conclusion, Miniature Schnauzers with a history of pancreatitis were 5 times 
more likely to have hypertriglyceridemia than age-matched control dogs of the same 
breed. In addition, Miniature Schnauzers with a history of pancreatitis were almost 15 
times more likely to have moderate to severe hypertriglyceridemia (>500 mg/dL) than 
controls. It is logical to assume that hypertriglyceridemia was a pre-existing condition in 
most Miniature Schnauzers with a history of pancreatitis in this study. This study shows 
that, in contrast to control dogs, the majority of Miniature Schnauzers with a history of 
pancreatitis have hypertriglyceridemia. Additional studies are needed to further clarify 
the role of hypertriglyceridemia in the development of pancreatitis in Miniature 
Schnauzers as well as other dog breeds. 
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a
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®
, IDEXX Laboratories, Inc., Westbrook, ME 
b
McCord, K., Davis, J, Leyva, F.et al. A multi-institutional study evaluating diagnostic 
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 in the diagnosis of acute pancreatitis in dogs. J Vet Int Med 23(3), 
734. 2009. 
c
Roche/Hitachi MODULAR ANALYTICS D 2400 module, Roche Diagnostics, 
Indianapolis, IN 
d
Free T4 (by ED), Antech Diagnostics, Irvine, CA   
e
Immulite 2000 Canine Total T4, Siemens Healthcare Diagnostics, Deerfield, IL 
f
Prism5, GraphPad, San Diego, CA 
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CHAPTER IV 
LIPOPROTEIN PROFILING USING DENSITY GRADIENT 
ULTRACENTRIFUGATION IN HEALTHY DOGS OF VARIOUS BREEDS, 
HEALTHY MINIATURE SCHNAUZERS, AND MINIATURE SCHNAUZERS 
WITH HYPERLIPIDEMIA 
 
Introduction  
The investigation of lipoprotein profiles in serum or plasma from healthy dogs 
has been the subject of research since the 1940s.
1,2,6,8
 Much of our current knowledge on 
canine lipoproteins in dogs originates from studies reported in the 1970s, which 
investigated dogs as possible models for human cardiovascular disease.
6,8,21
 More recent 
studies have investigated canine lipoproteins in association with several disease 
conditions or physiologic stages.
11,12,17,19-21,273
 These studies have provided important 
information on the major serum lipoprotein fractions found in dogs, namely 
chylomicrons, very low density lipoproteins (VLDL), low density lipoproteins (LDL), 
and high density lipoproteins (HDL). With the development and increased availability of 
advanced methodologies (e.g., nuclear magnetic resonance spectroscopy,
274
 newer 
density gradient ultracentrifugation techniques,
28,275
 surface enhanced laser desorption 
ionization time-of-flight mass spectrometry (SELDI-TOF MS)
276
), more detailed, 
accurate, and effortless characterization of lipoprotein profiles in dogs should be 
possible. Some studies in humans have suggested that the major serum lipoprotein 
classes are each a very heterogeneous group of molecules that can be subdivided into 
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several subfractions, with different disease associations for each subfraction.
277,278
 A 
significant body of research has been devoted to defining the role of these lipoprotein 
subfractions in a number of human diseases.
277,278
 Novel methodologies developed for 
the effective separation and study of lipoprotein subfractions have not previously been 
applied to dogs, and therefore the feasibility of application and usefulness of these 
techniques is not known in this species. 
Diseases that affect lipoprotein metabolism are common in dogs.
252
 By far, the 
most common disorders of lipoprotein metabolism in dogs are secondary to other 
diseases, such as diabetes mellitus, hypothyroidism, and hyperadrenocorticism.
252
 
Miniature Schnauzers are particularly interesting with regard to their serum lipids and 
lipoprotein profiles. Primary hypertriglyceridemia is a common condition in Miniature 
Schnauzers in the United States. In 1 study, hypertriglyceridemia was present in 32.8% 
of 192 Miniature Schnauzers investigated.
84
 In this breed, hyperlipidemia, and more 
specifically hypertriglyceridemia, might be associated with diseases such as 
hepatobiliary disease, pancreatitis, insulin resistance, and ocular disease.
123,252,279,280
 The 
biochemical, metabolic, and genetic bases of hypertriglyceridemia in Miniature 
Schnauzers have not been identified yet.
 
Previous studies have shown that 
hypertriglyceridemia in Miniature Schnauzers is mainly characterized by an abnormal 
accumulation of VLDL with or without hyperchylomicronemia.
17
 
Detailed characterization of serum lipids and lipoproteins in Miniature 
Schnauzers can provide a greater insight into the biochemical and metabolic bases of 
primary hypertriglyceridemia in this breed. In addition, characterization of serum lipids 
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and lipoproteins in healthy dogs of various breeds is important as a basis for further 
research in dogs with hyperlipidemia of different causes and the development of 
disorders as a result of hyperlipidemia. Despite the importance of lipoprotein research in 
dogs, the fact that most previously used methods for lipoprotein profiling are rather 
laborious and time-consuming has been a major obstacle to the wide application and use 
of lipoprotein profiling in this species. To this end, a convenient, economical, and robust 
method of lipoprotein profiling would be highly desirable. The aim of the present study 
was to assess the feasibility of a novel density gradient ultracentrifugation method in 
dogs, and to characterize and compare the lipoprotein profiles of healthy dogs of various 
breeds, healthy Miniature Schnauzers, and Miniature Schnauzers with primary 
hypertriglyceridemia using the same method.    
 
Materials and methods 
Dogs of various breeds (Group 1) 
A total of 35 healthy dogs of various breeds with serum triglyceride and 
cholesterol concentrations within their respective reference intervals were selected for 
enrollment into the study. Inclusion criteria included absence of any clinical signs at the 
time of blood collection and no history of diseases or current use of drugs known to 
affect lipid metabolism. Owners had been instructed not to feed their dogs for at least 12 
hours before the scheduled blood collection. Serum triglyceride and cholesterol 
concentrations were available for all dogs.  
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Miniature Schnauzers (Group 2) 
Thirty-one Miniature Schnauzers with serum triglyceride and cholesterol 
concentrations within their respective reference intervals (Group 2A) and 31 Miniature 
Schnauzers with hypertriglyceridemia (Group 2B) were also included in the study. 
Samples from these dogs were selected from a pool of >300 samples from Miniature 
Schnauzers that were collected as part of several ongoing projects related to 
hypertriglyceridemia in this breed. Dogs that were included in Group 2 had to have 
absence of any clinical signs at the time of blood collection and no history of diseases or 
current use of drugs known to affect lipid metabolism. Miniature Schnauzers in Group 
2A had to be 7 years of age or older in order to minimize the possibility of them 
developing hyperlipidemia in the near future. In addition, for the Miniature Schnauzers 
with hypertriglyceridemia (Group 2B), serum Spec cPL, glucose, total T4, and free T4 
(in cases in which serum total T4 was below the lower limit of the reference interval) 
concentrations were measured. Based on the historical information for each dog and the 
results of the tests performed, all hypertriglyceridemic dogs enrolled in this study were 
diagnosed as having primary idiopathic hypertriglyceridemia of Miniature Schnauzers. 
Serum cholesterol concentrations were measured in all dogs of Group 2. Owners of dogs 
in Group 2 had been instructed not to feed their dogs for at least 12 hours before the 
scheduled blood collection. 
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Blood collection and handling 
Owners living in relative proximity to the Gastrointestinal Laboratory at Texas 
A&M University were instructed to schedule an appointment for blood collection at that 
location. Owners that could not come to Texas A&M for blood collection were each sent 
a styrofoam box containing ice packs and the material necessary for blood collection, 
and were asked to schedule an appointment with their veterinarian for blood collection. 
Ten milliliters of blood were collected from each dog into a red-top tube (with no 
additive). Immediately after clot formation, the samples were centrifuged and the serum 
was separated from the clot. Samples not collected at Texas A&M University were sent 
to the Gastrointestinal Laboratory packed on ice by overnight courier. Serum samples 
were stored at -80
o
C until further use.  
 
Questionnaires and consent forms 
Owners of all dogs were asked to complete a questionnaire for each dog. 
Questions covered date of birth, sex, body weight, current diet(s), current medications, 
and current and past health history of the dogs. Questionnaires from all dogs were 
reviewed to determine whether the dogs fit the inclusion criteria for each group. All 
owners signed an informed owner consent form. The study protocol was reviewed and 
approved by the Clinical Research Review Committee at Texas A&M University. 
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Assays 
Serum triglyceride (reference interval: 26 to 108 mg/dL), cholesterol (reference 
interval: 124 to 335 mg/dL), and glucose (reference interval: 60 to 120 mg/dL) 
concentrations were measured by automated enzymatic assays.
a 
Serum Spec cPL 
concentrations (reference interval: ≤200 µg/L) were measured using an analytically 
validated immunoassay as described elsewhere.
178
 Serum total T4 concentrations were 
measured by a solid-phase chemiluminescent competitive assay.
b
 Serum free T4 
concentration was measured using a commercial equilibrium dialysis 
radioimmunoassay.
c 
 
Lipoprotein profile analysis 
Lipoprotein profiling was carried out using a bismuth sodium 
ethylenediaminetetraacetic acid (NaBiEDTA or NaBiY) density gradient 
ultracentrifugation method as previously described with some modifications.
281
 The 
sodium salt of BiEDTA has been described as a novel solute forming self-generating 
density gradient during ultracentrifugation of serum samples for the separation of 
lipoproteins.
281
 Briefly, for each sample, 1,284 µL of a 0.18M NaBiEDTA
d
 gradient 
solution was added into a 1.5 mL tube. The fluorescent probe 6-((N-(7-nitrobenz-2-oxa-
1,3-diazol-4-yl)amino)hexanoyl)sphingosine (NBD C6-ceramide)
e
 was reconstituted 
with 1 g/mL DMSO, and 10 µL of the 1 mg/mL solution were added to each tube to 
label the lipoproteins.  
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Finally, 6 µL of serum were added to each tube. The mixture was vortexed at 
1,400 rpm for 10 seconds and 1,150 µL of it were transferred into an ultracentrifuge 
tube.
f
 The mixture was allowed to incubate for 30 minutes at 5
o
C to allow for the 
fluorescent probe to saturate the lipoproteins. The solution was then centrifuged at 
120,000 rpm, at 5
o
C, for 6 hours in a Beckman Optima ultracentrifuge (TLX-110)
g
 with 
a 30
o 
fixed angle TLA 120.2 rotor
h
. A quality-control sample was included in each run to 
verify proper operating conditions were achieved. Immediately after ultracentrifugation, 
the top of each sample was carefully layered with 250 mL of hexane and imaged without 
delay.  
For imaging, each tube was placed in a custom, in-house imaging instrument as 
previously described.
281
 The samples were imaged using a custom-built fluorescence 
imaging system consisting of a digital camera
i
 with a MH-100 metal halide continuous 
light source
j
, located in a dark room (Figure 8).  
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Figure 8. Custom-built fluorescence imaging system consisting of a digital camera with 
a MH-100 metal halide continuous light source used for imaging of the tubes after 
ultracentrifugation. 
 94 
Two filters
k
 matching the excitation (blue-violet filter centered at 407 nm) and 
emission (a yellow emission long pass filter with a cut-on wavelength of 515 nm) 
characteristics of NBD C6-cermide were used. A gain of 1.0000, a target intensity of 
30%, and an exposure time of 53.3 ms were selected. In order to be analyzed, the image 
of the each tube following ultracentrifugation was converted to a density profile using a 
commercially available software program.
l
 A tube coordinate scale was established 
where 0.0 mm was the top of the tube and 34.0 mm was the bottom of the tube.
281
 The 
average intensity was then plotted as a function of tube coordinate. 
The ultracentrifugation method described above is able to identify 11 separate 
density lipoprotein fractions (TRL, 5 LDL fractions, and 5 HDL fractions). This 
separation is based solely on the density characteristics of the lipoprotein fractions and 
not on their functional properties. Therefore, this method was used to develop 
lipoprotein fingerprinting in canine serum based on lipoprotein densities alone. Density 
ranges were based on those previously published by several authors.
282
 Specifically, the 
11 fractions and their corresponding densities (d) were as follows:  chylomicrons and 
VLDL (d<1.017 g/mL), LDL1 (d=1.019 to 1.023 g/mL), LDL2 (d=1.023 to 1.029 g/mL),
 
LDL3 (d=1.029 to 1.039 g/mL), LDL4 (d=1.039 to 1.050 g/mL),
 
LDL5 (d=1.050 to 1.063 
g/mL), HDL2b (d=1.063 to 1.091 g/mL), HDL2a
 
(d=1.091 to 1.110 g/mL), HDL3a 
(d=1.110 to 1.133 g/mL), HDL3b (d=1.133
 
to 1.156 g/mL), and HDL3c (d=1.156 to 1.179 
g/mL).
282
 HDL1 is typically not found in healthy humans but it has been thought to occur 
in healthy dogs.
8,282
 However, it has not been convincingly shown that the previously 
described canine HDL1 molecule has the same function as human HDL1, and its density 
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range HDL1 has not been accurately determined (previously published densities vary 
between 1.025 and 1.1).
8
 Studies in humans that have determined the density of HDL1 
suggest that the density of this molecule is around 1.08 g/mL, which would suggest that 
it corresponds with HDL2b and possibly HDL2a.
283
 
 
Statistical analysis 
Commercial statistical software packages were used for all statistical 
analyses.
m,n,o
 Data were analyzed for normal distribution using the Shapiro-Wilk test. 
Normally distributed data were analyzed using t-tests, while not normally distributed 
data were analyzed using Mann-Whitney tests. Sliced-inverse regression was used to test 
the hypothesis that there is a relationship between the group and the lipoprotein profiles. 
Non-parametric correlations were used to test a linear relationship between parameters. 
Significance was set at P<0.05 for all analyses. 
 
Results 
Dogs in Group 1 
 The 35 dogs with serum triglyceride and cholesterol concentrations within the 
reference interval belonged to 19 different breeds (23 dogs), while 12 dogs were mixed-
breed. Sixteen dogs were female (15 spayed) and 19 dogs were male (16 castrated). The 
body condition score (BCS) of the dogs in this group ranged from 3.5/9 to 6/9 (median: 
5). The median age of the dogs was 4.4 years (range: 1.3 to 11.9 years). 
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Dogs in Group 2 
 Group 2A consisted of 31 Miniature Schnauzers with serum triglyceride and 
cholesterol concentrations within the reference interval. Fifteen dogs were female (9 
spayed) and 16 dogs were male (5 castrated). The BCS of the dogs in this group ranged 
from 3/9 to 7/9 (median: 5). The average age of the dogs in this group was 9.3 years 
(range: 7 to 12 years).  
 Group 2B consisted of 28 Miniature Schnauzers with hypertriglyceridemia. Ten 
of the dogs also had hypercholesterolemia. Nineteen dogs were female (16 spayed) and 9 
dogs were male (all castrated). The BCS of the dogs in this group ranged from 4/9 to 7/9 
(median: 5). The average age of the dogs in this group was 9.5 years (range: 4.5 to 14 
years).  
 There were no statistically significant differences in BCS among the 3 groups 
(P=0.478). Dogs in Group 1 were significantly younger than dogs of Group 2A 
(P<0.0001) and Group 2B (P<0.0001). There was no statistically significant difference 
in age between Groups 2A and 2B (P=1.0).    
 
Serum triglyceride and cholesterol concentrations of dogs in Groups 1 and 2A (dogs 
with serum triglyceride and cholesterol concentrations within the reference interval) 
 Serum triglyceride concentrations of dogs in Group 1 (median: 52 mg/dL; range: 
27 to 105 mg/dL), were not significantly different from those of dogs in Group 2A 
(median: 54 mg/dL; range: 19 to 108 mg/dL; p value > 0.05; Figure 9). Serum 
cholesterol concentrations of dogs in Group 1 (median: 221 mg/dL; range: 97 to 308 
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mg/dL) were significantly higher than those of dogs in Group 2A (median: 168 mg/dL; 
range: 74 to 316 mg/dL; p value= 0.003; Figure 10), although all values for both groups 
were within the reference interval.  
 
Serum triglyceride and cholesterol concentrations of dogs in Group 2B (Miniature 
Schnauzers with hypertriglyceridemia) 
Group 2B consisted of 31 Miniature Schnauzers with hypertriglyceridemia. 
Serum triglyceride concentrations ranged from 218 mg/dL to 3,975 mg/dL (median: 750 
mg/dL). Eleven of the 31 dogs (35%) also had hypercholesterolemia. Serum cholesterol 
concentrations ranged 158 mg/dL to 575 mg/dL (median: 296 mg/dL). As expected, both 
serum triglyceride (P<0.05) and cholesterol (P<0.05) concentrations were significantly 
higher in dogs of Group 2B than dogs of Group 2A (Figures 9 and 10).  Similarly, both 
serum triglyceride (P<0.05) and cholesterol (P<0.05) concentrations were significantly 
higher in dogs of Group 2B than dogs of Group 1 (Figures 9 and 10).  
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Figure 9: Serum triglyceride concentrations in dogs of other breeds (Group 1), 
Miniature Schnauzers with normal serum triglyceride concentrations (Group 2A), and 
Miniature Schnauzers with hypertriglyceridemia (Group 2B). Triglyceride 
concentrations of dogs in Groups 1 and 2A were all within the reference interval. 
Triglyceride concentrations of dogs in Group 2B were all above the reference interval. 
The dashed line represents the median for each group. Note: the Y-axis is split.
 99 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Serum cholesterol concentrations in dogs of other breeds (Group 1), 
Miniature Schnauzers with normal serum triglyceride concentrations (Group 2A), and 
Miniature Schnauzers with hypertriglyceridemia (Group 2B). Serum cholesterol 
concentrations of dogs in Groups 1 and 2A were all within the reference interval. Serum 
cholesterol concentrations were above the upper limit of the reference interval for 11 
dogs in Group 2B. The dashed line represents the median for each group.
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Lipoprotein profiles of dogs in Groups 1 and 2A (dogs with serum triglyceride and 
cholesterol concentrations within the reference interval) 
 Figure 11 on page 102 shows a representative lipoprotein profile from a dog in 
Group 1. It is clearly evident that the most abundant lipoprotein fraction is HDL, mainly 
HDL2 and HDL3, seen at a tube coordinate between 23 mm and 31 mm (Figure 11). 
LDL fractions are seen at a tube coordinate between 9 mm and 23 mm, but they were 
present in very small amounts, with the exception of LDL4 and LDL5. The fraction of 
triglyceride-rich lipoproteins (TRL) seen at a tube coordinate of 6 mm to 9 mm contains 
mainly chylomicrons, VLDL, and chylomicron and VLDL remnants. Triglyceride-rich 
lipoproteins were also found in very small amounts.   
 Figure 12 on page 103 shows a representative lipoprotein profile from a dog in 
Group 2A. The lipoprotein profiles of Miniature Schnauzers with serum triglyceride and 
cholesterol concentrations within the reference interval (Group 2A) were generally 
similar to the ones seen in dogs of Group 1 with regard to the abundance of major 
lipoprotein classes. However, most dogs in Group 2A showed some distinct differences 
in some lipoprotein fractions and subfractions.  
 Sliced inverse regression analysis was used to predict if differences in lipoprotein 
profiles were present between Groups 1 and 2A, and also to test whether lipoprotein 
profiles were effective in predicting to which group each dog belonged. Based on the 
classification table that documents the validity of predicted probabilities, the group to 
which each dog belonged (i.e., Miniature Schnauzer versus other breed) could be 
accurately predicted based on their lipoprotein profiles in 85% of the cases 
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(Eigenvalues=0.5455; P=0.00017; Figure 13). Specifically, 90% of Miniature 
Schnauzers could be classified as Miniature Schnauzers, and 80% of dogs of other 
breeds could be classified as other breeds based on their lipoprotein profiles alone. The 
most important lipoprotein fractions that served as predictors were the TRLs and the 
LDL fraction corresponding to LDL4 and LDL5 (Figures 11 and 12). Miniature 
Schnauzers had more prominent TRL peaks than dogs of other breeds, while dogs of 
other breeds had more prominent LDL4 and LDL5 peaks. 
 
Lipoprotein profiles of dogs in Group 2B (Miniature Schnauzers with 
hypertriglyceridemia) 
 Figures 14A and 14B show representative lipoprotein profiles from 2 dogs in 
Group 2B. Similarly to dogs in Groups 1 and 2A, HDLs were abundant and LDLs were 
low in this group. However, dogs of this group had prominent peaks corresponding to 
the TRL area. 
 Sliced inverse regression analysis was used to predict if differences in lipoprotein 
profiles were present between Groups 2A and 2B, and also to test whether and which 
lipoprotein profiles were effective in predicting which group each dog belonged to. The 
SIR model showed that the group to which each dog belonged (i.e., Miniature 
Schnauzers with serum triglyceride concentrations versus hypertriglyceridemic 
Miniature Schnauzers) could be accurately predicted based on their lipoprotein profiles 
in 95% of cases (Eigenvalues=0.7638; P=0.000002; Figure 15).  
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Figure 11: Representative lipoprotein density profile from a healthy dog of non-
Miniature Schnauzer breed (Group 1). This dog had serum triglyceride and cholesterol 
concentrations within the respective reference intervals. The most abundant lipoprotein 
fraction is HDL, mainly HDL2 and HDL3, seen at a tube coordinate between 23 mm and 
31 mm. LDL fractions are present in very small amounts and are seen at a tube 
coordinate between 9 mm and 23 mm. The fraction of TRLs seen at a tube coordinate of 
6 mm to 9 mm contains mainly chylomicrons, VLDL, and chylomicron and VLDL 
remnants. Triglyceride-rich lipoproteins were also found in very small amounts. 
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Figure 12: Representative lipoprotein density profile of a Miniature Schnauzer with a 
serum triglyceride concentration within the reference interval (Group 2A). This 
Miniature Schnauzer also had a serum cholesterol concentration within the reference 
intervals. The lipoprotein profiles of dogs in Group 2A were generally similar to the 
ones seen in dogs of Group 1 (Figure 11) with regard to the abundance of major 
lipoprotein classes. However, most dogs in Group 2A showed some distinct differences 
in some lipoprotein fractions and subfractions (e.g., more abundant TRLs and less 
abundant LDLs). 
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Figure 13. 1-dimensional sliced inverse regression plot showing classification of dogs 
into groups based on lipoprotein profile analysis (Group 1 vs Group 2A). The vertical 
line represents the line that separates the 2 groups based on their lipoprotein profile 
analysis. The LDA value provides a ranking value for each dog. The dogs represented by 
the dots that are at the bottom of the graph are the Miniature Schnauzers of Group 2A. 
Their lipoprotein profiles plot them all to the right of the vertical line, with the exception 
of 3 dogs (90% of dogs classified correctly). The dogs represented by the dots at the top 
of the graph are the dogs of other breeds (Group 1). Twenty-eight of the 35 dogs (80%) 
are classified as a separate group to the left of the vertical line. Seven of the 35 dogs are 
classified to the right of the vertical line together with the Miniature Schnauzers. 
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Figures 14A and 14B: Representative lipoprotein density profiles of Miniature 
Schnauzers with hypertriglyceridemia (Group 2B). Similarly to dogs in Groups 1 and 
2A, HDLs were abundant and LDLs were low in this group. However, dogs of this 
group had prominent peaks corresponding to the TRL area. Note the difference in the 
TRL fractions between the 2 dogs. 
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Figure 15. 1-dimensional sliced inverse regression plot showing classification of dogs 
into groups based on lipoprotein profile analysis (Group 2A vs Group 2B). The vertical 
line represents the line that separates the two groups based on their lipoprotein profile 
analysis. The LDA value provides a ranking value for each dog. The dogs represented by 
the dots that are at the bottom of the graph are the Miniature Schnauzers with 
hypertriglyceridemia. Their lipoprotein profiles plot them all to the right of the vertical 
line, with the exception of one dog with mildly increased serum triglyceride 
concentration (97% of dogs classified correctly). The dogs represented by the dots at the 
top of the graph are the Miniature Schnauzers with serum triglyceride concentrations 
within the reference interval. All but 2 dogs are classified as a separate group to the left 
of the vertical line (94% of dogs classified correctly). 
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Specifically, 97% of non-hypertriglyceridemic Miniature Schnauzers could be 
classified as correctly, and 94% of hypertriglyceridemic Miniature Schnauzers could be 
classified correctly based on their lipoprotein profiles alone. By far, the most important 
lipoprotein fraction that served as a predictor was the TRL fraction, which was more 
prominent in the dogs with hypertriglyceridemia. Fractions corresponding to LDL2, 
LDL3, LDL4, were more prominent in Miniature Schnauzers with serum triglyceride 
concentrations within the reference interval (Figures 14A and 14B). 
 
Correlations 
 Non-parametric correlation tests were used to test whether there was a linear 
relationship between lipoprotein fractions that showed significance in the SIR models 
and serum triglyceride and/or cholesterol concentrations. There was a significant 
positive correlation between TRL intensity and serum triglyceride concentration 
(Spearman r=0.81; 95% CI, 0.73 to 0.87; P<0.0001) and TRL intensity and serum 
cholesterol concentration (Spearman r=0.61; 95% CI, 0.46 to 0.72; P<0.0001). There 
were also significant, but weak, positive correlations between serum cholesterol 
concentration and LDL2 (Spearman r=0.42; 95% CI, 0.24 to 0.58; P<0.0001) and LDL4 
(Spearman r=0.31; 95% CI, 0.11 to 0.48; P=0.0023). 
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Discussion 
 The results of the present study suggest that density gradient ultracentrifugation 
using NaBiY is a useful method for lipoprotein fingerprinting in dogs. This method was 
found to be easy to perform and proved to be a quick and accurate screening method for 
lipoprotein analysis in dogs. Important differences in lipoprotein profiles between 
different groups of dogs were detected with this method. An important and novel finding 
of the present study is that Miniature Schnauzers with serum triglyceride and cholesterol 
concentrations within the reference interval have significantly different lipoprotein 
profiles than those of dogs of various other breeds. In addition, the present study 
confirmed and expanded the findings of previous studies reporting that specific 
lipoprotein classes are associated with hypertriglyceridemia in Miniature Schnauzers. 
 To our knowledge, this is the first study showing that Miniature Schnauzers with 
normal serum triglyceride and cholesterol concentrations differ significantly in certain 
lipoprotein fractions (TRL and LDL4) from dogs of various other breeds. A previous 
study
17
 identified a small number of healthy Miniature Schnauzers (4 out of 11 studied) 
that differed in some lipoprotein fractions (LDL and VLDL) compared with dogs of 
other breeds. However, in that particular study, Miniature Schnauzers were classified as 
non-lipemic based on the gross appearance of the plasma and not on a normal plasma 
triglyceride concentration. Indeed, all 4 of the non-lipemic Miniature Schnauzers 
classified as “different” had mild increases in plasma triglyceride concentrations, and 
therefore, mild lipid metabolism alterations were present.   
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The fraction of TRLs was a significantly higher in Miniature Schnauzers of 
Group 2A than in dogs of other breeds, despite the fact that there was no significant 
difference in serum triglyceride concentrations between the 2 groups and serum 
triglyceride and cholesterol concentrations were all within the reference interval. 
Interestingly, serum cholesterol concentrations were found to be significantly higher in 
dogs of other breeds compared to Miniature Schnauzers. This difference might be related 
to the fact that LDL4 was significantly higher in dogs of other breeds compared to 
Miniature Schnauzers. However, similarly to serum triglyceride concentrations, serum 
cholesterol concentrations were all within the reference interval. The marked differences 
in lipoprotein profiles between Miniature Schnauzers and dogs of other breeds despite 
the normal serum triglyceride and cholesterol concentrations clearly suggest that serum 
triglyceride and cholesterol concentrations are insensitive markers for detecting 
differences in lipoprotein metabolism in dogs. These differences in lipoprotein profiles 
could be identified in the vast majority of dogs, as about 90% of them could be classified 
to the correct group based on their lipoprotein profile alone.  
 The reason for the differences in lipoprotein profiles between Miniature 
Schnauzers and dogs of other breeds with normal serum triglyceride and cholesterol 
concentrations is unknown. The clinical importance of such finding is also unknown. 
One plausible scenario for such difference is that some Miniature Schnauzers might have 
an early disorder in lipoprotein metabolism that has not yet affected the overall serum 
triglyceride and cholesterol concentrations, but these concentrations might be affected in 
the future. This hypothesis is supported by the findings of a previous study that 
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suggested that hyperlipidemia is an age-related condition in Miniature Schnauzers.
84
 
However, this explanation does not seem very likely because all Miniature Schnauzers 
with serum triglyceride concentrations within the reference interval enrolled into this 
study were >7 years of age (median age: 9.3 years). Therefore, these dogs were already 
of a rather advanced age and it would seem unlikely that these dogs would develop 
hypertriglyceridemia later in life.
84
 Another possibility is that the majority of Miniature 
Schnauzers differ in their basic lipoprotein metabolism from dogs of other breeds but 
only a portion of these dogs have severe enough lipid metabolism disorders leading to 
hyperlipidemia. Clearly, further studies are needed to determine the reason for this 
finding and whether it has any clinical significance. 
 Lipoprotein profiles of Miniature Schnauzers with hypertriglyceridemia were in 
agreement with the findings of previous studies.
17
 It is interesting to note that the main 
difference between hyperlipidemic and normolipidemic Miniature Schnauzers involved 
significant increases of the TRL fraction in hyperlipidemic Miniature Schnauzers, and 
there was a strong correlation between TRLs and serum triglyceride concentrations. 
Similarly to previous studies, there was no difference in the HDL fractions.
17
 
Interestingly, the present study showed that a specific LDL fraction (LDL2) was 
significantly decreased in Miniature Schnauzers with hyperlipidemia. These findings 
support the findings of previous studies regarding increases in TRLs and decreases in 
LDLs, but also provide additional information about the specific LDL fraction affected.  
Another interesting observation is that the group of Miniature Schnauzers with 
hyperlipidemia, although different in their lipoprotein profiles from Miniature 
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Schnauzers without hyperlipidemia, was rather diverse and there were some distinct 
differences among dogs in the same group. These differences were not always related to 
the different degrees of hyperlipidemia in these dogs. For example, many hyperlipidemic 
Miniature Schnauzers had 2 distinct peaks in their TRL fractions (Figure 14B), while 
others only had 1 (Figure 14A). These 2 peaks likely represent chylomicrons and 
VLDLs, which have slightly different densities. This is in agreement with findings of an 
older study,
17
 in which it was shown that some hyperlipidemic Miniature Schnauzers had 
increases in VLDLs only, while others had increases in both VLDLs and chylomicrons. 
It is not known why some of the hyperlipidemic Miniature Schnauzers have only 1 TRL 
fraction affected while others have 2. In addition, as shown in previous studies,
17,84
 a 
fraction if these dogs had increases in serum cholesterol concentrations. Thus, it is 
obvious that hyperlipidemia in Miniature Schnauzers is not a phenotypically uniform 
disease. This might be the result of the effect of environmental factors or maybe due to 
genetic heterogeneity.  
Miniature Schnauzers of either group were significantly older that dogs of other 
breeds. This was the result of specific selection criteria. Hyperlipidemia in Miniature 
Schnauzers is known to be an age-related condition and, therefore, dogs in Group 2 had 
to be of older age in order to either have developed hyperlipidemia or to minimize the 
possibility that they would develop hyperlipidemia in the near future. For example, in 
one study, only 16% of Miniature Schnauzers between 1 and 3 years of age were 
hypertriglyceridemic, while 78% of Miniature Schnauzers >9 years of age were 
hypertriglyceridemic.  No association between age and serum triglyceride or cholesterol 
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concentrations have been reported or suspected in dogs of breeds other than Miniature 
Schnauzers. 
 In conclusion, the results of the present study suggest that density gradient 
ultracentrifugation using NaBiY is a useful screening method for the study of lipoprotein 
profiles in dogs. Important differences in lipoprotein profiles can be detected with this 
method even among dogs that have serum triglyceride and cholesterol concentrations 
within the reference interval. Miniature Schnauzers with serum triglyceride and 
cholesterol concentrations within the reference interval had significantly different 
lipoprotein profiles (mainly with regard to TRL and LDL4) than dogs of various other 
breeds. In addition, it was further established that specific lipoprotein classes (TRL and 
specific LDL fractions, mainly LDL2) are associated with hypertriglyceridemia in 
Miniature Schnauzers. Changes in these lipoprotein classes are not always uniform 
among Miniature Schnauzers with hyperlipidemia. Further studies are needed to evaluate 
the usefulness of density gradient ultracentrifugation using NaBiY in evaluating 
hyperlipidemia of other causes in dogs, and to establish the clinical significance of 
differences in lipoprotein profiles in Miniature Schnauzers.  
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CHAPTER V 
EFFECT OF A LOW-FAT DIET ON SERUM LIPID AND PANCREATIC 
LIPASE CONCENTRATIONS AND LIPOPROTEIN PROFILES IN 
MINIATURE SCHNAUZERS WITH HYPERLIPIDEMIA 
 
Introduction  
Canine primary hyperlipidemia is a metabolic disorder of likely diverse etiology 
that is more commonly seen in certain breeds.
252
 Primary hyperlipidemia of Miniature 
Schnauzers was the first primary hyperlipidemia disorder described in dogs, and to date, 
it has been reported in dogs of this breed in the United States and Japan.
15,84,284
 In 1 
study from the United States, hypertriglyceridemia was present in 32.8% of 192 
Miniature Schnauzers investigated.
84
 Hyperlipidemia of Miniature Schnauzers is 
typically characterized by hypertriglyceridemia of various degrees due to increases in 
serum very low density lipoproteins (VLDL) and chylomicrons, with or without the 
presence of hypercholesterolemia.
17,84
 In this breed, hypetriglyceridemia might be 
etiologically linked to disorders such as hepatobiliary disease, pancreatitis, insulin 
resistance, and ocular disease.
123,252,285
 The association between hypertriglyceridemia 
and pancreatitis is of particular interest in Miniature Schnauzers as studies have 
suggested that Miniature Schnauzers are also predisposed to pancreatitis.
63,163
 In fact, it 
is widely believed that hypertriglyceridemia predisposes Miniature Schnauzers to 
develop chronic pancreatitis based in part on the observation that dogs of this breed 
often appear to have multiple episodes of pancreatitis throughout their lives.
165,216
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The biochemical, metabolic, and genetic bases of hypertriglyceridemia in 
Miniature Schnauzers have not been elucidated.
 
Therefore, definitive recommendations 
for effective prevention and specific management of this condition are currently 
unavailable. The most commonly recommended initial approach in the management of 
primary hypertriglyceridemia in Miniature Schnauzers is the use of a low-fat diet.
131,252
 
Feeding a low-fat diet is also commonly the recommended approach in the management 
of dogs suspected of having chronic pancreatitis.
286
 There are several commercially 
available diets marketed as “low-fat”, although their actual lipid content might vary 
substantially between one another. To our knowledge, none of these diets have been 
evaluated with regard to their effectiveness in the management of primary 
hypertriglyceridemia in Miniature Schnauzers. Also, the effect of low-fat diets on serum 
concentrations of markers for pancreatitis has not been evaluated. Therefore, the aim of 
the present study was to evaluate the effect of a commercially available low-fat diet on 
serum lipid and pancreas-specific lipase (Spec cPL
®
) concentrations and lipoprotein 
profiles in Miniature Schnauzers with primary hypertriglyceridemia. 
 
Materials and methods 
Dogs 
Miniature Schnauzers with hypertriglyceridemia of various degrees were 
included in the study (Group 1). These dogs were selected from a pool of >300 
Miniature Schnauzers that were enrolled as part of several ongoing projects related to 
hypertriglyceridemia in this breed. The requirements for inclusion in the present study 
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were a diagnosis of hypertriglyceridemia and willingness of each dog’s owners to enroll 
their dog in the study. All dogs included in the study had to have absence of any clinical 
signs at the time of blood collection and no history of diseases or current use of drugs 
known to affect lipid metabolism. They also had to have a normal body condition score 
(BCS; between 4 and 6 on a scale of 1 to 9). In addition, for each dog, serum Spec cPL, 
glucose, total T4, and free T4 (by equilibrium dialysis) concentrations were measured. 
Based on the historical information for each dog and the results of the tests performed, 
all hypertriglyceridemic dogs enrolled in this study were diagnosed as having primary 
idiopathic hypertriglyceridemia. 
 A group of healthy Miniature Schnauzers with serum triglyceride and cholesterol 
concentrations within the respective reference intervals (Group 2) was used as a control 
group for the lipoprotein profile portion of the study. Dogs in Group 2 were used in 
order to obtain lipoprotein profiles from a group of healthy Miniature Schnauzers that 
could be used for illustration of whether lipoprotein profiles of hypertriglyceridemic 
Miniature Schnauzers tended to approach those of the healthy ones after the diet change. 
Dogs of Group 2 had to have absence of any clinical signs at the time of blood collection 
and no history of diseases or current use of drugs known to affect lipid metabolism. 
They also had to have a normal BCS (between 4 and 6 on a scale of 1 to 9) and be on 
diets that were not labeled as low-fat diets at the time of blood collection.  
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Study design 
 Each one of the dogs in Group 1 had a total of 4 blood samples collected. The 
first sample (sample 1) was used to diagnose primary hypertriglyceridemia. Then, in 
order to confirm the results of the initial sample and to investigate the variability of the 
findings, the owners were instructed to have a second sample (sample 2) collected 1 to 2 
months after the collection of the initial sample, and without making any changes to the 
diet of their dogs. If hypertriglyceridemia was confirmed in the second sample, the dogs 
were put on the study diet (see below). Owners were instructed to gradually switch their 
dogs from the original to the study diet over 7 days. Since all dogs had a normal BCS, 
the amount of diet was determined based on the normal weight guide on the package. In 
addition, the owners were instructed to weigh their dogs at weekly intervals and adjust 
the amount of food accordingly in order to maintain a relatively stable body-weight for 
the duration of the study. Additional instructions given to the owners involved ensuring 
that the study diet was fed exclusively to the dogs enrolled in the study, with the 
exception of small quantities of steamed vegetables (carrots and broccoli) that could be 
used as treats. Approximately 7 to 9 weeks after the dogs had been exclusively on the 
study diet, a third blood sample (sample 3) was collected. Finally, a fourth sample 
(sample 4) was collected approximately 2 to 4 weeks after the third sample. 
 Serum triglyceride, cholesterol, and Spec cPL concentrations were measured in 
all samples and compared between time-points. Lipoprotein profiles were also 
determined and compared between time-points and between groups.   
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 Dogs of Group 2 were enrolled on a one-time basis and no follow-up samples 
were collected from these dogs. As mentioned above, these dogs were only used for the 
lipoprotein profile portion of the study. Serum triglyceride, cholesterol, and Spec cPL 
concentrations were also measured in all samples of dogs in this group but were not used 
for any comparison with Group 1 (see above).  
 
Study diet 
 The diet selected for the present study was a commercially available therapeutic 
diet labeled as “low-fat” in dry form.a The fat content of the study diet was 18.6 grams 
of fat per 1,000 Kcal.    
 
Blood collection and handling 
Owners that agreed to participate in the study were each sent a styrofoam box 
containing ice-packs and the material necessary for blood collection, and were asked to 
schedule an appointment with their veterinarian for the blood collection. Ten milliliters 
of blood were collected from each dog into a red-top tube (with no additive). 
Immediately after clot formation, the samples were centrifuged and the serum was 
separated from the clot. The samples were sent to the Gastrointestinal Laboratory packed 
on ice by overnight courier. Serum samples were stored at -80
o
C until use.   
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Questionnaires and consent forms 
Owners of all dogs were asked to complete a questionnaire for each dog. 
Questions covered date of birth, sex, body-weight, BCS, current diet(s), current 
medications, and current and past health history of the dogs. Questionnaires from all 
dogs were reviewed to determine whether the dogs fit the inclusion criteria for each 
group. All owners signed an informed owner consent form. The study protocol was 
reviewed and approved by the Clinical Research Review Committee at Texas A&M 
University. 
 
Assays 
Serum triglyceride (reference interval: 26 to 108 mg/dL), cholesterol (reference 
interval: 124 to 335 mg/dL), and glucose (reference interval: 60 to 120 mg/dL) 
concentrations were measured by automated enzymatic assays.
b
 Serum Spec cPL 
concentration (reference interval: ≤200 µg/L) was measured using an analytically 
validated immunoassay as described elsewhere.
178
 Serum total T4 concentration was 
measured by a solid-phase chemiluminescent competitive assay.
c
 Serum free T4 
concentration was measured using a commercial equilibrium dialysis 
radioimmunoassay.
d 
 
Lipoprotein profile analysis 
Lipoprotein profiling was carried out using a bismuth sodium 
ethylenediaminetetraacetic acid (NaBiEDTA or NaBiY) density gradient 
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ultracentrifugation method as previously described, with some modifications.
281
 The 
sodium salt of BiEDTA has been described as a novel solute forming a self-generating 
density gradient during ultracentrifugation of serum samples for the separation of 
lipoproteins.
281
 Briefly, for each sample, 1,284 µL of a 0.18M NaBiEDTA
e
 gradient 
solution was added into a 1.5 mL tube. The fluorescent probe 6-((N-(7-nitrobenz-2-oxa-
1,3-diazol-4-yl)amino)hexanoyl)sphingosine (NBD C6-ceramide)
f
 was reconstituted with 
1 g/mL DMSO and 10 µL of the 1 mg/mL solution were added to each tube to label the 
lipoproteins. Finally, 6 µL of serum were added to each tube. The mixture was vortexed 
at 1,400 rpm for 10 seconds and 1,150 µL of the mixture were transferred into an 
ultracentrifuge tube.
g
 The mixture was allowed to incubate for 30 minutes at 5
o
C to 
allow for the fluorescent probe to saturate the lipoproteins. The solution was then 
centrifuged at 120,000 rpm, at 5
o
C, for 6 hours in a Beckman Optima ultracentrifuge 
(TLX-110)
h
 with a 30
o 
fixed angle TLA 120.2 rotor
i
. A quality control sample was 
included in each run to verify that proper operating conditions were achieved. 
Immediately after ultracentrifugation, the top of each sample was carefully layered with 
250 µL of hexane and imaged without delay.  
For imaging, each tube was placed in a custom, in-house imaging instrument as 
previously described.
281
 The samples were imaged using a custom-built fluorescence 
imaging system consisting of a digital camera
j
 with a MH-100 metal halide continuous 
light source
k
, located in a dark room. Two filters
l
 matching the excitation (blue-violet 
filter centered at 407 nm) and emission (a yellow emission long pass filter with a cut-on 
wavelength of 515 nm) characteristics of NBD C6-cermide were used. A gain of 1.0000, 
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a target intensity of 30%, and an exposure time of 53.3 ms were selected. In order to be 
analyzed, the image of the each tube following ultracentrifugation was converted to a 
density profile using a commercially available software program.
m
 A tube coordinate 
scale was established where 0.0 mm was the top of the tube and 34.0 mm was the bottom 
of the tube.
281
 The average intensity was then plotted as a function of the tube 
coordinate. 
The ultracentrifugation method described above has been described as being able 
to identify 11 distinct density lipoprotein fractions in humans (TRL, 5 LDL fractions, 
and 5 HDL fractions). This separation is based solely on the density characteristics of the 
lipoprotein fractions and not on their functional properties. Therefore, this method was 
used to develop lipoprotein fingerprinting in canine serum based on lipoprotein densities 
alone. Density ranges were based on those previously published for humans by several 
authors.
282
 Specifically, the 11 fractions and their corresponding densities (d) were as 
follows:  chylomicrons and VLDL (d<1.017 g/mL), LDL1 (d=1.019 to 1.023 g/mL), 
LDL2 (d=1.023 to 1.029 g/mL),
 
LDL3 (d=1.029 to 1.039 g/mL), LDL4 (d=1.039 to 1.050 
g/mL),
 
LDL5 (d=1.050 to 1.063 g/mL), HDL2b (d=1.063 to 1.091 g/mL), HDL2a
 
(d=1.091 to 1.110 g/mL), HDL3a (d=1.110 to 1.133 g/mL), HDL3b (d=1.133
 
to 1.156 
g/mL), and HDL3c (d=1.156 to 1.179 g/mL).
282
 HDL1 is typically not found in healthy 
humans but it has been thought to occur in healthy dogs.
8,282
 However, it has not been 
convincingly shown that the previously described canine HDL1 molecule has the same 
function as human HDL1, and its density range has not been accurately determined 
(previously published densities vary between 1.025 and 1.1).
8
 Studies in humans that 
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have determined the density of HDL1 suggest that the density of this molecule is around 
1.08 g/mL, which would suggest that it corresponds to HDL2b or possibly HDL2a.
283
  
 
Statistical analysis 
Commercial statistical software packages were used for all statistical 
analyses.
n,o,p
 Data were analyzed for normal distribution using the Shapiro-Wilk test. 
Normally distributed data were analyzed using t-tests, while not normally distributed 
data were analyzed using Mann-Whitney tests. For multiple comparisons, repeated 
measures one-way ANOVA was used for normally distributed data followed by 
Bonferroni analysis, while the Friedman’s test was used for not normally distributed data 
followed by Dunn’s multiple comparison tests. Proportions were compared between 
groups using Fisher’s exact tests. Sliced inverse regression or logistic regression was 
used to test whether there was a relationship between group and lipoprotein profiles. 
Significance was set at P<0.05 for all analyses. 
 
Results 
Dogs 
 A total of 39 dogs were initially considered for enrollment in Group 1. The 
owners of 11 of these 39 dogs submitted the initial 2 samples needed for the study 
(before the diet change), but decided to not proceed with the study at that time. Another 
12 dogs were excluded from the study because they were diagnosed with conditions that 
 123 
might affect lipid metabolism (hypothyroidism, pancreatitis, pregnancy). Thus, 16 dogs 
completed the study.  
 The 16 dogs that completed the study had a median BCS of 5 (range: 4 to 6) and 
a median age of 8.5 years (range: 6.7 to 11.9 years). Eleven dogs were female (all 
spayed) and 5 dogs were male (all castrated).  
 Group 2 consisted of 28 Miniature Schnauzers that had a median BCS of 5 
(range: 4 to 6) and a median age of 9.1 years (range: 7.1 to 12.2 years). Fourteen dogs 
were female (8 spayed) and 14 dogs were male (5 castrated).  
 
Serum triglyceride, cholesterol, and Spec cPL concentrations in Group 1 
 Analysis using the Friedman’s test (repeated measures non-parametric 1-way 
ANOVA) showed that serum triglyceride concentrations before the diet change (median 
of sample 1: 480 mg/dL; median for sample 2: 493 mg/dL) were significantly higher 
than after the diet change (median of sample 3: 177 mg/dL; median for sample 4: 168 
mg/dL; P=0.0001; Figure 16). Dunn’s post-test indicated that there were no significant 
differences between samples 1 and 2 (i.e., while dogs were on their original diets) or 
between sample 3 and 4 (i.e., while dogs were on the study diet). There were significant 
differences between samples before and after the diet change (P<0.05 for all). 
Significantly more dogs had hypertriglyceridemia in Group 1 before (16/16) than after 
the diet change (11/16; odds ratio: 15.8; 95% CI, 0.8 to 314.8; P=0.04). Also, 
significantly more dogs had serum triglyceride concentrations >500 mg/dL in Group 1 
 124 
before (8/16) than after the diet change (0/16; odds ratio: 33.0; 95% CI, 1.7 to 643.6; 
P=0.002).  
 Serum cholesterol concentrations were available for all 4 time-points for 14 of 
the 16 dogs in Group 1. Repeated measures 1-way ANOVA analysis showed that serum 
cholesterol concentrations before the diet change (mean of sample 1: 381 mg/dL; mean 
for sample 2: 380 mg/dL) were significantly higher than after the diet change (mean of 
sample 3: 257 mg/dL; mean for sample 4: 178 mg/dL; P<0.0001; Figure 17). Post-hoc 
ANOVA analysis using Bonferroni’s correction for multiple comparisons indicated that 
there were significant differences between all individual comparisons before and after 
the diet change (Figure 17). However, there was no difference in the proportion of dogs 
that had hypercholesterolemia before (8/16) and after the diet change (3/16; P=0.14).   
 Serum Spec cPL concentrations were available for all 4 time-points for 14 of the 
16 dogs in Group 1. Analysis using the Friedman’s test showed that serum Spec cPL 
concentrations before the diet change (mean of sample 1: 173 µg/L; mean for sample 2: 
109 µg/L) were not significantly different than after the diet change (mean of sample 3: 
144 µg/L; mean for sample 4: 137 µg/L; P=0.12; Figure 18). There was no statistically 
significant difference in the proportion of dogs that had Spec cPL concentration above 
the cut-off for a diagnosis of pancreatitis (>400 µg/L) before (2/16) and after the diet 
change (1/16; P=1.0).  
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Figure 16. Serum triglyceride concentrations in dogs with hypertriglyceridemia before 
and after diet change. Samples 1 and 2 were collected while dogs were on their original 
diets. Samples 3 and 4 were collected approximately 8 and 12 weeks after the dogs were 
placed on the study diet, respectively. There was a significant reduction in serum 
triglyceride concentration after the diet change (P<0.0001). The dashed line represents 
the upper limit of the reference interval. 
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Figure 17. Serum cholesterol concentrations in dogs with hypertriglyceridemia before 
and after diet change. Samples 1 and 2 were collected while dogs were on their original 
diets. Samples 3 and 4 were collected approximately 8 and 12 weeks after the dogs were 
placed on the study diet, respectively. There was a significant reduction in serum 
cholesterol concentration after the diet change (P<0.0001). The dashed line represents 
the upper limit of the reference interval. 
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Figure 18. Serum Spec cPL concentrations in dogs with hypertriglyceridemia before and 
after diet change. Samples 1 and 2 were collected while dogs were on their original diets. 
Samples 3 and 4 were collected approximately 8 and 12 weeks after the dogs were 
placed on the study diet, respectively. There was no significant difference in serum Spec 
cPL concentrations after the diet change (P=0.14). The dashed line represents the upper 
limit of the reference interval. The solid line represents the cut-off for pancreatitis.  
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Lipoprotein profile analysis 
 For analysis of the lipoprotein profiles in response to diet change, the lipoprotein 
profiles after the diet change were compared with those of the same dogs before the diet 
change as well as those of the group of healthy dogs. Before the diet change, there was a 
98% separation between Group 1 and Group 2 using SIR analysis (Eigenvalues=0.7748; 
P=0.0003; Figure 19). One Miniature Schnauzer from Group 1 had only a very mildly 
increased serum triglyceride concentration, and this dog was misclassified as a control 
dog). Therefore, 15/16 (94%) of hyperlipidemic Miniature Schnauzers were classified as 
hyperlipidemic based on their lipoprotein profiles alone. After the diet change, 
significantly fewer Miniature Schnauzers (7/16; 44%; odds ratio: 19.3; 95% CI, 2.0 to 
184.0; P=0.006) were still classified as hyperlipidemic by lipoprotein profile analysis, 
while the majority of the dogs of this group (56%) were classified as normal (Figure 20). 
This means that with the diet change >50% of hyperlipidemic dogs no longer had 
evidence of lipoprotein abnormalities based on their lipoprotein profiles. Logistic 
regression analysis of the baseline lipoprotein profiles (before the diet change) of dogs 
that eventually responded and dogs that did not respond to the diet change showed that 
dogs that responded to the diet change could be separated with 88% accuracy from the 
ones that did not respond based on lipoprotein profile analysis even before the diet 
change. The logistic regression model fit the data well (chi-square=8.99; P=0.003; -2 log 
likelihood=4.09; Nagelkerke R
2
=0.9; Hosmer-Lemeshow test p =1.0).  
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Figure 19. 1-dimensional sliced inverse regression plot showing classification of dogs 
into groups based on lipoprotein profile analysis before the diet change. The vertical line 
represents the line that separates the 2 Groups based on lipoprotein profile analysis. The 
LDA value provides a ranking value for each dog. The dogs represented by the dots that 
are at the bottom of the graph are the dogs of the control group. Their lipoprotein 
profiles plot them all to the right of the vertical line. The dogs represented by the dots at 
the top of the graph are the dogs of Group 1 (with hypertriglyceridemia) before the diet 
change. They are all classified as a separate group from the control dogs with the 
exception of 1 dog that is classified as borderline normal.   
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Figure 20. 1-dimensional sliced inverse regression plot showing classification of dogs 
into groups based on lipoprotein profile analysis after the diet change. The vertical line 
represents the line that separates the 2 groups based on their lipoprotein profile analysis. 
The LDA value provides a ranking value for each dog. The dogs represented by the dots 
that are at the bottom of the graph are the dogs of the control group. Their lipoprotein 
profiles plot them all to the right of the vertical line. The dogs represented by the dots at 
the top of the graph are the dogs of Group 1 (with hypertriglyceridemia) after the diet 
change. Nine of the 16 dogs are now classified to the right of the vertical line together 
with the control dogs, suggesting that they are considered normal based on their 
lipoprotein profile analysis. The remaining 7 dogs are classified separately from the 
control dogs even after the diet change. Note that there is a clear separation between 
dogs of Group 1 that responded to the diet change and those that did not. 
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Dogs that did not respond to the diet change tended to have lower LDL fractions (mainly 
LDL1 and LDL2) and higher HDL fractions (mainly HDL2a, HDL3b, and HDL3c) than the 
ones that responded. 
 The most important changes in lipoprotein fractions in response to diet change as 
determined by SIR were decreases in TRL and LDL1 and increases in LDL4 and HDL3c. 
Figures 21A and 21B show the lipoprotein density profiles from a representative dog in 
Group 1 before and after the diet change. 
 
Discussion 
 To our knowledge, this is the first study evaluating the effect of a commercially 
available low-fat diet on serum lipid concentrations and lipoprotein profiles in Miniature 
Schnauzers with hyperlipidemia. The results of this study suggest that the study diet 
significantly reduced serum triglyceride and cholesterol concentrations in 
hyperlipidemic Miniature Schnauzers within 2 months. In addition, the lipoprotein 
profiles of the hyperlipidemic Miniature Schnauzers changed significantly 2 months 
after the initiation of the study diet, and the majority of dogs could be classified as 
normal based on their lipoprotein profile analysis at that point. Lipoprotein fractions 
mainly affected by the diet change were the TRLs and LDL1 (which both decreased in 
response to feeding the low-fat diet) and LDL4 and HDL3c (which both increased in 
response to feeding the low-fat diet). 
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Figure 21. Lipoprotein density profiles from a representative dog with 
hypertriglyceridemia (Group 1) before and after the diet change. A. Lipoprotein profile 
of a dog with hypertriglyceridemia before the diet change. B. Lipoprotein profile of the 
same dog 8 weeks after the diet change. This dog had normal serum triglyceride and 
cholesterol concentrations at that point. Note the dramatic decrease in TRL. A decrease 
in LDL1 and increases in HDL2b and HDL2a are also evident. 
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Hypertriglyceridemia has been linked to several conditions in dogs (especially 
Miniature Schnauzers), including pancreatitis, insulin resistance, hepatobiliary disease, 
and ocular disease.
252
 The degree of hypertriglyceridemia seems to play an important 
role in most conditions.
252,279
 Therefore, management of hypertriglyceridemia with a 
goal to reduce serum triglyceride concentrations below 500 mg/dL is usually 
recommended even when clinical sings are not present.
252
 The results of the preset study 
suggest that the study diet is effective in lowering serum triglyceride concentrations to 
values below the ones considered to be associated with risk for disease (a recommended 
cut-off of 500 mg/dL was used in the present study), and in some cases it even led to 
normalization of serum triglyceride concentrations. 
From each dog in Group 1, 2 samples were collected before the diet change and 2 
after the diet change. This was done to ensure that dogs had persistent hyperlipidemia 
before the diet change and that some dogs would not spontaneously have serum and 
triglyceride concentrations within the reference range. For samples collected after the 
diet change, this was done to ensure that any reduction in serum and cholesterol 
concentration was not temporary or random. Therefore, each dog served as its own 
control. There was no significant difference in serum triglyceride or cholesterol 
concentrations between samples 1 and 2 (i.e., before the diet change) or between 
samples 3 and 4 (i.e., after the diet change). The fact that significant differences were 
detected only when serum triglyceride and cholesterol concentrations were compared 
between time-points before and after the diet change strongly suggests that this was due 
to an effect of the diet.  
 134 
It is interesting to note that there was great variation in serum triglyceride 
concentrations between samples 1 and 2 (i.e., sample before the diet change). There also 
was variation between samples 3 and 4 (i.e., after the diet change) but it was not as 
prominent as compared to before the diet change. As mentioned above, there was no 
statistically significant difference between these time-points overall, but there was 
considerable variation within individual dogs. This was despite the fact that the dogs had 
been fasted for >15 hours. A plausible explanation is that, because the diet was not 
controlled during the first 2 sample collections, food of a different fat content might have 
been consumed before each of the blood collections. Alternatively, this variation might 
be normal for this condition as no long-term studies have evaluated the fluctuation of 
serum triglyceride concentration over time in Miniature Schnauzers with hyperlipidemia. 
A similar observation of such variation has also been described in another study with 
Miniature Schnauzers with pancreatitis.
280
 This might suggest that at least 2 samples 
should be collected and evaluated during the diagnostic evaluation Miniature Schnauzers 
for hyperlipidemia to ensure that an accurate estimate of the severity of hyperlipidemia 
is obtained. 
Another observation was that, although >50% of the dogs were classified as 
normal after the diet change based on their lipoprotein profiles, a considerable 
percentage (44%) of dogs was still classified as hyperlipidemic based on their 
lipoprotein profiles. This is in agreement with the observation that serum triglyceride 
concentrations were significantly reduced but not normalized in some of the dogs 
(Figure 22). It is not known why the dogs responded to the diet change to different 
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degrees. One possible explanation is that some dogs might need more time than 2 to 3 
months to fully respond to the diet. Although there are no studies convincingly showing 
how many weeks are required for normalization of serum triglyceride concentrations 
after feeding a low-fat diet, clinical experience suggests that 2 to 3 months is usually 
sufficient. It is noteworthy that the baseline lipoprotein profiles (i.e., before the diet 
change) of the dogs that eventually responded to the diet were distinctly different from 
the ones of dogs that did not fully respond to the diet. This might suggest that 
hyperlipidemia in Miniature Schnauzers is a clinically diverse condition, which might 
have different underlying biochemical bases, and that certain phenotypes of the disease 
might not be as responsive to dietary management with low-fat diets. Data from the 
present study but also from older studies suggest that Miniature Schnauzers often have 
different biochemical abnormalities associated with hyperlipidemia. For example, in 1 
study it was shown that some hyperlipidemic Miniature Schnauzers have 
hyperchylomicronemia while others do not.
17
 Similarly, some Miniature Schnauzers 
with hypertriglyceridemia also have hypercholesterolemia while others do not.
17,84
 
Chylomicrons are dietary in origin and hyperchylomicroniemia is usually expected to 
respond to low-fat diets.
252
 Increases in VLDL are not necessarily responsive to low-fat 
diets because VLDLs are produced through the endogenous pathway.
252
 This finding 
further suggests that lipoprotein profile analysis might be useful in clinical practice as it 
provides important additional information to serum triglyceride and cholesterol 
concentration, and it might affect clinical decision making with regard to the 
management of dogs with hyperlipidemia.  
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 There was no significant effect of diet on serum Spec cPL concentration. This 
finding was not surprising, however, because the enrolled dogs did not have any clinical 
signs of pancreatitis and the majority of them had a normal serum Spec cPL 
concentration at time of enrollment. Thus, the effect of low-fat diets on the clinical 
course of pancreatitis needs to be evaluated in additional studies. 
In conclusion, this study evaluated the effect of a commercially available low-fat 
diet on serum lipid concentrations and lipoprotein profiles in Miniature Schnauzers with 
hyperlipidemia. The study diet was found to be effective in significantly reducing serum 
triglyceride and cholesterol concentrations within 2 months. The lipoprotein profiles of 
most hyperlipidemic dogs were shifted towards those of non-hyperlipidemic dogs within 
2 months. A subgroup of dogs did not fully respond to the diet change as indicated 
mainly by their serum triglyceride concentrations and lipoprotein profiles. The reason 
for this finding is not known at this point, but differences in the pathogenetic basis of 
hyperlipidemia among dogs might have played a role. Given the fact that the dogs 
enrolled in the present study had naturally occurring hyperlipidemia, the study diet 
should be expected to be beneficial in clinical practice. However, it is not clear whether 
other low-fat diets would have the same effect on the management of hyperlipidemia in 
Miniature Schnauzers.  
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a
Royal Canin Gastrointestinal
TM
 Low-fat
TM
, Royal Canin USA, Inc., St. Charles, MO   
b
Roche/Hitachi MODULAR ANALYTICS D 2400 module, Roche Diagnostics, 
Indianapolis, IN
  
c
Immulite 2000 Canine Total T4, Siemens Healthcare Diagnostics, Deerfield, IL  
d
Free T4 (by ED), Antech Diagnostics, Irvine, CA  
e
Bismuth Sodium Ethylenediaminetetraacetate, TCI AMERICA, Portland, OR 
 
f
NBD C6-ceramide, Molecular Probes, Inc. Eugene, OR  
g
Tube, Thickwall, Polycarbonate (1 mL, 11 x 34 mm), Beckman Coulter Inc., Brea, CA 
h
Beckman Coulter Optima TLX-120 Ultracentrifuge, Beckman Coulter Inc., Brea, CA 
i
TLA-120.2 rotor, Beckman Coulter Inc, Brea, CA 
j
Digital Microfire Camera, Optronics, Coleta, CA 
k
MH-100, Dolan-Jenner Industries, Boxborough, MA  
l
SCHOTT North America, Inc., Elmsford, NY 
m
Origin 7.0, Microcal Software Inc., Northampton, MA 
n
SPSS 16.0, SPSS Inc., Chicago, IL 
o
Prism5, GraphPad, San Diego, CA 
p
R, http://www.r-project.org/ 
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CHAPTER VI 
SERUM TRIGLYCERIDE AND CHOLESTEROL CONCENTRATIONS AND 
LIPOPROTEIN PROFILES IN DOGS WITH NATURALLY OCCURRING 
PANCREATITIS AND HEALTHY CONTROL DOGS 
 
Introduction  
The association between hyperlipidemia and pancreatitis remains obscure in 
dogs, but has been speculated to be bidirectional.
252
 Hyperlipidemia, and more 
specifically hypertriglyceridemia, has been hypothesized to be able to cause pancreatitis 
in some circumstances.
252
 This hypothesis is supported by the results of 2 recent clinical 
studies in dogs,
279,280
 and is further supported by in vitro studies
260
 and clinical studies in 
humans.
254,267
 On the other hand, hyperlipidemia has also been hypothesized to be the 
result of pancreatitis.
165,254
 Although this hypothesis is widely believed to be true, 
evidence supporting this hypothesis has not been documented in dogs with naturally 
occurring pancreatitis. Hypertriglyceridemia has been commonly reported in dogs with 
pancreatitis, but the etiology of hypertriglyceridemia often remains unknown in these 
cases.
19,21,63-65
 Furthermore, with the exception of the results of 1 older study,
261
 
hypertriglyceridemia has not been reported to be a consequence of experimental 
pancreatitis in dogs.
18-20
 However, experimental models of pancreatitis do not always 
mirror the pathophysiologic mechanisms that apply to spontaneous disease. 
Studies specifically investigating the lipid status and lipoprotein profiles of dogs 
with spontaneous pancreatitis have not been reported. Characterization of the lipid 
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concentrations and lipoprotein profiles of dogs with pancreatitis might help to clarify the 
association between hyperlipidemia and pancreatitis. Therefore, the aims of the present 
study were: a) to measure serum triglyceride and cholesterol concentrations in dogs with 
naturally occurring pancreatitis and compare them with those of healthy dogs, and b) to 
determine the lipoprotein profiles of dogs with naturally occurring pancreatitis and 
compare them with those of healthy dogs.  
 
Materials and methods 
Dogs with pancreatitis (Group 1) 
  Dogs with a clinical diagnosis of pancreatitis were enrolled into this study. 
Serum samples from these dogs had been submitted to the Gastrointestinal Laboratory at 
Texas A&M University by veterinarians located throughout the United States as part of 
their diagnostic evaluation, and were stored at -80
o
C until use. The submitting 
veterinarians were contacted and asked to complete a questionnaire for each dog. 
Questions covered the date of birth, sex and sexual status, body-weight and body 
condition score (BCS), current diet(s), current medications, and the current and past 
health history of the dogs. Questionnaires from all dogs were reviewed to determine 
whether the dogs fit the inclusion criteria for the study. Food had to be withheld for ≥12 
hours prior to blood collection for all dogs enrolled into the study. The dogs were 
enrolled on a sequential basis based on whether the submitting veterinarian had agreed to 
complete the questionnaire and whether the dogs fit the inclusion criteria. No preference 
was given to lipemic samples.  
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 The diagnosis of pancreatitis was based on: a) the presence of compatible 
historical findings of at least 2 of the following clinical signs (vomiting, anorexia, 
depression, abdominal pain, or diarrhea) and b) a serum Spec cPL
®
 concentration ≥400 
μg/L (the currently recommended cut-off value for pancreatitis).178,180 Although dogs 
with concurrent diseases or those receiving medications that might affect lipid 
metabolism were initially included in this group in order to determine the overall 
prevalence of hyperlipidemia in this group, they were subsequently excluded from the 
analysis and only dogs that had pancreatitis without any recognized risk factors for 
hyperlipidemia were eventually included in this group. These dogs were designated as 
Group 1. Dogs with hyperlipidemia secondary to diseases other than pancreatitis or 
medications
252
 were identified based on the clinical history, physical examination, and 
results from the serum chemistry profile (without the results for serum cholesterol and 
triglyceride concentrations) and specific tests (such as serum total and free T4 
concentrations).  
 
Healthy control dogs (Group 2) 
 Healthy dogs were enrolled into the study and served as controls. The dogs 
belonged to students and staff of the College of Veterinary Medicine and Biomedical 
Sciences at Texas A&M University. The owners were asked to complete a questionnaire 
for each dog. Questions covered date of birth, sex and sexual status, body-weight and 
BCS, current diet(s), current medications, and the current and past health history of the 
dogs. Questionnaires from all dogs were reviewed to determine whether the dogs fit the 
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inclusion criteria for the study. All owners signed an informed owner consent form. The 
study protocol was reviewed and approved by the Clinical Research Review Committee 
at Texas A&M University. 
Inclusion criteria for the control group were: a) absence of any clinical signs at 
the time of blood collection, b) no major abnormalities on the serum chemistry profile, 
c) a serum Spec cPL concentration within the reference interval, and d) no history of 
diseases or current drug use known to affect lipid metabolism.
252
 Blood samples were 
collected from these dogs after food had been withheld for at least 12 hours. The blood 
samples were collected into red-top tubes (with no additive), allowed to clot for 20 
minutes, centrifuged, and the serum was aliquotted out and stored at -80
o
C until analysis.  
 
Assays 
Serum triglyceride (reference interval: 26 to 108 mg/dL), cholesterol (reference 
interval: 124 to 335 mg/dL), and glucose (reference interval: 60 to 120 mg/dL) 
concentrations were measured by automated enzymatic assays.
a 
Serum Spec cPL 
concentrations (reference interval: ≤200 µg/L) were measured using a commercially 
available immunoassay that has been described elsewhere.
178
 Serum total T4 
concentrations were measured by a solid-phase chemiluminescent competitive assay.
b
 
Serum free T4 concentration was measured using a commercially available equilibrium 
dialysis radioimmunoassay.
c 
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Lipoprotein profile analysis 
Lipoprotein profiling was carried out using a bismuth sodium 
ethylenediaminetetraacetic acid (NaBiEDTA or NaBiY) density gradient 
ultracentrifugation method as previously described with some modifications.
281
 The 
sodium salt of BiEDTA has been described as a novel solute forming a self-generating 
density gradient during ultracentrifugation of serum samples for the separation of 
lipoproteins.
281
 Briefly, for each sample, 1,284 µL of a 0.18M NaBiEDTA
d
 gradient 
solution was added into a 1.5 mL tube. The fluorescent probe 6-((N-(7-nitrobenz-2-oxa-
1,3-diazol-4-yl)amino)hexanoyl)sphingosine (NBD C6-ceramide)
e
 was reconstituted 
with 1 g/mL DMSO and 10 µL of the 1 mg/mL solution were added to each tube to label 
the lipoproteins. Finally, 6 µL of serum was added to each tube. The mixture was 
vortexed at 1,400 rpm for 10 seconds and 1,150 µL of it were transferred into an 
ultracentrifuge tube.
f
 The mixture was allowed to incubate for 30 minutes at 5
o
C to allow 
for the fluorescent probe to saturate the lipoproteins. The solution was then centrifuged 
at 120,000 rpm and 5
o
C for 6 hours in a Beckman Optima ultracentrifuge (TLX-110)
g
 
with a 30
o 
fixed angle TLA 120.2 rotor.
h
 A quality control sample was included in each 
run to verify that proper operating conditions had been achieved. Immediately after 
ultracentrifugation, the top of each sample was carefully layered with 250 µL of hexane 
and imaged without delay.  
For imaging, each tube was placed in a custom, in-house imaging instrument as 
previously described.
281
 The samples were imaged using a custom-built fluorescence 
imaging system consisting of a digital camera
i
 with a MH-100 metal halide continuous 
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light source
j
, located in a dark room. Two filters
k
 matching the excitation (blue-violet 
filter centered at 407 nm) and emission (a yellow emission long pass filter with a cut-on 
wavelength of 515 nm) characteristics of NBD C6-cermide were used. A gain of 1.0000, 
a target intensity of 30%, and an exposure time of 53.3 ms were selected. In order to be 
analyzed, the image of the each tube following ultracentrifugation was converted to a 
density profile using a commercially available software program.
l
 A tube coordinate 
scale was established where 0.0 mm is the top of the tube and 34.0 mm is the bottom of 
the tube.
281
 The average intensity was then plotted as a function of the tube coordinate. 
The ultracentrifugation method described above has been shown to identify 11 
distinct density lipoprotein fractions in human serum (TRL, 5 LDL fractions, and 5 HDL 
fractions). This separation is based solely on the density characteristics of the lipoprotein 
fractions and not on their functional properties. Therefore, this method was used to 
develop lipoprotein fingerprinting in canine serum based on lipoprotein densities alone. 
Density ranges were based on those previously published for humans by several 
authors.
282
 Specifically, the 11 fractions and their corresponding densities (d) were as 
follows: chylomicrons and VLDL (d<1.017 g/mL), LDL1 (d=1.019 to 1.023 g/mL), 
LDL2 (d=1.023 to 1.029 g/mL),
 
LDL3 (d=1.029 to 1.039 g/mL), LDL4 (d=1.039 to 1.050 
g/mL),
 
LDL5 (d=1.050 to 1.063 g/mL), HDL2b (d=1.063 to 1.091 g/mL), HDL2a
 
(d=1.091 to 1.110 g/mL), HDL3a (d=1.110 to 1.133 g/mL), HDL3b (d=1.133
 
to 1.156 
g/mL), and HDL3c (d=1.156 to 1.179 g/mL).
282
 HDL1 is typically not found in healthy 
humans, but has been speculated to be present in healthy dogs.
8,282
 However, it has not 
been convincingly shown that the previously described canine HDL1 molecule has the 
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same function as human HDL1, and its density range has not been accurately determined 
(previously published densities vary between 1.025 and 1.1).
8
 Previous studies in 
humans that have reported the density of HDL1 suggest that the density of this molecule 
is around 1.08 g/mL, which would suggest that it corresponds to HDL2b, or possibly 
HDL2a.
283
 
 
Statistical analyses 
Commercially available statistical software packages were used for all statistical 
analyses.
m,n,o
 Data were analyzed for normal distribution using the Shapiro-Wilk test. 
Normally distributed data were analyzed using t-tests. Non-normally distributed data 
were analyzed using Mann-Whitney tests. Proportions were compared between groups 
using the Fisher’s exact test. Sliced inverse regression (SIR) was used to test whether 
there was a relationship between group and lipoprotein profiles. Significance was set at 
P<0.05 for all analyses. 
 
Results 
Dogs with pancreatitis (Group 1) 
Twenty-eight dogs with a clinical diagnosis of pancreatitis were initially 
evaluated for inclusion into the study. Of these 28 dogs with pancreatitis, 11 had 
concurrent diseases that might have affected lipid metabolism and thus were excluded 
from the study. Specifically, 5 dogs had been diagnosed and/or were treated for diabetes 
mellitus, 3 dogs had been diagnosed and treated for hypothyroidism, 1 dog had been 
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diagnosed with hyperadrenocorticism and protein losing nephropathy, 1 dog had severe 
protein losing enteropathy, and 1 dog was being treated with prednisone.  
Thus, Group 1 consisted of 17 dogs that had pancreatitis, but did not have any 
recognized risk factors for hyperlipidemia. These dogs belonged to 10 breeds while 2 
dogs were mixed-breed. Nine dogs were female (all spayed) and 8 dogs were male (7 
castrated). The body condition score (BCS) of the dogs in this group ranged from 3/9 to 
7/9 (median: 4.5). The mean age of the dogs was 7.4 years (range: 1 to 14 years). 
 
Healthy dogs 
A total of 53 healthy dogs were enrolled in Group 2 as controls. Dogs of Group 2 
belonged to 20 different breeds (34 dogs), while 19 dogs were mixed-breed. Twenty-six 
dogs were female (23 spayed) and 27 dogs were male (23 castrated). The body condition 
score (BCS) of the dogs in this group ranged from 4/9 to 7/9 (median: 5). The mean age 
of the dogs was 5.2 years (range: 1 to 13.5 years).  
Serum triglyceride and cholesterol concentrations of all 53 dogs were compared 
to those of dogs in Group 1. However, lipoprotein profile analysis was only performed 
on 29 of the 53 healthy dogs of Group 2, that were selected to match the age of the dogs 
in Group 1. 
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Serum triglyceride and cholesterol concentrations 
 Twelve of the 28 dogs (43%) with pancreatitis initially considered for enrollment 
into Group 1 of the study had an increased concentration of serum triglycerides, serum 
cholesterol, or both.  
Five of 17 dogs (29%) of Group 1 had an increased concentration of serum 
triglycerides, serum cholesterol, or both. In contrast, only a total of 5 of the 53 healthy 
dogs (9%) had an increased concentration of serum triglycerides, serum cholesterol, or 
both. This difference approached but did not reach statistical significance (P=0.055).  
In Group 1 (dogs with pancreatitis, but no risk factors of hyperlipidemia), 3 of 
the 17 dogs (18%) had hypertriglyceridemia (Figure 22 on page 148). 
Hypertriglyceridemia was mild (<350 mg/dL) in all 3 cases. The median serum 
triglyceride concentration was 67 mg/dL (range: 48 – 324 mg/dL). Of the 53 control 
dogs in Group 2, 4 (7.5%) had hypertriglyceridemia. Hypertriglyceridemia was mild in 
all 4 cases (<300 mg/dL). There was no statistically significant difference in the 
proportion of dogs that had hypertriglyceridemia between dogs with pancreatitis (18%) 
and healthy controls (7.5%; P=0.35). However, there was a statistically significant 
difference in serum triglyceride concentrations between Group 1 (median: 67 mg/dL; 
range: 48 – 324 mg/dL) and Group 2 (median: 54 mg/dL; range: 26 – 257 mg/dL; 
P=0.0026; Figure 22). As mentioned above, serum triglyceride concentrations were 
within the reference interval for the majority of dogs in both groups.   
 Of the 17 dogs in Group 1, 4 (24%) had hypercholesterolemia. The median 
serum cholesterol concentration was 209 mg/dL (range: 102 – 849 mg/dL; Figure 23). 
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Of the 53 control dogs in Group 2, 1 (1.9%) had hypercholesterolemia. There was a 
statistically significant difference in the proportion of dogs that had 
hypercholesterolemia between dogs with pancreatitis (Group 1) and healthy control dogs 
(P=0.011). However, there was no statistically significant difference in serum cholesterol 
concentrations between Group 1 (median: 209 mg/dL; range: 142 – 849 mg/dL) and 
Group 2 (median: 227 mg/dL; range: 97 – 338 mg/dL; P=0.565; Figure 23). 
    
Lipoprotein profile analysis 
All 17 dogs of Group 1 were used for lipoprotein profile analysis. In contrast, 
only a fraction of dogs in Group 2 (29 dogs) with ages similar to the dogs of Group 1 
were selected for lipoprotein profile analysis. 
Sliced inverse regression analysis showed that lipoprotein profiles were distinctly 
different between dogs with pancreatitis and healthy control dogs (Eigenvalues = 
0.6719; P=0.0012). Dogs could be classified in the correct group (healthy versus 
pancreatitis) with 89% accuracy based on their lipoprotein profiles alone (Figure 24). 
The most important differences in the lipoprotein profiles between dogs with pancreatitis 
and healthy dogs involved increases in LDL2, LDL3, and LDL4, and less prominent 
decreases in TRL, HDL2a, and HDL3c. Figure 25A shows the lipoprotein density profile 
of a representative dog with pancreatitis. Figure 25B shows the lipoprotein density 
profile of a representative healthy dog. It is clear that the main differences between these 
two exemplary lipoprotein profiles involved the LDL fractions, while the differences in 
TRLs and HDL fractions were less prominent. 
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Figure 22. Serum triglyceride concentrations in dogs with pancreatitis (Group 1) and 
healthy control dogs (Group 2). Dogs in Group 1 had significantly higher (P=0.0026) 
serum triglyceride concentrations than dogs in Group 2. However, the majority of dogs 
in both groups had serum triglyceride concentrations within the reference interval. 
Hypertriglyceridemia, when present, was always mild. The dashed line represents the 
upper limit of the reference interval (108 mg/dL).  
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Figure 23. Serum cholesterol concentrations in dogs with pancreatitis (Group 1) and 
healthy control dogs (Group 2). There was no statistically significant difference in serum 
cholesterol concentration between the 2 groups (P=0.565). The majority of dogs in both 
groups had serum cholesterol concentrations within the reference interval, while a small 
number of dogs had a mildly increased serum cholesterol concentration. The dashed line 
represents the upper limit of the reference interval (335 mg/dL). 
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Figure 24. 1-dimensional sliced inverse regression plot showing classification of dogs 
into groups based on lipoprotein profile analysis (Group 1 vs Group 2). The vertical line 
represents the line that separates the two groups based on lipoprotein profile analysis. 
The LDA value provides a ranking value for each dog. The dogs represented by the dots 
that are at the bottom of the graph are healthy (Group 2). The majority of dogs (except 
for 2 dogs) have a lipoprotein profile that plots to the right of the vertical line. The dogs 
represented by the dots at the top of the graph are dogs with pancreatitis (Group 1). The 
majority of these dogs (with the exception of 3) have a lipoprotein profile that is 
different from that of the healthy dogs. Sliced inverse regression analysis correctly 
classified approximately 90% of the dogs based on their lipoprotein profiles.  
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Figure 25. Lipoprotein density profiles from a representative dog with pancreatitis (A) 
and a representative healthy control dog (B). The dog in panel A shows profound 
increases in the LDL fractions (mainly LDL2 through LDL5) compared to the healthy 
control dog shown in panel B. Decreases in the TRL, HDL2b,  and HDL2a fractions might 
also be present in the dog in panel A compared to the dog in panel B. Both dogs had 
serum triglyceride and cholesterol concentrations within their respective reference 
intervals.  
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Discussion 
 The purpose of the present study was to investigate the serum lipid and 
lipoprotein abnormalities associated with naturally occurring pancreatitis in dogs. Mild 
increases in serum triglyceride and/or cholesterol concentrations were seen in a 
relatively small proportion of dogs with pancreatitis. The majority of dogs (>70%) with 
pancreatitis had serum triglyceride and cholesterol concentrations within the respective 
reference intervals. In contrast, important differences were identified in lipoprotein 
profiles between dogs with pancreatitis and healthy dogs. Specifically, dogs with 
pancreatitis had higher LDL fractions (mainly LDL2, LDL3, and LDL4) and lower TRL 
and HDL fractions (mainly HDL2a and HDL3c) than healthy dogs. These changes in 
lipoprotein profiles were evident in the majority of dogs with pancreatitis, even in cases 
in which serum concentrations of triglyceride and cholesterol were normal. 
In the group of dogs investigated here, those with pancreatitis tended to more 
commonly have an increased concentration of serum triglycerides, serum cholesterol, or 
both (about 30%) than healthy dogs (about 10%), although this difference did not reach 
statistical significance. Serum triglyceride concentrations overall were higher among 
dogs with pancreatitis than among healthy dogs. However, this difference was not 
clinically important because the majority of dogs (>80%) had serum triglyceride 
concentrations within the reference interval, and there was no statistically significant 
difference in the proportion of dogs with hypertriglyceridemia between the 2 groups. On 
the other hand, a higher proportion of dogs with pancreatitis had hypercholesterolemia 
(24%) compared to healthy dogs (1.9%). It is of note, however, that > 75% of dogs with 
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pancreatitis had normal serum cholesterol concentrations. Also, overall, serum 
cholesterol concentration was not significantly higher in dogs with pancreatitis, 
suggesting that hypercholesterolemia was generally mild in those cases. In fact, only 1 
dog had a serum cholesterol concentration >800 mg/dL, while the majority of dogs had 
normal serum cholesterol concentrations. 
 The above findings contradict a commonly held belief that pancreatitis is 
commonly associated with increases in serum triglyceride and/or cholesterol 
concentrations in dogs. This belief is most likely based on clinical studies in dogs that 
show a relatively high prevalence of hyperlipidemia in dogs with pancreatitis.
63,64
 For 
example, in 1 study
64
, 48% and 26% of dogs with pancreatitis were reported to have 
hypercholesterolemia and grossly lipemic serum, respectively. However, in those 
studies, dogs with secondary hyperlipidemia (e.g., due to diabetes mellitus or 
hypothyroidism) were not excluded from the calculation of the prevalence of 
hyperlipidemia, and it is very likely that most dogs had hyperlipidemia as a result of 
diseases other than pancreatitis. This is supported by the findings of the present study; 
before the exclusion of dogs that had secondary causes of hyperlipidemia (mainly 
diabetes mellitus and hypothyroidism), the overall prevalence of hyperlipidemia was 
43%. However, when only dogs with pancreatitis and no other diseases were included in 
the present study, the prevalence of hyperlipidemia was much lower (29%) and it was 
mild in almost all cases.  
The present study suggests that the majority of dogs (>70%) with pancreatitis 
have normal serum triglyceride and cholesterol concentrations, while only a small 
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fraction of these dogs (about 30% overall) have increases in serum triglyceride and/or 
cholesterol concentrations. About 20% of dogs had hypertriglyceridemia, and another 
20% of dogs had hypercholesterolemia. It is equally important to note that both 
hypertriglyceridemia and hypercholesterolemia were mild when present in dogs with 
pancreatitis (typically <200 mg/dL and <400 mg/dL, respectively; Figures 22 and 23). 
Therefore, it might be recommended that when dramatic increases in serum triglyceride 
and/or cholesterol concentrations are present in dogs with pancreatitis, other causes of 
secondary hyperlipidemia or primary hyperlipidemia should be investigated. 
The findings of the present study are in accordance with findings of studies on 
experimentally induced pancreatitis in dogs.
18-20
 In general, most of those studies have 
come to the conclusion that hypertriglyceridemia is not a consequence of experimentally 
induced pancreatitis in dogs.
18-20
 In 1 study, statistically significant increases in serum 
triglyceride concentrations were noted, but serum triglyceride concentrations remained 
within the reference interval throughout the study period.
20
 Similar findings were 
reported regarding hypercholesterolemia in those studies.
18-20
    
Although major changes in serum triglyceride and cholesterol concentrations 
were not found in dogs with pancreatitis in the present study, there were profound 
differences in lipoprotein profiles between dogs with pancreatitis and healthy controls. 
The dogs could be correctly classified in almost 90% of the cases as having or not 
having pancreatitis based on their lipoprotein profile alone. The main changes in the 
lipoprotein profiles involved increases in the LDL fractions (mainly LDL2, LDL3, and 
LDL4). Decreases in HDL fractions such as HDL2a, HDL3c, and TRLs were also present. 
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Both LDL and HDL fractions contain mainly cholesterol.
252
 The fact that the overall 
serum cholesterol concentration was normal in the majority of dogs with pancreatitis 
might be explained by the fact that increases in LDL fractions were balanced by a 
concurrent decrease in the HDL fractions. It is possible that during pancreatitis 
lipoprotein metabolism is altered in a way that facilitates redistribution of lipid 
components (mainly cholesterol) between LDL and HDL fractions. Further studies are 
needed to elucidate the mechanism of lipoprotein metabolism alterations in dogs with 
pancreatitis.  
The changes in lipoprotein profiles in dogs with pancreatitis described in the 
present study are in agreement with the findings of studies on experimentally induced 
pancreatitis in dogs.
18-20
 Those studies have all reported similar findings, including 
increases in LDL and decreases in HDL fractions. Based on these findings, serum 
alterations in the major lipoprotein fractions are similar between naturally occurring and 
experimentally induced pancreatitis. However, changes in lipoprotein subfractions as a 
result of experimental pancreatitis have not been reported in other studies and 
differences might be present. 
TRLs were overall decreased in dogs with pancreatitis in the present study. To 
the authors’ knowledge, this has not been described before in dogs with pancreatitis 
without concurrent diseases affecting the lipoprotein metabolism. Since TRL are the 
main lipoprotein fractions containing triglycerides, this finding contradicts another 
finding of the present study, which showed that serum triglyceride concentrations were 
significantly higher in dogs with pancreatitis. This finding might suggest that the content 
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of lipoproteins might also have changed in dogs with pancreatitis, and that TRL, LDL, 
and/or HDL contained higher concentrations of triglycerides than those in healthy dogs. 
Further studies are needed to describe the lipid content of the lipoprotein fractions of 
dogs with pancreatitis. 
Overall, some of the changes observed in the present study with regard to serum 
lipid concentrations and lipoprotein profiles are similar to the changes reported in 
humans or animal models with various types of inflammation or infection.
287-289
 Similar 
to the changes in acute phase proteins that occur during inflammation, major changes 
take place in lipoprotein metabolism in response to inflammation. These changes affect 
both the concentration and composition of serum lipoproteins and are mainly mediated 
by hormones and cytokines.
287-289
 Typical lipoprotein changes in response to 
inflammation in humans include an increase in serum triglyceride concentration (due to 
an increased production of triglycerides and VLDL by the liver), and a decrease in HDL 
cholesterol.
287-289
 Similar changes were observed in the present study. Changes in LDL 
molecules are more difficult to compare between humans and dogs because these 2 
species differ substantially in their LDL metabolism. Nevertheless, inflammation in 
humans appears to induce a shift in LDL profiles leading to the appearance of small 
dense LDL molecules that correspond to fractions LDL4 and LDL5, a finding that was 
also observed in the dogs of Group 1 in the present study. It seems likely that, as in 
humans, changes in serum lipid concentrations and lipoprotein profiles in dogs with 
pancreatitis might be the result of a general inflammatory response rather than a 
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pancreatitis-specific change. Additional research is required to compare the lipoprotein 
profiles between dogs with different inflammatory conditions.   
 In conclusion, the majority of dogs with naturally occurring pancreatitis in the 
present study (>70%) had serum triglyceride and cholesterol concentrations within their 
respective reference intervals. In the relatively small percentage of dogs that showed 
increases in serum triglyceride and/or cholesterol concentrations those increases were 
generally mild. Therefore, profound increases in serum triglyceride and/or cholesterol 
concentrations in dogs with pancreatitis are unlikely to be the result of pancreatitis, and 
warrant further diagnostic investigation. In sharp contrast, important differences were 
identified in lipoprotein profiles between dogs with pancreatitis and healthy control 
dogs. Dogs with pancreatitis had higher LDL fractions (mainly LDL2, LDL3, and LDL4) 
and lower TRL and HDL fractions (mainly HDL2a and HDL3c) than healthy control 
dogs. These changes in lipoprotein profiles were evident in the majority of dogs with 
pancreatitis, even in cases in which serum concentrations of triglyceride and cholesterol 
were normal. Further studies are needed to elucidate the mechanisms responsible for the 
changes in lipoprotein metabolism in dogs with pancreatitis. Also, additional research is 
required to determine whether these changes are pancreatitis-specific or a result of an 
inflammatory state in dogs. 
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Footnotes 
a
Roche/Hitachi MODULAR ANALYTICS D 2400 module, Roche Diagnostics, 
Indianapolis, IN
  
b
Immulite 2000 Canine Total T4, Siemens Healthcare Diagnostics, Deerfield, IL  
c
Free T4 (by equilibrium dialysis), Antech Diagnostics, Irvine, CA  
d
Bismuth Sodium Ethylenediaminetetraacetate, TCI AMERICA, Portland, OR 
e
NBD C6-ceramide, Molecular Probes, Inc. Eugene, OR  
f
Tube, thickwall, Polycarbonate (1 mL, 11 x 34 mm), Beckman Coulter Inc., Brea, CA 
g
Beckman Coulter Optima TLX-120 Ultracentrifuge, Beckman Coulter Inc., Brea, CA 
h
TLA-120.2 rotor, Beckman Coulter Inc, Brea, CA 
i
Digital Microfire Camera, Optronics, Coleta, CA 
j
MH-100, Dolan-Jenner Industries, Boxborough, MA  
k
SCHOTT North America, Inc., Elmsford, NY 
l
Origin 7.0, Microcal Software Inc., Northampton, MA 
m
SPSS 16.0, SPSS Inc., Chicago, IL 
n
Prism5, GraphPad, San Diego, CA 
o
R, http://www.r-project.org/ 
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CHAPTER VII 
SUMMARY AND CONCLUSIONS 
 
An association between hyperlipidemia and pancreatitis was first noted in 
humans by Speck in 1865.
253
 Several clinical and experimental studies in humans and 
animals, respectively, have been conducted since then, and today, severe 
hypertriglyceridemia is a well recognized risk factor for pancreatitis in humans.
254-257
 
The mechanism by which hypertriglyceridemia induces pancreatitis is not clear, but it 
has been suggested that serum triglycerides are hydrolyzed by the action of pancreatic 
lipase, leading to excessive production of free fatty acids, which are toxic to the 
pancreatic acinar cell.
259,260
 Another possible hypothesis is that hyperviscosity develops 
as a result of increased chylomicrons and/or VLDLs within the capillaries, which in turn 
leads to ischemia of pancreatic tissue.
258
 Finally, genetic factors, such as mutations of 
the cystic fibrosis transmembrane conductance regulator gene or the SPINK1 gene may 
play a role by sensitizing the pancreas to the effects of hypertriglyceridemia.
258
   
A similar relationship between hypertriglyceridemia and pancreatitis has been 
suggested for dogs, and co-existence of the 2 conditions has been frequently 
described.
15,33,34,37,49,52,66,83,165
 However, this association remains obscure in dogs because 
the etiology of hypertriglyceridemia cannot always be determined in these studies. It has 
been speculated that the presence of hypertriglyceridemia in dogs with pancreatitis might 
be due to a pre-existing disorder of lipid metabolism, which may or may not be related to 
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the etiology of pancreatitis, but might also be the result of pancreatitis, or it might just be 
an incidental finding in some cases.
252
  
Miniature Schnauzers are a unique breed in regards to both hyperlipidemia and 
pancreatitis. Miniature Schnauzers have been reported to develop pancreatitis more 
commonly than dogs of other breeds, and this high prevalence of pancreatitis in 
Miniature Schnauzers has been attributed to the fact that dogs of this breed commonly 
develop hypertriglyceridemia.
33,49,66,165
 Available clinical and experimental data to 
support these hypotheses are limited, however. Clinical studies have shown an 
association between hyperlipidemia and pancreatitis in dogs, although it is not clear 
whether hyperlipidemia was the cause or the result of pancreatitis, or even just an 
incidental finding in some cases.
15,19,21,63-66
 Secondary hyperlipidemia seen in dogs with 
some endocrinopathies (e.g., hyperadrenocorticism) or obesity may be responsible for 
the increased risk for pancreatitis associated with these diseases.
11,65,65,172
 
 The hypotheses of the present study were that: 1) hypertriglyceridemia, 
especially when severe, is a risk factor for pancreatitis in Miniature Schnauzers, 2) 
primary hypertriglyceridemia and possibly subclinical pancreatic inflammation in 
Miniature Schnauzers will respond, at least partially, to feeding an ultra low-fat diet, and 
3) dogs with pancreatitis will exhibit changes in their serum triglyceride and cholesterol 
concentrations, as well as in their lipoprotein profiles when compared to healthy dogs.   
The objectives of the present study were: 1) to investigate a possible associations 
between serum triglyceride and canine pancreatic lipase immunoreactivity (cPLI) 
concentrations in Miniature Schnauzers, 2) to compare serum triglyceride concentrations 
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in Miniature Schnauzers with a recent history of pancreatitis to those without a history of 
pancreatitis, 3) to evaluate the feasibility and assess the usefulness of a novel method for 
ultracentrifugal separation of lipoproteins as a means for lipoprotein fingerprinting in 
dogs, 4) to compare the lipoprotein profiles among dogs of various breeds, healthy 
Miniature Schnauzers, and Miniature Schnauzers with hyperlipidemia, 5) to evaluate the 
effect of a commercially available ultra-low-fat diet on serum triglyceride, cholesterol, 
and Spec cPL concentrations, as well as the lipoprotein profiles, in Miniature Schnauzers 
with suspected primary hypertriglyceridemia, and 6) to evaluate serum triglyceride and 
cholesterol concentrations and describe the lipoprotein profiles in dogs with and without 
pancreatitis. 
In the first part of the study, the objective was to investigate a possible 
association between serum triglyceride and canine pancreatic lipase immunoreactivity 
(cPLI) concentrations in Miniature Schnauzers. One hundred and ninety-five Miniature 
Schnauzers were enrolled and divided into 2 groups based on whether they had normal 
(Group 1) or increased (Group 2) serum triglyceride concentrations. Serum triglyceride 
and cPLI concentrations were measured and compared between groups. There was a 
significant but weak positive correlation between serum triglyceride and cPLI 
concentrations (r=0.321; P<0.0001). Miniature Schnauzers with hypertriglyceridemia 
had significantly higher serum cPLI concentrations (median: 99.5 μg/L) than Miniature 
Schnauzers with normal serum triglyceride concentrations (median: 39.3 μg/L; 
P=0.0001). A cut-off value of 862 mg/dL was selected for serum triglyceride 
concentration based on ROC analysis, and this concentration had an increased risk of 4.5 
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times (P=0.0343) for a serum cPLI concentration that is considered to be consistent with 
a diagnosis of pancreatitis with the assay used (>200 μg/L). Thus, this study supports an 
association between hypertriglyceridemia, especially when severe, and high cPLI 
concentrations in Miniature Schnauzers. 
 The objective of the second part of the study was to compare serum triglyceride 
concentrations between Miniature Schnauzers with and without a recent history of 
pancreatitis. To that end, 17 Miniature Schnauzers with a history of pancreatitis (Group 
1) and 34 age-matched Miniature Schnauzers without a history of pancreatitis (Group 2) 
were prospectively enrolled. Two samples were collected from each of the 17 Miniature 
Schnauzers with pancreatitis: 1 during pancreatitis and 1 after clinical and biochemical 
resolution of pancreatitis. Serum triglyceride and cholesterol concentrations were 
compared between Group 1 (after resolution of pancreatitis) and Group 2. Miniature 
Schnauzers in Group 1 were significantly more likely to have hypertriglyceridemia 
(71%) after resolution of pancreatitis than Miniature Schnauzers in Group 2 (33%; odds 
ratio=5.02; 95% CI, 1.4 to 17.8; P=0.0163). Serum triglyceride concentrations were 
significantly higher in dogs of Group 1 (median: 605.0 mg/dL) after resolution of 
pancreatitis than in dogs of Group 2 (median: 73.5 mg/dL; P=0.002). Miniature 
Schnauzers with a history of pancreatitis were 5 times more likely to have 
hypertriglyceridemia than controls. Based on the results of this part of the study, 
hypertriglyceridemia appears to be associated with the development of pancreatitis in 
some dogs of this breed. 
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 In the third part of the study, the goal was to assess the feasibility and usefulness 
of a novel, convenient, and economical density gradient ultracentrifugation method as a 
means for lipoprotein fingerprinting in dogs, and to characterize and compare the 
lipoprotein profiles of healthy dogs of various breeds, healthy Miniature Schnauzers, and 
Miniature Schnauzers with primary hypertriglyceridemia using the same method.  
Thirty-five healthy dogs of various breeds with serum triglyceride and cholesterol 
concentrations within their respective reference intervals (Group 1), 31 Miniature 
Schnauzers with serum triglyceride and cholesterol concentrations within their 
respective reference intervals (Group 2A), and 31 Miniature Schnauzers with 
hypertriglyceridemia (Group 2B) were included in the study. The most abundant 
lipoprotein fraction in dogs of Group 1 was HDL, mainly HDL2 and HDL3. LDL 
fractions were present in very small amounts, with the exception of LDL4 and LDL5. 
Triglyceride-rich lipoproteins were also found in very small amounts. The lipoprotein 
profiles of Miniature Schnauzers with serum triglyceride and cholesterol concentrations 
within the reference interval (Group 2A) were generally similar to the ones seen in dogs 
of Group 1 with regard to the abundance of major lipoprotein classes. However, most 
dogs in Group 2A showed some distinct differences in some lipoprotein fractions and 
subfractions. Using sliced inverse regression analysis, the group to which each dog 
belonged (i.e., Miniature Schnauzer versus other breeds) could be accurately predicted 
based on their lipoprotein profiles in 85% of the cases (P=0.00017). The most important 
lipoprotein fractions that served as predictors were the TRLs and the LDL fraction 
corresponding to LDL4 and LDL5. Miniature Schnauzers had more prominent TRL 
 164 
peaks than dogs of other breeds, while dogs of other breeds had more prominent LDL4 
and LDL5 peaks. Sliced inverse regression analysis in Groups 2A and 2B showed that 
the group to which each dog belonged (i.e., Miniature Schnauzers with normal serum 
triglyceride concentration versus Miniature Schnauzers with hypertriglyceridemia) could 
be accurately predicted based on their lipoprotein profiles in 95% of cases (P=0.000002). 
By far, the most important lipoprotein fraction that served as a predictor was the TRL 
fraction, which was more prominent in the dogs with hypertriglyceridemia. Fractions 
corresponding to LDL2, LDL3, LDL4, were more prominent in Miniature Schnauzers 
with serum triglyceride concentrations within the reference interval. 
 The aim of the fourth part of the study was to evaluate the effect of a 
commercially available low-fat diet on serum lipid and pancreas-specific lipase (Spec 
cPL
®
) concentrations and lipoprotein profiles in Miniature Schnauzers with primary 
hypertriglyceridemia. Sixteen Miniature Schnauzers with hypertriglyceridemia of 
various degrees were included in the study (Group 1). A group of 28 healthy Miniature 
Schnauzers with serum triglyceride and cholesterol concentrations within the respective 
reference intervals (Group 2) was used as a control group for the lipoprotein profile 
analysis portion of the study. Dogs in Group 2 were used in order to obtain lipoprotein 
profiles from a group of healthy Miniature Schnauzers that could be used for illustration 
of whether lipoprotein profiles of hypertriglyceridemic Miniature Schnauzers tended to 
approach those of the healthy ones after the diet change. Each one of the dogs in Group 
1 had a total of 4 blood samples collected. The first sample (sample 1) was used to 
diagnose primary hypertriglyceridemia. Then, in order to confirm the results of the 
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initial sample and to investigate the variability of the findings, the owners were 
instructed to have a second sample (sample 2) collected 1 to 2 months after the 
collection of the initial sample, and without making any changes to the diet of their dogs. 
If hypertriglyceridemia was confirmed in the second sample, the dogs were put on the 
study diet. Approximately 7 to 9 weeks after the dogs had been exclusively on the study 
diet a third blood sample (sample 3) was collected. Finally, a fourth sample (sample 4) 
was collected approximately 2 to 4 weeks after the third sample. Serum triglyceride 
concentrations before the diet change (median of sample 1: 480 mg/dL; median of 
sample 2: 493 mg/dL) were significantly higher than after the diet change (median of 
sample 3: 177 mg/dL; median of sample 4: 168 mg/dL; P=0.0001). Serum cholesterol 
concentrations before the diet change (mean of sample 1: 381 mg/dL; mean of sample 2: 
380 mg/dL) were significantly higher than after the diet change (mean of sample 3: 257 
mg/dL; mean of sample 4: 178 mg/dL; P<0.0001). Serum Spec cPL concentrations 
before the diet change (mean of sample 1: 173 µg/L; mean of sample 2: 109 µg/L) were 
not significantly different than after the diet change (mean of sample 3: 144 µg/L; mean 
of sample 4: 137 µg/L; P=0.12). For analysis of the lipoprotein profiles in response to 
the diet change, the lipoprotein profiles after the diet change were compared with those 
of the same dogs before the diet change as well as those of the group of healthy dogs. 
Before the diet change, there was a 98% separation between Group 1 and Group 2 using 
SIR analysis (P=0.0003). Therefore, 15/16 (94%) of hyperlipidemic Miniature 
Schnauzers were classified as hyperlipidemic based on their lipoprotein profiles alone. 
After the diet change, significantly fewer Miniature Schnauzers (7/16; 44%; odds ratio: 
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19.3; 95% CI, 2.0-184.0; P=0.006) were still classified as hyperlipidemic by lipoprotein 
profile analysis, while the majority of the dogs of this group (56%) were classified as 
normal.  Logistic regression analysis of the baseline lipoprotein profiles (before the diet 
change) of dogs that eventually responded and dogs that did not respond to the diet 
change showed that dogs that responded to the diet change could be separated with 88% 
accuracy from the ones that did not respond, based on lipoprotein profile analysis even 
before the diet change. Dogs that did not respond to the diet change tended to have lower 
LDL fractions (mainly LDL1 and LDL2) and higher HDL fractions (mainly HDL2a, 
HDL3b, and HDL3c) than the ones that responded. 
The aims of the last part of the study were: a) to measure serum triglyceride and 
cholesterol concentrations in dogs with naturally occurring pancreatitis and compare 
them with those of healthy dogs, and b) to determine the lipoprotein profiles of dogs 
with naturally occurring pancreatitis and compare them with those of healthy dogs. 
Seventeen dogs with pancreatitis and 53 healthy control dogs were enrolled. There was 
no statistically significant difference in the proportion of dogs that had 
hypertriglyceridemia between dogs with pancreatitis (18%) and healthy controls (7.5%; 
P=0.35). However, there was a statistically significant difference in serum triglyceride 
concentrations between dogs with pancreatitis (median: 67 mg/dL; range: 48 – 324 
mg/dL) and dogs healthy control dogs (median: 54 mg/dL; range: 26 – 257 mg/dL; 
P=0.0026). There was a statistically significant difference in the proportion of dogs that 
had hypercholesterolemia between dogs with pancreatitis (Group 1) and healthy control 
dogs (P=0.011). However, there was no statistically significant difference in serum 
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cholesterol concentrations between dogs with pancreatitis (median: 209 mg/dL; range: 
142 – 849 mg/dL) and healthy control dogs (median: 227 mg/dL; range: 97 – 338 
mg/dL; P=0.565). Sliced inverse regression analysis showed that lipoprotein profiles 
were distinctly different between dogs with pancreatitis and healthy control dogs 
(P=0.0012). Dogs could be classified in the correct group (healthy versus pancreatitis) 
with 89% accuracy based on their lipoprotein profiles alone. The most important 
differences in the lipoprotein profiles between dogs with pancreatitis and healthy dogs 
involved increases in LDL2, LDL3, and LDL4, and less prominent decreases in TRL, 
HDL2a, and HDL3c. 
In summary, the main conclusions of the present study were:  
1) Hypertriglyceridemia, especially when severe, is a risk factor for pancreatitis in 
Miniature Schnauzers. Therefore, it might be recommended that when 
hypertriglyceridemia is detected in dogs of this breed it should be treated and monitored. 
2) Density gradient ultracentrifugation using NaBiEDTA as described in the present 
study is a useful screening method for the study of lipoprotein profiles in dogs. 
Important differences in lipoprotein profiles can be detected with this method even 
among dogs that have serum triglyceride and cholesterol concentrations within the 
reference interval.  
3) Miniature Schnauzers with serum triglyceride and cholesterol concentrations within 
the reference interval appear to have significantly different lipoprotein profiles (mainly 
with regard to TRL and LDL4) than dogs of various other breeds.  
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4) Specific lipoprotein classes (TRL and specific LDL fractions, mainly LDL2) are 
associated with hypertriglyceridemia in Miniature Schnauzers. Changes in these 
lipoprotein classes are not always uniform among Miniature Schnauzers with 
hyperlipidemia.  
5) The commercially available ultra-low-fat diet used in the present study was found to 
be effective in significantly reducing serum triglyceride and cholesterol concentrations 
within 2 months.  
6) The commercially available ultra-low-fat diet used in the present study was found to 
be effective in shifting the lipoprotein profiles of most hyperlipidemic dogs towards 
those of non-hyperlipidemic dogs within 2 months.  
7) A subgroup of Miniature Schnauzers appeared to not fully respond to the diet used in 
the present study as indicated mainly by their serum triglyceride concentrations and 
lipoprotein profiles. The reason for this finding is not known at this point, but 
differences in the pathogenetic basis of hyperlipidemia among dogs might have played a 
role.  
8) The majority of dogs with naturally occurring pancreatitis appear to have serum 
triglyceride and cholesterol concentrations within their respective reference intervals. In 
the relatively small percentage of dogs that showed increases in serum triglyceride 
and/or cholesterol concentrations, those increases were generally mild. It might be 
recommended that profound increases in serum triglyceride and/or cholesterol 
concentrations in dogs with pancreatitis are unlikely to be the result of pancreatitis, and 
warrant further diagnostic investigation.  
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9) Important differences exist in lipoprotein profiles between dogs with pancreatitis and 
healthy control dogs. Dogs with pancreatitis have higher LDL fractions (mainly LDL2, 
LDL3, and LDL4) and lower TRL and HDL fractions (mainly HDL2a and HDL3c) than 
healthy control dogs. These changes in lipoprotein profiles are evident in the majority of 
dogs with pancreatitis, even in those dogs with serum concentrations of triglyceride and 
cholesterol within the reference interval.  
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